Exploring the context and potential benefits of implementing an Intermittent Preventive Treatment for malaria in infants (IPTi) in Papua New Guinea by Senn, Nicolas
 I
 
Exploring the context and potential benefits of 
implementing an Intermittent Preventive Treatment for 
malaria in infants (IPTi) in Papua New Guinea 
 
 
INAUGURALDISSERTATION 
 
zur 
Erlangung der Würde eines Doktors der Philosophie 
 
Vorgelegt der Philosophisch-Naturwissenschatlichen Fakultät 
Der Universität Basel 
 
 
 
von 
Nicolas Senn 
aus Auenstein (AG) 
 
Basel, Juni 2012 
  
II
Genehmigt von der Phiosophisch-Naturwissenschaftlichen Fakultät auf Antrag 
von Prof Dr Blaise Genton, Prof Dr Marcel Tanner, Prof  Dr David Schellenberg 
und Dr Ivo Mueller 
 
Basel, den 21. Juni 2011
  
III
 
« Tandis que le sage cherche le pont, le fou traverse la rivière » 
      Proverbe nord-iranien 
  
IV
 
  
V
Table of Contents 
 
SUMMARY .............................................................................................................................................. XIII 
ZUSAMMENFASSUNG ........................................................................................................................ XVII 
LIST OF ABBREVIATIONS ................................................................................................................... XX 
LIST OF FIGURES ................................................................................................................................ XXII 
LIST OF TABLES ................................................................................................................................ XXIII 
LIST OF GRAPHS ............................................................................................................................... XXIV 
1 INTRODUCTION ............................................................................................................................1 
1.1 EPIDEMIOLOGY, DIAGNOSIS AND TREATMENT OF MALARIA ..........................................................1 
1.1.1 Epidemiology of malaria world wide ...............................................................................1 
1.1.2 Epidemiology of malaria in Papua New Guinea (PNG) ..................................................1 
1.1.3 Diagnosis of malaria in routine practice .........................................................................3 
1.1.4 Diagnosis of malaria in PNG ..........................................................................................4 
1.1.5 Treatment of malaria .......................................................................................................5 
1.1.6 Treatment of malaria in PNG ..........................................................................................6 
1.1.7 Malaria control strategies ...............................................................................................6 
1.1.8 Malaria control strategies in PNG ..................................................................................7 
1.2 EXPANDED PROGRAM OF IMMUNIZATION (EPI) AND MOTHER & CHILD HEALTH CLINICS (MCH) .7 
1.3 GENERAL CONCEPT OF IPTI...........................................................................................................9 
1.4 BURDEN OF DISEASES AND INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS (IMCI) IN PAPUA 
NEW GUINEA ........................................................................................................................................... 12 
2 GOAL, OBJECTIVES AND METHODS .................................................................................... 13 
2.1 GOAL .......................................................................................................................................... 13 
2.2 OBJECTIVES................................................................................................................................. 13 
2.3 METHODS .................................................................................................................................... 14 
2.3.1 Brief outline of the design of each of the objective ........................................................ 14 
2.4 IPTI STUDY DESIGN AND PROCEDURES ........................................................................................ 15 
2.5 STUDY AREA AND POPULATION ................................................................................................... 17 
2.5.1 Study area ...................................................................................................................... 17 
2.5.2 Study population ............................................................................................................ 18 
2.5.3 Ethics ............................................................................................................................. 18 
3 POPULATION HEMOGLOBIN MEANS AND ANEMIA PREVALENCE: NEW METRICS 
FOR DEFINING MALARIA ENDEMICITY? ........................................................................................ 21 
3.1 ABSTRACT ................................................................................................................................... 22 
3.2 INTRODUCTION ............................................................................................................................ 24 
3.3 METHODS .................................................................................................................................... 27 
3.4 RESULTS...................................................................................................................................... 29 
3.5 DISCUSSION................................................................................................................................. 34 
4 UNIFIED TREATMENT WITH ARTEMETHER-LUMEFANTRINE BASED ON RDT 
RESULTS: AN EFFECTIVENESS STUDY IN PNG INFANTS WITH P. FALCIPARUM AND 
VIVAX MALARIA ...................................................................................................................................... 41 
4.1 ABSTRACT ................................................................................................................................... 42 
4.2 INTRODUCTION ............................................................................................................................ 44 
4.3 METHODS .................................................................................................................................... 45 
4.4 RESULTS...................................................................................................................................... 52 
  
VI
4.5 DISCUSSION................................................................................................................................. 63 
5 PROTECTIVE EFFICACY OF INTERMITTENT PREVENTIVE TREATMENT IN 
PAPUA NEW GUINEAN INFANTS EXPOSED TO PLASMODIUM FALCIPARUM AND P. 
VIVAX: A RANDOMIZED, PLACEBO-CONTROLLED TRIAL ........................................................ 67 
5.1 ABSTRACT ................................................................................................................................... 68 
5.2 INTRODUCTION ............................................................................................................................ 70 
5.3 METHODS .................................................................................................................................... 72 
5.4 RESULTS...................................................................................................................................... 81 
5.5 DISCUSSION................................................................................................................................. 95 
5.6 CONCLUSIONS ........................................................................................................................... 100 
6 IMCI SUPPLEMENTED WITH MALARIA RAPID DIAGNOSTIC TEST AND 
INTERMITTENT PREVENTIVE TREATMENT (IPTI): IMPACT ON DISEASES INCIDENCE 
RATES AND CASE MANAGEMENT IN PAPUA NEW GUINEA. ................................................... 103 
6.1 ABSTRACT ................................................................................................................................. 104 
6.2 BACKGROUND ........................................................................................................................... 106 
6.3 METHODS .................................................................................................................................. 109 
6.4 RESULTS.................................................................................................................................... 115 
6.5 DISCUSSION............................................................................................................................... 126 
6.6 CONCLUSIONS ........................................................................................................................... 133 
7 COMMUNITY RESPONSE TO INTERMITTENT PREVENTIVE TREATMENT OF 
MALARIA IN INFANTS (IPTI) IN PAPUA NEW GUINEA ............................................................... 135 
7.1 ABSTRACT ................................................................................................................................. 136 
7.2 BACKGROUND ........................................................................................................................... 137 
7.3 METHODS .................................................................................................................................. 139 
7.4 RESULTS.................................................................................................................................... 141 
7.5 DISCUSSION............................................................................................................................... 145 
7.6 CONCLUSIONS ........................................................................................................................... 149 
8 GENERAL DISCUSSION ........................................................................................................... 151 
8.1 RATIONALE ............................................................................................................................... 151 
8.2 DISEASES BURDEN IN PNG ........................................................................................................ 152 
8.2.1 Respiratory infections .................................................................................................. 152 
8.2.2 Malaria ........................................................................................................................ 154 
8.2.3 Gastroenteritis ............................................................................................................. 156 
8.2.4 Acute otitis media (AOM) ............................................................................................ 156 
8.2.5 Burden of diseases and public health implications ...................................................... 157 
8.3 MAIN FINDINGS ABOUT IPTI IN PNG ......................................................................................... 158 
8.4 THE DETERMINANTS OF IPTI EFFECTIVENESS IN PNG ............................................................... 159 
8.4.1 IPTi coverage depends on EPI coverage ..................................................................... 159 
8.4.2 Changes in transmission intensity of malaria in PNG ................................................. 161 
8.4.3 Effect on overall morbidity, severe illnesses and mortality ......................................... 161 
8.4.4 The choice of the drug combination ............................................................................. 167 
8.4.5 Acceptability ................................................................................................................ 168 
8.4.6 Feasibility of IPTi in PNG ........................................................................................... 169 
8.4.7 Cost-effectiveness of IPTi in PNG ............................................................................... 170 
8.4.8 Implications for policy decision ................................................................................... 171 
8.5 CLINICAL MANAGEMENT OF MALARIA AND OTHER DISEASES IN PNG ....................................... 174 
8.5.1 Safety of RDT & utility within IMCI ............................................................................ 174 
8.5.2 Safety and effectiveness of artemether-lumefantrine for Pf and Pv ............................. 175 
8.5.3 Feasibility of using RDT-based unified treatment with AL in PNG ............................. 177 
8.5.4 Performance of IMCI on non-malaria illnesses .......................................................... 178 
8.5.5 Implications for policy decision of updating IMCI with RDT-based treatment ........... 179 
  
VII
9 CONCLUSIONS ........................................................................................................................... 181 
10 RECOMMENDATIONS AND FUTURE RESEARCH AREAS ............................................. 183 
10.1 RECOMMENDATIONS FOR HEALTH AUTHORITIES AND POLICY MAKERS IN PNG ........................ 183 
10.2 GENERAL RECOMMENDATIONS FOR IMCI GUIDELINES ............................................................. 185 
10.3 GENERAL RECOMMENDATIONS FOR THE IPTI INTERVENTION ................................................... 186 
10.4 FURTHER RESEARCH AREAS ...................................................................................................... 187 
11 BIBLIOGRAPHY ......................................................................................................................... 189 
APPENDIX 1: PICTURE-BASED INFORMATION BROCHURE PROVIDED TO PARENTS OF 
STUDY PARTICIPANTS ......................................................................................................................... 205 
APPENDIX 2: CASE REPORT FORMS USED IN THE IPTI TRIAL TO RECORD ALL SIGNS, 
SYMPTOMS, DIAGNOSES AND TREATMENTS OF ILLNESS EPISODES ................................. 207 
APPENDIX 3: TREATMENT OF MALARIA & ANEMIA (IPTI TRIAL PROCEDURES) AND 
EXTRACTS OF THE PNG TREATMENT BOOK (IMCI) FOR DANGER SIGNS, FEVER, 
RESPIRATORY INFECTIONS, GASTROENTERITIS AND OTITIS .............................................. 209 
CURRICULUM VITAE ........................................................................................................................... 217 
 
  
VIII
  
IX
Acknowledgments 
 
This work was a fantastic journey, not only into medical research, but also and 
maybe foremost a unique opportunity to meet a lot of extraordinary people in 
Papua New Guinea and elsewhere. 
 
I would like first to express my sincere gratitude to Prof Blaise Genton who was 
my supervisor for the thesis. For almost 10 years, he has been my mentor and 
made me discover the world of tropical medicine. I not only owe him all the things 
that I have learned in research but also the incredible opportunity to discover 
PNG.  
 
At the PNG Institute of Medical Research, I would like first to thank my wantok Dr 
Ivo Mueller, principal investigator of the IPTi study and former deputy director of 
the Institute, who first proposed me to do a PhD and always encouraged me to 
do the present thesis. He always had good advice when I was sweating on 
statistical analysis or epidemiological concepts. I would like also to thank warmly 
John Taime, site manager of the PNG IMR in Madang for his kindness, wisdom 
and guidance to solve community problems. Merci infiniment à Dr Pascal Michon, 
actuellement doyen de la faculté des sciences médicales de l’Université Devine 
Word de Madang, pour sa gentillesse et son amitié. I would like to also to thank 
Dr Danielle Stanisic who contributed to the success of the study by overlooking 
all laboratory activities.  Thanks also to her for her friendship, we shared many 
good moments in Madang.  
 
I would like to thank especially the nurses of the IPTi trial with whom I spent so 
many days in the field and who gave me my first tok pisin lectures in the field. 
They made a fantastic job looking after the kids enrolled in the study in Madang 
and Maprik with patience and professionalism. I will always keep a bright 
souvenir from all of them:  Alberta Siuru, Albina Teleki, Alida Sagem, Anastasia 
Kali, Anselm Masalan, Brenda WingiI, Carol Kinminja, Cathy Wepo, Doi Gong, 
  
X
Doris Manong, Doris Wamo, Dulcie Ganawi, Elite Maki, Gumul Yadi, Jack Larry, 
Jeniffer Igu, Jonah Iga, Lisa Takura, Lorraine Ivakia, Mama Mary Salib, Nelly 
Sanuku, Petronila Wopan, Samela Gime, Sine Ineme, Alois Bai, Mary Suano, 
Maureen Neirahi, Nathalie Baida, Peter Kulin, Richard Piko and Veronica Marfu.  
 
The study would not have worked without a strong and efficient management 
team. I would like especially to thank Carole Davy, Carole Taime, Gilda Tobby, 
Lisa Kandi, Leah Tekis, Lynette Bureng, Edmund Polut and Mark Buka for 
looking after all the heavy administrative work load. Thank you also to the drivers 
Michael Bureng, Richard Bafor, Mangan Wangalai and John Petau who drove us 
on adventurous roads day after day. I can’t name them all, but my thoughts go 
also to all the community reporters who were taking care of the study participants 
in the villages. Thank you also to the data management unit: Rose Sabub, Apa 
Paranuga, Stuart Dobbie and Yangta Ura. Special thanks to Thomas Adiguma for 
all his kind help every time we had problems with the databases. Many thanks 
also to the laboratory staff: Jack Taraika, Sarah Javati, Heather Huape, Anselm 
Masalan and the microscopy section for their excellent job, looking after the 
samples and reading so many slides generated by the study. Thank you also 
very much to Dr Jo Nale and Dr Bridget Barber, who worked hard as study 
clinicians in Maprik. Thank you also very much to Prof Peter Siba, director of the 
PNG IMR and the members of the institutional review board (IRB) of the PNG 
IMR with who I could learn so much about ethics and research in PNG while 
taking part to the meetings of the board. 
 
I would like to especially thank Dr Patricia Rarau, who made an incredible job as 
study clinician and coordinator in Madang and Maprik. But foremost, I am deeply 
grateful to her for her friendship, happiness and for making us discover her 
country, East New Britain, and many other things about PNG, catch mulai! 
 
My sincere thanks go also to Prof Stephen Rogerson and his family in 
Melbourne. We would not have gone to PNG if he would not have employed me! 
  
XI
He has always been very supportive when I encountered difficult times. I would 
like especially to thank him and his family for kindly accommodating us every 
time we were coming to Melbourne.   
 
To Prof Marcel Tanner, the director of the Swiss TPH, I would like also to express 
my gratitude for his strong support to do a PhD in Basel at the Swiss TPH. 
 
I would like to express my sincere thanks to my parents, sisters and family-in-law 
for their support, encouragements and for visiting us in PNG!  
 
I would like to express my deep gratefulness to Aita Jamlang, for her friendship 
and infinite kindness while she was looking after our children in Madang. She is 
the person who gave a sense to our stay in PNG. 
 
Finally, all this work would not have been possible without the inestimable 
support of my wife and my children. I will always be grateful to Michèle for her 
enthusiasm to come with me to PNG and for enjoying exploring together what 
was for us a New World. I am also very grateful to my daughter Chloé and my 
two sons Guillaume and Mathieu for their “joie de vivre” in the country of birds of 
paradise, eating saksak or swimming with clown fishes.    
  
XII
  
XIII
Summary 
Background 
Intermittent preventive treatment (IPTi) is an intervention aiming to reduce the 
risk of malaria in infants. Its concept is to deliver a full treatment course of 
antimalarial drugs to infants, three or four times during the first year of life, 
following the expanded program of immunization (EPI) schedule and regardless 
of clinical malaria episodes. 
Mainly Sulphadoxine/pyrimthamine (SP) was studied and demonstrated to 
reduce the risk of malaria by 30% in Africa, where Plasmodium falciparum (Pf) is 
the predominant species. No study has been carried out in regions of the world 
with a significant burden of non-Pf infections. There is therefore a need to 
investigate the potential benefits of IPTi in areas, such as Papua New Guinea 
(PNG), highly endemic for Plasmodium vivax (Pv) malaria.  
Apart from efficacy, which is the corner stone of an intervention, it is essential to 
have a clear picture of the context in which such an intervention might be 
implemented. Indeed, determinants of effectiveness such as the malaria context 
(epidemiology and case management), the acceptability and the access to the 
intervention need to be investigated prior to the implementation of IPTi. 
The present study investigates the efficacy of IPTi in PNG as well as some key 
aspects of infant’s health in PNG that might help to understand the context in 
which IPTi could be implemented.  
 
Methods 
Randomized controlled trial investigating the protective efficacy of 4 doses of SP 
associated to 3 days of artesunate (SP-AS3) or 3 days of amodiaquine (SP-AQ3) 
given at 3-month intervals during the first year of life. Most of infants were 
followed-up for an additional 12 months. The study took place in Madang and 
Maprik (PNG) from 2006 to 2010, but only the Madang cohort was used for the 
IPTi efficacy analyses. 
Making use of the morbidity passive case detection of the trial, the following 
aspects of infant’s health in PNG were investigated: 
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• Effectiveness of treating infants with a unified treatment 
(artemther/lumefantrine, AL) for Pf & Pv malaria based on the result of the 
rapid diagnostic test (RDT) 
• The incidence of common illnesses based on RDT and syndromic 
definitions of diseases and the impact of IPTi on them. 
• The performances of the integrated management childhood illness (IMCI) 
supplemented with RDT & IPTi for the management of common 
syndromes/diseases in PNG.   
The acceptability of IPTi was also assed alongside the drug trial. 
 
Findings 
1605 infants 3 months old were enrolled in the IPTi trial, 1125 in Madang and 480 
in Maprik. The intention-to-treat relative risk (RR) at 15 months of age (Madang 
site only) was 0.72 (95%CI, 0.57 - 0.90) on all malaria episodes with SP-AQ3 and 
0.88 (95%CI, 0.70 - 1.10) with SP-AS3, overall p=0.017. Using SP-AQ3, the RR 
was 0.63 (95%CI, 0.45 - 0.88) on Pf and 0.78 (95%CI, 0.60 - 1.01) on Pv. No 
difference was observed in the incidence of overall morbidity, severe diseases 
and non-malarial illnesses between the placebo and IPTI intervention arms. 
Fewer deaths were observed in the treatment arms compared to placebo: 
placebo=8, SP-AQ3=1 and SP-AS3=3. 
7223 fever episodes occurred (in Madang and Maprik) during the study and 5670 
had a negative RDT result. Out of them, 133 (3.4%) re-attended the clinic within 
7 days for fever, and 1 died of lower respiratory tract infection (LRTI). 23 (0.6%) 
infants re-presented with a severe illness (4 with positive BS and/or RDT). 1728 
children with positive RDT results were treated with artemether/lumefantrine (AL). 
30 (1.7%) re-attended within 7 days for fever, none died. 
Out of the total cohort, incidence rates (episodes/child/year) for common 
syndromes/diseases were: 0.85 (95%CI, 0.81-0.90) for LRTI, 0.72 (95%CI, 0.65-
0.93) for gastroenteritis (GI), 0.62 for malaria (95%CI, 0.58 - 0.66)  and 0.08 
(95%CI, 0.07-0.09) for otitis.  
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The introduction of RDT led to a high accuracy of “on site” malaria diagnosis (К 
=0.99). On the opposite, the clinical diagnosis accuracy for others syndromes 
was poor: К=0.47 for LRTI, К=0.52 for GI and К= 0.52 for otitis.  
25% of illness episodes were inappropriately treated: 6% did not receive 
antibiotics when they should have and 19% received antibiotics when they should 
not have (according to recommendations). The prescription’s rate of antibiotics 
was 56% when the RDT for malaria was negative and 16% when the RDT was 
positive (p<0.001). The acceptability of IPTi appears to be good in Melanesian 
populations. 
 
Conclusion 
The use of RDT and artemether/lumefantrine is a safe and effective strategy for 
the management of malaria cases in PNG and could be implemented very easily. 
IPTi has demonstrated its efficacy to reduce both Pf and Pv episodes. However, 
the apparent absence of benefit on the overall morbidity and on severe illnesses 
is a concern and mitigates the interest of implementing this intervention in PNG.  
Furthermore, other factors such as a low EPI coverage and rapidly changing 
malaria endemicity due to the recent introduction in PNG of insecticide treated 
nets (ITN) and artemisinin combination therapies (ACT) are likely to jeopardize 
the potential benefits of IPTi in PNG. 
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Zusammenfassung 
Hintergrund 
Intermittent preventive treatment in infants (IPTi) ist eine Intervention mit dem 
Ziel, das Risiko von Malaria bei Kleinkindern zu reduzieren. Sein Konzept ist den 
Säuglingen Behandlung mit Malariamedikamenten, drei oder viermal während 
des ersten Lebensjahres, nach dem Zeitplan des Erweitertens Programms der 
Immunisierung (EPI) und unabhängig von klinischen Malaria Episoden. 
Haupsächlich Sulfadoxin/pyrimthamine (SP) wurde studiert und zeigte, dass das 
Risiko von Malaria um 30% in Afrika reduziert wurde, wo Plasmodium falciparum 
(Pf) die vorherrschende Spezies ist. Keine Studie wurde in den Regionen der 
Welt mit einer signifikanten Belastung durch nicht-Pf-Infektionen durchgeführt. Es 
besteht daher ein Bedarf, die potenziellen Vorteile der IPTi in Bereichen wie 
Papua-Neuguinea (PNG), hoch endemisch für Plasmodium vivax (Pv) Malaria, 
zu untersuchen. 
Abgesehen von Wirksamkeit, die der Grundstein für eine Intervention ist, ist es 
wichtig, ein klares Bild des Kontextes zu haben, in dem ein solcher Eingriff 
durchgeführt werden könnte. Tatsächlich, Determinante der Wirksamkeit wie der 
Malariakontext (Epidemiologie und Case Management), die Akzeptanz und der 
Zugang auf die Intervention, muss vor der Durchführung von IPTi untersucht 
werden. 
Die vorliegende Studie untersucht die Wirksamkeit von IPTi in PNG sowie einige 
der wichtigsten Aspekte der kindlichen Gesundheit von Kleinkindern in PNG, die 
helfen könnten, den Kontext, in dem IPTi implementiert werden könnte, zu 
verstehen. 
 
Methoden 
Randomisierte kontrollierte Studie, die die schützende Wirkung untersucht von 
vier Dosen von SP und 3 Tagen von Artesunat (SP-AS3) oder 3 Tage von 
Amodiaquin (SP-AQ3) in 3-monatigen Abständen, gegeben während des ersten 
Lebensyahres. Die meisten Kinder wurden für weitere 12 Monate beobachtet. 
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Die Studie fand in Madang und Maprik (PNG) von 2006 bis 2010 statt, aber nur 
die Madang Kohorte wurde für die IPTi Wirksamkeit Analyse verwendet. 
Folgende Aspekte der Gesundheit der Kleinkinder in PNG wurden untersucht, 
indem die passiven Fälle der Studie registriert wurden: 
• Wirksamkeit der Behandlung von Säuglingen mit einer einheitlichen 
Behandlung (artemther / Lumefantrin, AL) für Pf & Pv Malaria, dem Ergebnis des 
rapid diagnostic test  (RDT) nach. 
• Die Inzidenz von gewöhnlichen Krankheiten nach RDT und syndromalen 
Definitionen von Krankheiten und die Auswirkungen von IPTi auf ihnen. 
• Die Leistungen des integrierten Managementsystems Kinderkrankheiten (IMCI) 
ergänzt mit RDT & IPTi für die Bewirtschaftung der gewöhnlichen Syndrome / in 
PNG. 
Die Akzeptanz von IPTi wurde während dieser Studie bestimmt . 
 
Resultate 
1605 3-Monate alt Säuglinge wurden in die IPTi Studie eingezogen, 1125 in 
Madang und 480 in Maprik. Intention-to-treat relative Risiko (RR) bei 15 Monaten 
alt betrug 0.72 (95% CI, 0.57 bis 0.90) auf allen Malariaepisoden mit SP-AQ3 
und 0.88 (95% CI, 0.70 bis 1.10) mit SP-AS3, Insgesamt p = 0.017. Mit SP-AQ3 
wurde das RR 0.63 (95% CI, 0.45 bis 0.88) auf Pf und 0.78 (95% CI, 0.60 bis 
1.01) auf Pv. Es wurde kein Unterschied in der Inzidenz von insgesamter 
Morbidität, schwere Erkrankungen und nicht-Malaria-Erkrankungen zwischen der 
Placebo-und IPTi Intervention Arme beobachtet. Nur wenige Todesfälle wurden 
in den Behandlungsgruppen im Vergleich zu Placebo beobachtet: Placebo = 8, 
SP-AQ3 = 1 und SP-AS3 = 3 ist. 
 
7223 Fieberepisode (in Madang und Maprik) sind während der Studie 
aufgetreten und 5670 hatten einen negativen RDT. Aus ihnen, 133 (3.4%) 
besuchten die Klinik innerhalb von 7 Tagen bei Fieber wieder und 1 starb an 
unteren Atemwegeinfektion (LRTI). 23 (0.6%) Säuglinge kamen erneut mit einer 
schweren Krankheit (4 mit positiven BS und / oder RDT). 1728 Kinder mit 
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positiven RDT Ergebnissen wurden mit Artemether / Lumefantrin (AL) behandelt. 
30 (1.7%) besuchten die klinik innerhalb von 7 Tagen bei Fieber wieder, keiner 
starb. 
Von der insgesamten Kohorte waren Inzidenzraten (Episode / Kind / Jahr) für 
gemeinsame Syndrome / Krankenheiten : 0.85 (95% CI, 0.81-0.90) für LRTI, 0.72 
(95% CI, 0.65-0.93) für Gastroenteritis (GI), 0.62 f!ur malaria (95%CI, 0.58 - 0.66)  
und 0.08 (95% CI, 0.07-0.09) für Otitis. 
 Die Einführung von RDT führte zu einer hohen Genauigkeit von "on site" 
Malaria-Diagnose (К = 0.99). Im gegenteil, war die Genauigkeit klinischer 
Diagnose für andere Syndrome schlecht : К = 0.47 für LRTI, К = 0.52 für GI und 
К = 0.52 für Otitis. 
25% der Krankheitsepisoden wurden unsachgemäß behandelt: 6% erhielten 
keine Antibiotica, wenn sie sie haben sollten und 19% erhielten Antibiotika, wenn 
sie sie nicht haben sollten (den Empfehlungen nach). Die Verschreibung von 
Antibiotika war 56% wenn der RDT für Malaria negative war und 16% wenn der 
RDT postiv war (p <0.001). Die Akzeptanz für IPTi scheint in melanesischen 
Bevölkerung gut zu sein. 
 
Schlussvolgernd 
Die Verwendung von RDT und Artemether / Lumefantrin ist eine sichere und 
wirksame Strategie für die Verwaltung der Malariafälle in PNG und könnte sehr 
leicht realisiert werden. IPTi hat seine Wirksamkeit demonstriet, sowohl Pf und 
Pv Episoden zu reduzieren. Allerdings ist die offensichtliche Abwesenheit von 
Vorteilen auf die gesamte Morbidität und auf schwere Krankheiten ein Anliegen, 
und mildert das Interesse der Durchführung dieser Intervention in PNG. Darüber 
hinaus gibt es andere Faktoren, wie eine niedrige EPI Berichterstattung und die 
sich rasch verändernde Malaria endemizität durch die kürzliche Einführung in 
PNG von Insektiziden behandelte Moskitonetze (ITN) und Artemisinin-
Kombinationstherapien (ACT), die die potenziellen Vorteile der IPTi in PNG 
gefährden könnten. 
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1 Introduction               
1.1 Epidemiology, diagnosis and treatment of malaria  
1.1.1 Epidemiology of malaria world wide 
Malaria is considered to be one of the major contributors to the burden of 
diseases in tropical countries. About 236 millions cases of malaria and 781’000 
deaths were reported in 2009 according to the World Malaria report of WHO 
(WHO 2010). Theses figures are approximations based on presumptive 
diagnosis of malaria, meaning that most cases of malaria reported are not 
confirmed by the presence of circulating parasites, but only assumed because of 
the presence of fever or history fever. This approach towards the estimation of 
the malaria burden creates some problems for public health authorities. Indeed, 
one of the challenges when implementing control strategies for malaria is to 
measure accurately the true burden of the disease. This will be extensively 
discussed in chapter 3, but as an example, we can observe that in the world 
malaria report (WHO 2009) 236 millions of malaria cases are reported which are 
in fact suspected cases (based on presumptive diagnosis) and only 82 millions 
(one third) are confirmed cases by microscopy or rapid diagnostic tests (RDT). At 
a country level, this difference can have important implications for planning 
control interventions.  
1.1.2 Epidemiology of malaria in Papua New Guinea (PNG) 
In 2009, 1.6 millions of febrile episodes were reported as suspected malaria 
cases in PNG. Only 250’000 had a blood examination and one third were found 
positive(WHO 2009). A survey performed in 2008 in Madang Province (at sea 
level), found out that approximately half of the patients (general population) with 
fever visiting an health facility had a positive RDT and/or blood slide (BS) for 
malaria (Senn, Luang-Suarkia et al. 2011)  
Due to its geography and climate, PNG is presenting a wide range of malaria 
transmission intensities (See figure 1.1). It is highly prevalent at sea level, where 
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rainfalls can be very abundant (up to 7000mm/year). Parasite prevalence rate as 
high as 50% is reported in asymptomatic school children on the North coast of 
Madang. (Michon, Cole-Tobian et al. 2007) On the opposite, in the Highlands 
(above 1500m), malaria transmission is less stable, but is generally much lower 
as altitude increases. It is however frequent to observe localized and often 
severe epidemics. For example, in Simbu Province the prevalence rate of malaria 
parasites was around 5% and climbed up to 13-36% during epidemics.(Mueller, 
Kundi et al. 2004) Important variations can also occur in low land areas, the 
South part of the country (much dryer) and some Islands having a lower 
endemicity.(Mueller, Bockarie et al. 2003) Other factors such as distance to 
health facilities have also been described to significantly change the distribution 
of malaria: the longer the distance is the higher the prevalence of malaria is. 
(Myers, Myers et al. 2009) In past surveys, the entomological inoculation rate 
(EIR) varied between 1-400 (Mueller, Bockarie et al. 2003). 
Transmission of malaria is perennial on costal areas with limited variations 
across seasons. (Mueller, Bockarie et al. 2003) All four species of plasmodium 
are present in PNG. Plasmodium falciparum (Pf) and Plasmodium vivax (Pv) are 
more or less equally prevalent in PNG. (Mueller, Kundi et al. 2004) However, this 
ratio can vary from one place to another, sometimes in favor of Pf and sometimes 
in favor of Pv. The age pattern of Pf and Pv clinical infections are different, Pv 
being more frequently associated with diseases in younger age.(Lin, Kiniboro et 
al. 2010) Mixed infections with two or more species are also frequently reported. 
(Mehlotra, Lorry et al. 2000)  
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Figure 1-1: Geographical distribution of the reported number of suspected 
malaria cases per 1000 persons for the year 2008 in PNG 
(WHO 2009) 
 
 
1.1.3 Diagnosis of malaria in routine practice 
For very long, presumptive diagnosis was used to guide treatment in endemic 
areas. This means that patients visiting health facilities with fever or history of 
fever were treated with antimalarials. This strategy, advocated by WHO for many 
years, is no longer acceptable because of the lack of specificity of fever to make 
the diagnosis of malaria (D'Acremont, Lengeler et al. 2009). Indeed, this has led 
to the rapid increase of resistance of parasites against antimalarial drugs, the 
potential for patients to experience unnecessary side effects and to delay proper 
management of other causes of fever.  Therefore, new recommendations include 
the need to confirm a malaria infection by either microscopy or RDT. (WHO 
2010) If the reading of blood smears (thick and thin films) is still considered by 
some experts to be the gold standard to confirm clinical malaria it has also 
limitations in routine practice. Indeed, it requires highly skilled microscopists, 
important resources and takes a lot of time.  
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Nowadays, there is growing evidence that RDT could be the best option for an 
accurate and easy to perform diagnosis of malaria in routine practice. 
(D'Acremont, Lengeler et al. 2009) All RDT for malaria are working on the same 
principle. They are based on the detection of circulating antigens of malaria 
parasites. Usually, an antigen common to all malaria species, the parasite-
specific lactate dehydrogenase (pLDH) and an antigen specific for Pf 
identification, histidine-rich protein-2 (HRP2) are used. Depending on the local 
epidemiological context, only one of the antigens will be used. For example, in 
Africa, mainly RDT detecting HRP2 are used as Pf is the predominant species.  
On the other hand, in regions such as PNG where both Pv and Pf species are 
present, a test combining both antigens need to be used. Identification of 
antigens is based on antibodies - antigens reactions. After adding a buffer to a 
few µl of blood, liquid will migrate on filter paper where specific antibodies are 
bound to the strip and will react in case of presence of antigens. One or more 
color lines will then appear on the strip of test allowing the health worker to 
confirm or not a malarial diagnosis. Performances of RDT have been investigated 
by WHO(WHO 2008) and the usual accepted threshold for parasites detection is 
100 parasites/µl. It is however clear, that detecting antigens is not the same thing 
as detecting whole parasites, therefore RDT and microcpy should not be seen as 
looking exactly at the same thing and should not be directly compared in terms of 
performances, especially when assessing patients that were recently treated. All 
these procedures are explained in details in a document published by WHO. 
(WHO 2006)  
1.1.4 Diagnosis of malaria in PNG 
In PNG, until recently, most health facilities were still using presumptive 
diagnosis for malaria. Only reference hospitals could usually perform a 
microscopy examination of blood films. A national program was launched in 2010 
and aim to implement RDT-based diagnosis in all health facilities.  
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In the present study, we used a RDT able to detect both antigens for all species 
and specific for Pf (ICT combo®, Cape Town, South Africa). Figure 1.2 shows a 
picture of the test used.  
 
Figure 1-2: ICT Combo® malaria RDT with it interpretation 
 
 
 
If the performances of these tests are well established in African countries where 
Pf is the predominant species, their effectiveness in children under 5 years in 
regions of the world with a high burden of non-Pf infections remain unknown. 
Indeed, these tests are known to have a lower sensitivity for Pv. This important 
issue will be addressed in chapter 4.  
 
1.1.5 Treatment of malaria 
One of the main achievements for malaria treatment in the past 10 years is the 
successful introduction of highly efficacious artemininin combination therapies 
(ACT). Indeed, the “rediscovery” of artemisinin, an old Chinese drug, and its 
derivates (artemether, artesunate,…) has significantly changed the face of 
malaria treatment.  This highly effective, well tolerated and short acting drug has 
been introduced in many African countries as first line treatment in combination 
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with a long acting drug. One of the most well known combinations is artemether-
lumefantrine (AL, Coartem® manufactured by Novartis, Switzerland).  
1.1.6 Treatment of malaria in PNG 
Unlike Africa, PNG did not change its malaria treatment policy until 2010. Indeed, 
first line treatment for children was a combination of a single dose sulphadoxyne-
pyrimethamine (SP) and 3 days amodiaquine (AQ) or chloroquine (CL). Second 
line treatment was SP associated to 3 days of artesunate (AS). Patients with 
severe malaria received im artemether with oral SP or quinine in second line. 
Resistance levels against SP, AQ and CL are very high in PNG.(Marfurt, de 
Monbrison et al. 2008) Reasons for not having changed policies are numerous, 
but the most important was the lack of scientific evidence on the efficacy of the 
new ACT on non-Pf malaria. (Douglas, NM. et al. 2010) Only very limited highly 
controlled trials have specifically looked at their efficacy against Pv and 
concluded that efficacy might be sub-optimal. (Karunajeewa, Mueller et al. 2008) 
Effectiveness of AL in PNG will be discussed in chapter 4. More generally, it is of 
interest to clarify if AL could be used as a unified therapy, meaning that it is able 
to treat all malaria species, which might be relevant in regions of the world highly 
endemic for Pf and Pv such as PNG. AL was the drug used to treat malaria 
episodes in children enrolled in the IPTi trial (see below).  
 
1.1.7 Malaria control strategies 
Malaria control programs that were implemented in the last decade in most 
endemic countries were successful and contributed to dramatically decrease the 
endemicity of malaria worldwide. (Feachem, Phillips et al. 2010) Beside the 
important increases of financial resources and a better political commitment, 
interventions such insecticide treated nets (ITN), (Lengeler 2004) indoor residual 
spraying (IRS), (Pluess, Tanser et al. 2010) accurate diagnosis based on rapid 
diagnostic tests (RDT) and  efficient treatment based on artemisinin combination 
therapies (ACT) have demonstrated to be efficient tools to decrease the burden 
of malaria. (Ansah, Narh-Bana et al. 2010; d'Acremont, Malila et al. 2010 ; 
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Uzochukwu, Onwujekwe et al. 2011) Due to these efficient strategies, almost half 
of the endemic countries (42 out of 98) have reported a decrease of 50% or more 
over the past 10 years. (WHO 2010)  
 
1.1.8 Malaria control strategies in PNG 
Unlike many countries, Papua New Guinea is still facing high malaria endemicity 
in most parts of the country and no reduction was observed in the past decade. 
This is mainly due to delays in implementing control strategies. Indeed, ITN were 
only introduced in the country in 2009, IRS is not yet available and ACT-based 
treatments are only going to be implemented in 2011. This is especially 
preoccupying as most of the surrounding countries such as Indonesia and 
Salomon Islands are on the way towards malaria elimination through an 
international initiative called the Asia Pacific Malaria Elimination 
Network.(APMEN)  
 
1.2 Expanded program of immunization (EPI) and mother & 
child health clinics (MCH) 
Most developing countries have implemented their own immunization schedules, 
known as expanded program of immunization (EPI) as per the recommendations 
of WHO. The aim is to immunize infants against most common vaccine-
preventable diseases according to a standard schedule. It is usually performed 
during ad hoc health care visits, or alongside mother and child health clinics 
(MCH). Small differences between countries may exist both for the type of 
vaccines provided and the time of immunization. The PNG EPI schedule is 
shown in table 1.1.  
In PNG, immunization is provided during MCH clinics (“bebi klinik”), mainly along 
monthly outreach clinics in villages. Indeed, most of the PNG population is 
widespread in the countryside; therefore, the only way to achieve reasonable 
access to vaccine is for health workers to visit the children in their place of 
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residency instead of making the parents to come to the local health centers. This 
is not without creating organizational challenges, which is reflected by a low 
immunization coverage. For example, in 2009, the reported vaccine coverage for 
the first dose of measles was lower than 60%(WHO 2009). Figure 1.3 shows a 
typical scene of one of those clinics. 
 
Table 1-1: Immunization schedule in PNG (Hib vaccine was introduced in 
2007) 
0 1 2 3 6 9 12
BCG X
Oral polio vaccine (OPV) X X X X
Hepatitis B (HBV) X X X
Diphtheria - pertussis - tetanus (DPT) X X X
Haemophilus influenza (Hib) X X X
Measles X X
Vitamin A X X
Age (months)
 
 
 
Figure 1-3: EPI / MCH clinic in Basken village, North Coast of Madang, 
Papua New Guinea 
 
 
 
From a practical point of view, each child in PNG receives at birth a health book 
(helt buk in tok pisin) where all attendances to health facilities are recorded 
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(figure 1.4). This includes the vaccine status and a brief summary of each 
medical visit performed (history, diagnosis and treatment)   
 
Figure 1-4: Nurses checking health books of sick children during outreach 
MCH clinics & a cover page of a health book 
 
                 
 
1.3 General concept of IPTi 
Several preventive interventions have proven to be efficient in reducing to risk of 
malaria. Apart from ITN and IRS, intermittent preventive treatments (IPT) have 
demonstrated some benefits, in particular in pregnant women (IPTp). (Rogerson, 
Chaluluka et al. 2000) The overall concept is to deliver a full treatment of 
antimalarial drugs to a given population at fix intervals independently of the 
malaria status. The concept of intermittent preventive treatment in infants (IPTi) 
was developed in the late 90’. The aim is to use EPI facilities to deliver 
antimalarial treatments to infants at the same time as they come for the 
immunization during the first year of life. WHO is recommending IPTp in all 
endemic areas and IPTi in some regions with high a endemiciy of malaria (WHO 
2010). 
 
Several randomized control trials have investigated IPTi in different African 
countries with various drug regimens. Sulfadoxine-pyrimethamine (SP) 
dispensed as a single dose three or four times during the first year of life is the 
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most studied drug and has shown to have a protective efficacy against clinical 
malaria episodes of 30% and 21% against anemia (Aponte, Schellenberg et al. 
2009). IPTi with SP is still effective in areas with moderate resistance (Mayor 
2008; Griffin, Cairns et al. 2010), however, when resistance raises, SP appears 
to fail to prevent malaria (Gesase, Gosling et al. 2009; Gosling, Gesase et al. 
2009). Two clinical trials have investigated other drug regimens including 
mefloquine (125 mg single dose), a combination of single dose of SP and 3 days 
of artesunate (AS) or amodiaquine associated to 3 days of AS. All these 
treatments have similar efficacies compare to SP used alone, ranging from 26 to 
38% (Gosling, Gesase et al. 2009; Odhiambo, Hamel et al. 2010). While 
mefloquine showed the highest efficacy, its tolerability was poor. Shorter acting 
drug such as dapsone/chlorproguanil used alone did not show any efficacy 
against malaria (Gosling, Gesase et al. 2009; Odhiambo, Hamel et al. 2010). 
This is probably due to the fact that IPTi works mainly through a prophylactic 
effect achieved by long acting drugs (prevention of new infections) rather than 
through a therapeutic effect (cure of existing parastiemia). (May, Adjei et al. 
2008) Table 1.2 is summarizing the characteristics and main outcomes of the 
different trials. 
 
All IPTi studies have been exclusively carried out in Africa where Pf is the 
predominant parasite. No studies have been done in regions also highly endemic 
for Pv, which is a major source of morbidities in young children. African results 
cannot be easily extrapolated to these regions, because of the ability of Pv to 
relapse from dormant forms in the liver and to quickly acquired resistance to SP 
(Tjitra, Anstey et al. 2008). 
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Table 1.2: Main characteristics and outcomes of the height IPTi trials carried out in Africa 
Investigators place
Endemicity of 
malaria 
(incidence)
drugs 
regimen*
number of 
doses
morbidity & 
follow-up**
Iron 
suppl.
treatment for 
acute malaria
Protective 
efficacy 
malaria
Protective 
efficacy anemia
 (<8 g/dl)
Protective 
efficacy 
hospit.
Protective 
efficacy on 
outpatient visits
Schellenberg 
 Tanzania 0.43 SP (stat) 2M-3M-9M Passive +2 CS
Yes 
regular SP + quinine 59% 50% 30% no
Chandramohan 
 Ghana 1 SP (stat) 3M-4M-9M-12M
Passive +
 4 CS 
Yes 
regular
CQ + SP or 
quinine 25% no
35% 
(anemia)
only 1 month 
after dose 
1(OR=0.8) & 3 
(OR=0.71)
Macete Mozambique 0.55 SP (stat) 3M-4M-9M Passive + 2CS none Quinine 22%
70-81% 1 month 
after dose 1 &2 19%
only 1 month 
after dose 1 for 
chest indrawing 
(RR=0.57)
Kobbe Ghana 1.29 SP (stat) 3M-9M-15M Passive +CS monthly none Art + AQ
20% (After 
first 2 doses 
only)
30% (after dose 1 
only) no no
Grobusch 
 Gabon 0.22 SP (stat) 3M-9M-15M Passive +CS monthly none
AS5  then AS-
AQ
no (17% no 
sign) no (22% no sign) no n/a
Mockenhaupt Ghana hyperendemic SP (stat) 3M-9M-15M Passive +CS 3-monthly  if Hb low AS 5d 23% 24%
33% (1 
month after 
dose 1)
no
Gossling Tanzania (2 sites)
moderate and 
low 
MEF (stat)
SP (stat) 
 CD (stat)
2M-3M-9M Passive +5 CS  if Hb low
AQ then Art + 
AQ then 
Coartem
38% (MEF) no no n/a
Odhiambo Kenya app. 1.0 (seasonal)
SP (stat) 
AQ- AS3
CD3
2M-3M-9M Passive Yes 
regular
Quinine then 
Coartem
26% (SP-AS)
26% (AQ-AS) no no no
* SP (stat): sulphadoxyne-pyrimethamine single dose, AS: artesunate, MEF=mefloquine, CD: chlorproguanil - dapsone, AQ: amodiaquine, stat=single dose
** CS: cross-sectional surveys (active case detection)
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1.4 Burden of diseases and integrated management of 
childhood illness (IMCI) in Papua New Guinea 
 
In children under five years, pneumonia, malaria and diarrhoea are the leading 
causes of death worldwide with an estimate of 5 millions of deaths yearly. More 
than 90% of them occurred in Africa and countries with limited resources(Bryce, 
Boschi-Pinto et al. 2005). Morbidity reveals similar pattern with acute respiratory 
infections, diarrhea and malaria being responsible for the majority of the burden 
of diseases in developing countries. (Velema, Alihonou et al. 1991; Roca, Quinto 
et al. 2006; Deressa, Ali et al. 2007; Animut, Mekonnen et al. 2009; Feikin, Olack 
et al. 2011). In PNG, very limited data are available on the burden of diseases 
apart from those collected through sporadic local surveys. Indeed, except for 
malaria, rotavirus and vaccine-preventable diseases, no regular surveillance 
system exists in the country. (WHO 2009)  
Case management of sick children under five in developing countries is usually 
based on syndromes (presence/absence of signs and symptoms) rather than on 
etiologies. This strategy has been recommended by the World Health 
Organization (WHO) who developed the Integrated Management of Childhood 
Illness (IMCI)(Gove 1997)  guidelines for this purpose. Most of the developing 
countries have adapted these strategies. PNG makes no exception and has 
adopted the IMCI guidelines. The only changes made compare to the original 
from WHO are modifications made to stick to the local epidemiology of certain 
diseases. For example, a special section for Pigbel (a severe gastro-intestinal 
disease) has been added to the guidelines, including immunization and special 
care recommendations.  
Few studies have looked at the performances of IMCI and potential ways to 
improve it in PNG. (Moti and Vince 2008 Sep-Dec) This will be the aim of 
chapter 6, where in-depth investigations of the appropriateness of IMCI as well 
as the potential benefits of adding RDT for malaria and IPTi to IMCI will be 
discussed.   
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2 Goal, objectives and methods 
2.1 Goal  
Exploring the context of children’s health in Papua New Guinea and the potential 
benefits of implementing an Intermittent Preventive Treatment for malaria in 
infants (IPTi)  
2.2 Objectives 
 
Objective 1 
Assessing population hemoglobin means and anemia prevalence used as 
metrics for defining malaria endemicity 
 
Objective 2 
Assessing the effectiveness of treating young children with a unified treatment of 
artemether-lumefantrine based on RDT result in PNG, a highly endemic country 
for Plasmodium falciparum and vivax 
 
Objective 3 
Investigating the efficacy of IPTi with Sulphadoxine/Pyrimethamine  associated to 
either amodiaquine or artesunate on malaria-related morbidity and anemia in 
Papua New Guinea (all species) 
 
Objective 4 
 
Investigating the potential benefits on diseases management of updating IMCI 
with rapid diagnostic test and intermittent preventive treatment for malaria in 
PNG 
 
Objective 5 
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Investigating the community response (acceptability) to intermittent preventive 
treatment of malaria in infants (IPTi) in PNG 
 
2.3 Methods  
Preliminary comment 
Except for chapter 3, all data used for the present work were collected 
exclusively alongside a randomized controlled trial (RCT) carried out in PNG. 
Therefore the next two sections (2.3.1 and 2.3.2) refer to this trial.  
 
2.3.1 Brief outline of the design of each of the objective 
Objective 1 
Convenience sample, multisite cross-sectional household surveys. Correlations 
(r2) between population Hb mean and anemia prevalence and altitude, parasite 
rate and spleen rate were investigated in children age 2-10 years and in the 
general population 
Objective 2 
Longitudinal prospective study assessing rates of re-attendance and occurrence 
of serious adverse events according to RDT results and treatment with AL if 
positive 
Objective 3 
 Individually randomized, double blind, placebo-controlled trial of two different 
regimes [sulfadoxine/pyrimethamine (stat) with either 3 days of amodiaquine 
(SP-AQ3) or 3 days of artesunate (SP-AS3)] of IPTI 
Objective 4 
Longitudinal study assessing the performances of IMCI+ by looking at the 
accuracy of diagnosis, the rates of antibiotics’ prescriptions, the re-attendance 
rates according to the initial diagnosis and treatment and the efficacy of IPTi on 
the overall morbidity and main syndromes 
Objective 5 
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Qualitative assessment of the acceptability of IPTi by administrating 
questionnaires to mothers whose infants participated in the randomised placebo 
controlled trial of IPTi. Mothers whose infants participated and who refused to 
participate in the trial, health workers, community reporters and opinion leaders 
were interviewed. Men and women from the local community also participated in 
focus group discussions.  
 
2.4 IPTi study design and procedures  
Between 2006 and 2010 a RCT on intermittent preventive treatment for malaria 
in infants (IPTi) was carried out in two provinces of PNG: Madang and Maprik. It 
was a double blind, placebo-controlled trial of two different drugs regimes: 
sulfadoxine/pyrimethamine (stat) with either 3 days of amodiaquine (SP-AQ3) or 
3 days of artesunate (SP-AS3). All drugs were given at EPI time points at 3, 6, 9 
& 12 months (see table 1.1 for vaccines schedule, chapter 1). The efficacy of the 
intervention was assessed at 15 months of age.  Afterwards children continued to 
be monitored every 3 months for up 12 additional months (see study profile, 
table 3) 
The 40 study villages are serviced by 4 major health centres (Mugil & 
Alexishafen in Madang and Kaugia & Kunjingini in the Sepik) and several aid 
posts. All health centers are responsible to deliver the EPI program in 
surrounding villages through monthly outreach clinics. 
Infants could be enrolled in the trial if the met the following inclusion criteria: 
 1) Permanent resident of the area 
 2) Aged 2-4 months old 
 3) No disability 
 4) No chronic illness 
 5) No allergy to study drugs 
 6) Hb>5g/l 
 7) Weight for age > 60%.  
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Children were recruited into the IPTi study alongside monthly outreach MCH 
clinics by specifically trained study nurses jointly with medical staff of both health 
centres under the supervision of two study physicians. Regular meetings were 
carried out to train study nurses to high quality standards for both the study 
procedures and health care management of sick study participants (figure 2.1).  
  
Figure 2-1: Staff training session in Megiar, North Coast of Madang. 
 
 
The main activities of the IPTi trial are summarized in table 2.1 (see also chapter 
5). 
Table 2.1: Summary of visits performed along the IPTi study 
Type of Visit
2 3 6 9 12 15 18 21 24 27
Pre-screening
IPTi treatment IPTi 1 IPTi 2 IPTi 3 IPTi 4
Primary efficacy assessment
Follow-up 
Final assessment
Passive case detection
OPV3 OPV4
HBV3
DPT2 DPT3
Meas 1Meas 2
Vit A Vit A
During schedulded visits
 blood collection from finger prick 500µl 250µl 250µl 1 ml 250µl 250µl 250µl 250µl 1ml
Hb level & spleen measurment 
Age (months)
Immunization
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Throughout the study period, a passive case detection system was maintained at 
all health facilities where all study participants were reviewed when they were 
sick. In case of history of fever, axillary temperature > 37.5° or signs/symptoms of 
anemia, the children had a finger prick performed for malaria (RDT) and anemia 
diagnosis. Apart from malaria and anemia, sick study participants were treated 
according to IMCI.   
See chapter 5 and appendix 3 for details on the procedures of the trial. 
 
2.5 Study area and population 
2.5.1 Study area  
Papua New Guinea occupies the eastern part of the tropical island of New 
Guinea (which is shared with the Indonesian’s territory of Irian Jaya) as well as 
numerous smaller islands and atolls in the Pacific, for an area of more than 
460’000 sq km (figure 2.2). The central part of the island rises into a wide ridge 
of mountains known as the Highlands (Higher summit: Mt Wilhelm, 4509 meters). 
The coastlines of these islands are volcanic, with steep mountain ranges. The 
climate is tropical with constant temperature all year around (24°C – 37°C) and 
abundant rainfalls during the rainy season (October to June).  
Most of the project took place in the coastal and lowland provinces of Madang 
and East Sepik (approximately 500’000 people). Some data used for 
investigating the relationship between malaria and anemia (chapter 3) were 
collected throughout the Highlands. 
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Figure 2-2: Map of PNG with study area 
 
2.5.2 Study population  
About 6.5 millions people are leaving in PNG. The cultural diversity is very broad 
with more than 800 different languages and as many different communities. Most 
of the population is leaving in rural areas (about 85%) and the literacy rate, with 
56%, is one of the lowest in the Pacific region. Life expectancy at birth is 53 
years, the fertility rate is 4.6 births/women and the population growth is 2.7%. 
The study population is exclusively situated in rural areas. Most of the 
participants are leaving in two well delimited regions: Sumkar district (Madang 
Province) and Maprik district (East Sepik Province). It is estimated that a 
population of about 40’000 people are leaving in these two areas.  
 
2.5.3 Ethics 
The study was carried out in accordance with Good Clinical Practice (GCP) 
guidelines as required by the International Conference on Harmonization (ICH) 
GCP E6 and monitored by an independent external monitor. A data and safety 
monitoring board (DSMB) composed of 2 clinicians and one statistician was 
responsible to monitor the safety of the study. The protocol was approved by the 
PNG Medical Research Advisory Committee (MRAC number 05.20). The trial 
was registered on www.clinicaltrials.gov (number NCT00285662) and formed 
part of the IPTi consortium (www.ipti-malaria.org).  
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Parents of study participants had to sign a written consent. In case of illiteracy, a 
witness was asked to sign. Systematically, a picture-based information notice 
was shown and given to parents (See Appendix 1) 
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3.1 Abstract 
Background  
The hypothesis is that hemoglobin-based metrics are useful tools for estimating 
malaria endemicity and for monitoring malaria control strategies. The aim of this 
study is to compare population hemoglobin mean  and anemia prevalence to 
established indicators of malaria endemicity, including parasite rates, rates of 
enlarged spleens in children and records of (presumptive) malaria diagnosis 
among populations living with different levels of malaria transmission. 
 
Methodology / Principal Findings 
Convenience sample, multisite cross-sectional household surveys conducted in 
Papua New Guinea (PNG). Correlations (r2) between population Hb mean and 
anemia prevalence and altitude, parasite rate and spleen rate were investigated 
in children age 2-10 years and in the general population. 21,664 individuals from 
156 different communities were surveyed. Altitude ranged from 5 to 2120m. In 
young children, correlations between altitude and parasite rate, population Hb 
mean, anemia prevalence and spleen rate were high (r2: -0.77, 0.73, -0.81 and -
0.68; p<0.001). In the general population, correlations between altitude and 
population Hb mean and anemia prevalence were 0.83 and 0.85, respectively. 
Among young children, parasite rate correlated highly with anemia prevalence, 
population Hb mean and spleen rate (r2: 0.81, -0.81 and 0.86; p<0.001). 
Population Hb mean (corrected for direct altitude effects) increased with altitude, 
from 10.5 g/dl at <500 m to 12.8 g/dl at >1500 m (p<0.001)  
 
Conclusions 
In PNG, where Plasmodium vivax accounts for an important part of all malaria 
infections, population hemoglobin mean and anemia prevalence correlate well 
with altitude, parasite and spleen rates. Hb measurement is simple and 
affordable, and may be a useful new tool, alone or in association with other 
metrics, for estimating malaria endemicity and monitoring effectiveness of 
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malaria control programs. Further prospective studies in areas with different 
malaria epidemiology and different factors contributing to the burden of anemia 
are warranted to investigate the usefulness of Hb metrics in monitoring malaria 
transmission intensity. 
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3.2 Introduction 
Malaria, with about 500 million cases reported per year worldwide, remains one 
of the predominant diseases in tropical countries. The intensity of malaria 
transmission depends on a variety of factors such as climate and geographical 
context, human population, socio-economical level and vector ecology, as well as 
the type of control strategies in place. Nowadays, several efficient strategies are 
being used to decrease the malaria burden. Most prominent among them are 
insecticide treated bed nets (ITN), indoors residual spraying (IRS), artemisinin 
combination treatments (ACT)(Ogbonna and Uneke ; Lengeler 2004; Beier, 
Keating et al. 2008) and intermittent preventive treatment strategies in pregnant 
women or infants(Meremikwu, Donegan et al. 2008). Adequately and simply 
measuring malaria endemicity is thus of prime importance in order to plan and 
monitor effectiveness of these control interventions.  
 
Different tools and metrics have been used for more than 150 years to 
investigate the level of malaria endemicity in a given population. Traditionally, the 
spleen rate (SR), i.e. the prevalence of splenomegaly in a population, has been 
used to classify malarial endemicity(Dempster 1848 (reprint in 1930)). This 
measure however suffers from a lack of specificity. Indeed, many diseases highly 
prevalent in the tropics may also lead to splenomegaly like visceral leishmaniasis 
or schistosomiasis. More importantly, it has been shown in Papua New Guinea 
(PNG) by Brabin et al. that the spleen rate may vary between sub-populations of 
non-pregnant women with similar levels of exposure to malaria(Brabin, Brabin et 
al. 1988), probably due to differences in immune response to malaria. 
Splenomegaly can also be difficult to measure reproducibly.  
 
In the 1950’s, the prevalence of blood stage malaria parasites (parasite rate for 
all species, PR) was introduced as the principal metric for monitoring malarial 
endemicity and remains the method of choice(Metselaar and Van Theil 1959). 
This metric is much more specific but tends to be influenced by seasonal 
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fluctuations and is strongly age-dependent. In addition, it requires blood 
collection and expert microscopy that may not be available in resource-limited 
settings. Utilizing both SR and PR in children 2-10 years, a classification of 
malaria endemicity was proposed by WHO and revised by Metselaar et 
al(Metselaar and Van Theil 1959): hypoendemic if SR 2-10 or PR 2-10 is <10%, 
mesoendemic if SR 2-10 or PR 2-10 is 10-50%, hyperendemic if SR 2-10 or PR 
2-10 is 51-75% and holoendemic if SR 2-10 or PR in children < 1year is >75%. 
These measures may provide good estimates of malaria endemicity in areas 
where malaria is highly prevalent, but they are less accurate when malaria 
transmission is lower(Yekutiel 1960) such as in an aggressive control program. 
The Annual Parasite Incidence (API = number of malaria cases/population, 
usually expressed per 1000, a malaria episode is confirmed by a positive blood 
slide) is thus often used in areas of lower transmission. However, this metric 
requires even more resources than measuring PR including a reliable reporting 
system for malarial episodes.  
 
All these different metrics have been integrated into control strategies such as 
the Global Malaria Eradication Programme coordinated by the World Health 
Organization (WHO) since the mid 1950’s. More recently the Malaria Atlas 
Project (www.map.ox.ac.uk), used the Plasmodium falciparum (Pf) parasite Rate 
(PfPR), usually in children 2-10 years(Smith, Guerra et al. 2007), and Pf Annual 
Parasite Incidence (PfAPI) to map Pf endemicity. As part of this work, Hay and 
colleagues published an extensive and detailed review on the tools and 
strategies available to monitor malaria endemicity (Hay, Smith et al. 2008).   
 
Given the limitations of the traditionally used measures of malaria endemicity 
outlined above, there is therefore a need to identify additional easily 
implementable tools for the accurate measurement of malaria endemicity in a 
variety of transmission settings.  
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It is well known that one of the main clinical features of malaria at an individual 
level is a fall in hemoglobin (Hb), often resulting in anemia (Hedberg, Shaffer et 
al. 1993; Slutsker, Taylor et al. 1994 ; Price, Simpson et al. 2001). However, little 
is known of how Hb varies at a population level relative to changes in malaria 
transmission intensity. Two studies have shown associations between altitude 
variations and changes in malaria prevalence, with Pf prevalence decreasing with 
altitude(Akhwale, Lum et al. 2004; Drakeley, Carneiro et al. 2005). In the same 
studies, Hb concentrations of individuals were also found to increase with 
altitude. This suggests that both the population hemoglobin mean (popHb) and 
anemia prevalence (AP), following correction for altitude, correlate directly with 
the variations of malaria transmission intensity and may thus be useful as 
measures of malaria endemicity. However, the evidence for this direct correlation 
is lacking as the existing data are limited by the sample size or the number of 
locations. Furthermore, all studies have been performed in Africa where Pf is the 
predominant species. Therefore, there is a need to investigate the association 
between Hb measurements at a population level and malaria in larger datasets 
from areas with a wider range of altitude, malaria prevalence and plasmodium 
species.  
 
PNG is situated in the South-West Pacific and presents a wide range of malaria 
endemicity due to its mountainous geography, ranging from highly prevalent at 
sea level to absent in the highlands (up to 4000 meters)(Mueller, Bockarie et al. 
2003). Another characteristic of PNG is that all four species of plasmodium are 
present, with Plasmodium falciparum (Pf) responsible for more than 50% of all 
clinical malaria episodes, and Plasmodium vivax (Pv)  being responsible for most 
of the remaining cases. In past surveys, entomological inoculation rate (EIR) has 
varied between <1 and 400(Mueller, Bockarie et al. 2003). Overall, malaria is the 
main cause of hospital admissions in lowland areas, but is absent in much of the 
highlands. Thus, PNG is an ideal site to investigate the relationship and 
correlation between classical measures of malaria transmission intensity, altitude 
and variations of population Hb levels and anemia prevalence.  
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3.3 Methods 
Study site and patients 
Individual informed consent was obtained from all participants or in case of 
children their guardians before enrolment into the study. Malaria surveys 
conducted in the Highlands of PNG (Mueller, Bjorge et al. 2003; Mueller, Taime 
et al. 2003; Mueller, Kundi et al. 2004; Mueller, Ousari et al. 2006) were 
performed on behalf of the PNG National Department of Health and the consent 
was verbal. In the lowlands surveys that were parts of research studies, written 
consent was obtained. All participants specifically consented for a finger prick 
blood sample to be collected and assessed for the presence of malaria and 
anaemia. This Consent process was approved by the PNG Medical Research 
Advisory Council of Papua New Guinea (respective approval numbers are: 
Highlands: 00.26, Sepik: 05.08 and Madang: 05.20)  
The study was performed in PNG alongside a series of household malaria 
surveys performed in three different regions of the country: the Highlands (inland, 
500 – 2100m), the Middle Sepik (lowland, <500 m) and Madang (coastal, 
<500m). The different villages were chosen according to their location and 
representativeness in terms of presumptive malaria endemicity and population 
diversity. Further details of the selection of Highlands and Sepik survey locations 
and of the survey methodology are given by Mueller et al. (2003-2009) (Mueller, 
Bjorge et al. 2003; Mueller, Taime et al. 2003; Mueller, Kundi et al. 2004; Mueller, 
Ousari et al. 2006; Mueller, Sie et al. 2007; Mueller, Yala et al. 2007; Mueller, 
Widmer et al. 2009; Maraga, Plüss et al. in press). In short, within each village a 
household based survey was conducted using convenience sampling. All 
members of a participating household were enrolled in the surveys after 
individual consent. Medical history of malaria (history of fever, treatment for 
malaria and other spontaneously reported symptoms) and a brief medical 
examination including spleen measurement (using Hackett’s classification), 
axillary temperature and targeted clinical examination were performed. All 
patients presenting with signs or symptoms of malaria had a rapid diagnostic test 
performed, and malaria treatment was provided if positive. A finger prick was 
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performed on each participant, blood slides with thick and thin films for malaria 
microscopy were made and Hb was measured using a portable Hemocue 201® 
machine (Angelholm, Sweden) in g/dl.  The Madang surveys were conducted in 
the context of preparatory works for a trial of intermittent preventive treatment in 
infants (IPTi), using the same methodology. Surveys conducted in villages with 
epidemic outbreaks of malaria were not used for this study.  
All blood smears were stained with 2.5% buffered Giemsa (pH 7.2) for 35 
minutes and examined by light microscopy. Slides were declared negative if no 
parasites were seen in 100 thick film fields by two different microscopists. The 
parasite species in positive films were identified and densities were recorded as 
the number of parasites/200 WBC. Densities were calculated assuming 8,000 
WBC/µl (Genton, Al Yaman et al. 1995). All slides with densities less than 200/µl, 
along with a randomly selected 20% of all blood films were routinely re-
examined. If less than 80% concordance was achieved between evaluations, the 
entire batch of slides was re-read.      
 
There is no standardized cut-off value for defining anemia for individuals (Beutler 
and Waalen 2006) in tropical countries. In order to calculate the prevalence of 
anemia (AP) for each community, we defined a cut-off value of 11g/dl which is 
clinically meaningful, easy to interpret from a public health perspective and gives 
a good proxy to anemia (see supplementary material). Crude and adjusted 
population hemoglobin mean values (popHb) were calculated for all communities. 
Adjustment was done for sex, age and altitude. Sex and age were adjusted using 
non-parametric regression splines. Hb was adjusted for altitude using the model 
published by the CDC (CDC 1989; CDC 1998; Ruiz-Arguelles 2006) with the 
following formula calculating the correcting factor for the different Hb values: ∆Hb 
[g/L] = -0.32 x (altitude[m] x 0.0033) + 0.22 x (altitude[m] x 0.0033)2.  
All metrics (popHb, AP, SR and PR) were calculated for both the general 
population and children 2-10 years. Indeed, spleen rate and parasite rate are 
usually calculated in this age group for defining malaria endemicity 
categories(Metselaar and Van Theil 1959).   
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Statistical methods 
All data were analyzed using STATA software, version 10.0.  Correlations 
between the different metrics and altitude were investigated by calculating 
Pearson’s correlation coefficients (r2); significance was assessed by calculating 
p-values. The same software was used to draw a graph of the correlations 
between the different metrics weighted for the number of individuals per village. 
We performed also an ANOVA analysis to investigate the variation of the 
different metrics across altitude strata. As both Hb metrics and prevalence of 
infection are subject to measurement and sampling errors, major axis regression 
(Smith 2009) was used to determine the symmetric relationship between Hb 
metrics and prevalence of infection in children 2-10 yrs. The resulting 
relationships are bi-directional, i.e. prevalence of infection can be predicted from 
Hb metrics and vice versa All analyses were done on data aggregated at the 
village/population level and did not include measures of individual level variation. 
 
3.4 Results 
21,664 individuals from 156 different communities were surveyed from the 
Highlands, Madang and Sepik areas, altitudes ranged from 5 to 2120m above 
sea level. On average there were 143 participants in a village (range [35 - 387]). 
Overall, the median for age was 14.9 years (range [0 - 99]) with 51.4% of 
participants female.  Among the villages, 27 were at elevations below 500m, 17 
were between 500 and 999m, 55 were between 1000 and 1499m and 57 were 
above 1500m altitude. The ratio of Pf/Pv prevalence rates among the 145 
villages is 2.04 (range [0 - 17]) 
 The PR in 2-10 (F3, 148= 75.6, p < 0.001) and SR 2-10 (F3,147= 47.0, p < 0.001) 
were found to decrease significantly from 58.1 % and 37.8% in villages < 500 m 
to 4.3% and 1.6% in those >1500 m. AP also decreased significantly with altitude 
(<500 m: 62.8%, >1500 m: 12.3%, F3,143= 114.0, p < 0.001) while PopHb 
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increased (altitude adjusted: <500 m 10.5g/dl, >1500 m 12.8 g/dl, F3,148= 74.3, p 
< 0.001). Complete altitude stratification data are shown in Table 3.1.  
Overall, very high correlations were observed between altitude and the different 
metrics for malaria endemicity, as shown in table 2, both in the general 
population: PR = -0.80, SR = -0.60, crude popHb =0.83 and AP = -0.85 and in 
children 2-10 years: PR 2-10 = -0.77, SR 2-10 = -0.68, crude popHb 2-10 = 0.73 
and AP 2-10 = -0.81 (all correlations: n = 156, p < 0.001). Similarly high 
correlations were found between PR (overall and in children 2-10) and other 
metrics (Table 3.2, p < 0.001). Plots of individual measures however do reveal 
differences between the different measures (Figure 3.1).  
 
PopHb and AR decrease linearly at altitudes above 500 m but do vary less at 
lower altitudes, while at altitude > 1500 m rates of enlarged spleens were very 
low. Accordingly, the strength of the association between the different metrics 
varied across altitudinal strata (Table 3.3). The correlations between Hb metrics 
(popHb and AP) and PR 2-10 were strongest between 1000-1499 m altitude, and 
disappeared above 1500 m: r2 < 500 m: -0.42 & 0.48, 500 – 999 m: -0.53 & 0.43, 
1000 – 1499 m: -0.62 & 0.68 and >=1500 m: -0.14 & 0.2. 
Using major axis regression, the following relationships were found to best 
describe the (linear) relationship between Hb metrics and the prevalence of 
infections in children 2 to 10 years and Hb metrics: P2to10 = 0.854 * AP – 0.162 
and P2to10 = -0.204 * PopHB + 2.73. 
  
31
Figure 3-1: Scatter plots of correlations with altitude and Parasite Rate 2-10 years for different metrics. 
The different metrics are: Population hemoglobin mean (PopHb), Anemia Prevalence (AP), both in general 
population and 2-10 years and Spleen Rate in 2-10 years (SR 2-10). Each circle represents one village.  
 
  
32
Table 3-1: Metrics for village malaria endemicity by altitude. AP = anemia prevalence, SR 2-10 = spleen rate in 
children 2 to 10 years and PR 2-10 = parasite rate in children 2 to 10 years. 
Altitude < 500m 500 - 999 m 1000 - 1499 m > 1500m
n=27 n = 17 n=55 n=57 p
Mean CI95% range Mean CI95% range Mean CI95% range Mean CI95% range
PopHb (crude) 10.5 10.4-10.7 9.0-11.3 11.2 10.9-11.6 10.0-12.9 12.4 12.2-12.6 10.5-14.4 13.3 13.1-13.4 11.7-14.7 < 0.001
PopHb Adj* 10.5 10.4-10.7 9.0-11.3 11.2 10.8-11.5 10.0-12.8 12.2 11.9-12.4 10.2-14.1 12.8 10.4-10.7 11.4-14.2 < 0.001
AP 0.63 0.60-0.66 0.52-0.82 0.46 0.39-0.53 0.17-0.68 0.25 0.21-0.29 0.01-0.58 0.12 0.1-0.14 0-0.35 < 0.001
SR 2 - 10 0.38 0.31-0.44 0-0.6 0.36 0.23-0.49 0-0.75 0.12 0.08-0.16 0-0.68 0.02 0.01-0.02 0-0.14 < 0.001
PR 2- 10 0.58 0.51-0.65 0.1-0.92 0.41 0.30-0.51 0.05-0.69 0.2 0.15-0.25 0.0-0.68 0.04 0.03-0.06 0.0-0.21 < 0.001
* adjusted for altitude
 
 
Table 3-2: Summary of Pearson's coefficients of correlation (r2) between altitude (Alti), population haemoglobin 
mean (PopHb) crude or adjusted (for age, sex and altitude), anaemia prevalence (AP), parasite rate (PR) and 
spleen rate (SR) in the general population (Pop) and children 2-10 years, in non-epidemic context*. AP = anemia 
prevalence, SR = spleen rate and PR = parasite rate.    
Crude PopHb 
(pop)
Crude PopHb (2-
10 y) Adjusted PopHb AP (pop) AP (2-10 y) PR (pop) PR (2-10 y) SR (pop) SR (2-10 y)
Alti 0.83 0.73 0.78 -0.85 -0.81 -0.8 -0.77 -0.6 -0.68
Crude PopHb Pop 0.94 0.99 -0.98 -0.95 -0.79 -0.81 -0.67 -0.75
2-10 years 0.95 -0.93 -0.95 -0.7 -0.77 -0.65 -0.75
Adjusted PopHb Pop -0.97 -0.94 -0.77 -0.79 -0.65 -0.74
AP Pop 0.96 0.79 0.81 0.67 0.76
2-10 years 0.75 0.79 0.65 0.74
PR Pop 0.96 0.71 0.82
2-10 years 0.76 0.86
SR Pop 0.93
2-10 years
* All coeficients have a p<0.001
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Table 3-3: Correlations between different measures of malaria endemicity by altitudinal strata. AP = anemia 
prevalence and PR 2-10 = parasite rate in children 2 to 10 years. 
Altitude < 500m 500-999m 1000-1499m >= 1500m
n=154 n=147 n=151 n=152
HbPop AR SR 2-10 HbPop AR SR 2-10 HbPop AR SR 2-10 HbPop AR SR 2-10
PR 2-10 -0.42** 0.48** 0.83* -0.53** 0.43*** 0.55** -0.62* 0.68* 0.32* -0.14*** 0.2*** 0.32**
HbPop -0.93* -0.29*** -0.96* -0.52** -0.96* -0.6* -0.9* -0.19***
AR 0.52** 0.62* 0.65* 0.18***
* p<0.01, ** p<0.05, ***p>0.05
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3.5 Discussion  
Using a very large data set from Papua New Guinea, this study has investigated 
the correlation between altitude, commonly used metrics (spleen rate and 
parasite rate in children 2 -10 years and records of febrile illnesses) and 
hemoglobin levels expressed as population mean hemoglobin (PopHb) and 
prevalence of anemia (AP) per community. As shown in earlier studies in 
Tanzania and Kenya (Akhwale, Lum et al. 2004; Drakeley, Carneiro et al. 2005), 
in PNG PR and SR were strongly correlated with altitude indicating that altitude is 
a reasonable proxy for malaria endemicity in PNG. In the present study, it was 
observed that both PopHb and AP were also strongly associated with altitude 
variations. Crude measures of Hb performed as well as those that were adjusted 
for effects of age, gender and altitude. Hb measurements were also closely 
correlated with PR and SR.  
 
In an altitude-stratified analysis, a progressive increase of PopHb is observed, 
from 10.5 g/dl on average below 500 m, to 12.8 g/dl above 1500 m, after 
correction for altitude. Of factors other than altitude itself which may explain 
these variations, malaria is likely to be the most important one. Other 
“prevalence” metrics (AP, SR 2-10 and PR 2-10) all show progressive decreases 
with increasing altitude. Correlation of Hb metrics and PR 2-10 are stronger at 
altitude between 500 and 1500 m, where endemicity is higher (see Figure 3.1 & 
Table 3.3).    
 
By nature, single cross-sectional surveys are not well suited to describe malaria 
endemicity in areas of significant seasonality. Although Hb level also show some 
seasonal variations (Koram, Owusu-Agyei et al. 2003), they are more strongly 
associated with the history of parasitaemia preceding the Hb measurement than 
with concurrent parasite densities (McElroy, ter Kuile et al. 2000). Mean Hb 
levels thus are a measure of mean exposure in the preceding 3 months rather 
than representing a single time point like parasite prevalence rate. Nevertheless, 
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when comparing Hb metrics between areas or over the time of an antimalarial 
intervention, it is important to either conduct surveys during the same period of 
the year or to adjust for seasonal variations in the relationship between malaria 
and Hb levels. 
 
Throughout PNG P. falciparum, P. vivax, P. malariae and P. ovale are co-
endemic. In most areas P. falciparum is the most common infection followed by 
P. vivax and in particular in highly endemic areas mixed species infection are 
very common (Kasehagen, Mueller et al. 2006; Mueller, Widmer et al. 2009). 
While infections with any species can result in anemia, P. falciparum infection 
tend to be associated with a stronger reduction in Hb levels (Mueller, Sie et al. 
2007; Mueller, Yala et al. 2007; Maraga, Plüss et al. in press) and the higher risk 
of severe anemia (Wildig, Michon et al. 2006; Genton, D'Acremont et al. 2008) 
than P. vivax. However, as prevalence of infection with all species increases in 
parallel with increasing endemicity, it is difficult to attribute parts of the observed 
effect of malaria on Hb levels to individual species. Consequently, overall 
prevalence rates show stronger association with Hb metrics than either P. 
falciparum or P. vivax specific prevalence rates (data not shown). Finally, it is 
likely that increasing drug resistance to malaria infections will not have the same 
effect on the different metrics. A recent study in the Gambia showed higher rates 
of severe anemia in children infected with chloroquine resistant P. falciparum 
(Meerman, Ord et al. 2005). Similarly, the high rates of severe anemia observed 
in both hospitalized P. falciparum and P. vivax patients in Indonesian Papua was 
linked to the very high rate of drug resistance (Tjitra, Anstey et al. 2008). It is thus 
possible that that an increase in drug resistance might change the pattern of 
clinical malaria episodes and that consequently Hb levels might be affected 
differently from PR. 
 
Besides malarial infections there are a number of different factors that also 
impact on Hb levels. Of these, it is straightforward to control for altitude, sex and 
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age. As shown in this study, such adjustment may however not necessarily 
improve the strength of the association between Hb and malarial endemicity.  
 
Other important contributors to the burden of anemia include infections, nutrition 
status and host genetic traits such as common red blood cell polymorphisms. 
Among infections, hookworm infestation is probably the most important in PNG. It 
is highly prevalent throughout the country (Pritchard, Quinnell et al. 1990; 
Barnish 1992). Although high egg loads may be associated with anemia in some 
populations of PNG(Shield, Scrimgeour et al. 1980), other studies did not find 
such a link (Pritchard, Quinnell et al. 1990). Adjusting for the presence of 
helminth infections would thus potentially improve the accuracy of Hb metric. 
Unfortunately these data are not available for the PNG surveys. Given the nation-
wide presence of hookworm and the lack of consensus on its impact on Hb levels 
in PNG it is however unlikely that this would have substantially changes the 
observed relationships between Hb and malaria at the population level. 
Parvovirus B19 infection has recently been identified as a significant risk factor 
for severe anemia in PNG(Wildig, Michon et al. 2006), but as an infection of 
young children with limited variation between populations(Wildig, Mueller et al. 
2007) the effect of B19 infection will mainly affect this age group and to a lesser 
extent the adult population. To-date, no studies have investigated the overall 
contribution of B19 infections to the burden of anemia. Schistosomiasis, which 
contributes a lot to the burden of anemia elsewhere, is not present in PNG. In 
other malaria endemic areas like Africa, it will however be necessary to take into 
account other infectious agent. In particular, Schistosomiasis as an important 
confounder and adjustment might thus be required where it is endemic. In 
conclusion, whereas co-infections might potentially affect population Hb levels, 
the actual impact will depend on epidemiological context and due to the lack of 
appropriate co-infection data is often difficult to quantify.  
 
Secondly, dietary factors such as malnutrition or micronutrient deficiencies 
impact on Hb levels. A recent review by Metz has shown that folate and vitamin 
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B12 deficiency, even though very frequent in developing countries, do not 
significantly affect the prevalence of anemia(Metz 2008). Vitamin A (by affecting 
erythropoiesis(Cusick, Tielsch et al. 2005)) and Iron deficiencies are the two 
micronutrients which are contributing the most to anemia. Low levels of Vitamin A 
may also contribute to an increase risk of malaria (Shankar, Genton et al. 1999). 
In the 2005 PNG National Malnutrition survey 15% of children <5 years had low 
levels of VitA with little regional difference. VitA deficiency was however almost 
completely absent in adults (Saweri, pers. communication). In the same survey 
23% of people had elevated transferrin receptor (TfR) levels that were indicative 
of iron deficiency.  Although the prevalence of elevated TfR varied significant with 
age and among regions, the prevalence of elevated TfR among anemic 
participants (defined as <10 g/dl for children < 11 for adults) was similar in 
children and adults (42-47%), albeit lower in highlands (19-32%) compared to 
lowlands population (38-64%). While chronic protein energy malnutrition and 
resulting growth stunting is highly prevalent throughout PNG (Mueller, Vounatsou 
et al. 2001), acute malnutrition is less common overall but more important in the 
coastal areas than in the highlands (Edwards 2000). The relationship between 
protein-energy malnutrition, malaria and anemia is complex and not fully 
understood. Some recently published data suggest that malnutrition contributes 
to both malaria associated morbidity and anemia (Caulfield, Richard et al. 2004; 
Friedman, Kwena et al. 2005; Ehrhardt, Burchard et al. 2006) while an earlier 
study in lowlands PNG found a reduced risk of malaria in stunted children 
(Genton, Al Yaman et al. 1998). However, in studies in highly endemic areas 
where both have been assessed malaria is usually a much stronger contributor to 
anemia than malnutrition(Ronald, Kenny et al. 2006). Whereas adjusting for 
nutritional status might thus improve the accuracy and predictive value of Hb 
metrics, such data is rarely collected in malariological surveys.  
 
Finally, there are a number of genetic traits that are known to impact on 
hemoglobin levels. By far the most important one in PNG is alpha-thalassemia 2 
(-α) which is very common in lowlands PNG but virtually absent in highlands 
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populations(Serjeantson 1992). This form of alpha-thalassemia only causes mild 
symptoms and even in its homozygote presentation, it has only a minor effect on 
hemoglobin levels(Weatherall and Clegg 2001). The homozygote however has a 
significant protection against severe malaria (including severe malarial anaemia) 
and severe non-malarial illnesses(Allen, O'Donnell et al. 1997). Thus, a potential 
negative effect of alpha-thalassaemia on population Hb may be off-set by a 
reduction in risk of malaria associated (severe) anemia. Its overall impact on 
popHb and AR is likely to be limited. The other two common red blood cell 
polymorphisms are South East Asia Ovalocytosis(Genton, Ai-Yaman et al. 1995) 
and the Gerbich blood group(Sheral, Christopher et al. 2004). Although both 
traits are restricted to malaria endemic areas(Mgone, Koki et al. 1996), they both 
cause little or no difference in Hb levels(Palek and Jarolim 1993). Sickle cell 
anemia is not present in PNG. Consequently, the impact of host genetic 
polymorphisms on the association between Hb levels or anemia prevalence and 
malaria exposure is likely to be minor in PNG. Importantly, changes in malaria 
transmission intensity will occur much more rapidly than those in frequency of 
host genetic polymorphisms. Thus, even if such traits may affect Hb levels, 
changes in popHb or AR over time would still correctly reflect changes in malaria 
endemicity.  
 
After consideration of these important potential confounders, the correlations 
between Hb metrics and altitude, parasite prevalence and spleen rates appear to 
remain robust. This study therefore provides good evidence that popHb and AP 
are valuable metrics to estimate the burden of malaria in PNG even without 
adjusting for potential confounders.  Before applying them to other settings, in 
particular those where schistosomiasis is highly prevalent, it will be important to 
cautiously consider the impact of such confounders when interpreting Hb levels 
as malaria metics.  
 
The major advantages of using Hb metrics as measures for malaria endemicity is 
that they require limited resources to be recorded, they are immediately available 
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in the field and are more reproducible than estimating spleen rate. In addition, 
popHb is very easy to calculate and AP easy to interpret. Last but not least they 
also provide important additional information on the health status of a population. 
 
Hb metrics thus appear to be promising alternative tools for measuring malaria 
burden, on their own or in combination with other traditional or more recent 
serological(Shekalaghe, Alifrangis et al. 2009) measures of malaria endemicity, 
even in areas of high prevalence of non-falciparum infections. They may be 
particularly useful in areas of moderate to low transmission and could therefore 
be of best use in public health when monitoring malaria control interventions 
programs during the preparatory and attack phases(Hay, Smith et al. 2008). 
Additional in-depth studies are warranted to better characterize the relationship 
between Hb levels and malaria transmission and determine the optimal use as 
new malaria metrics. In addition, prospective studies in areas with different 
malaria epidemiology and in the context of malarial control initiatives are 
required. The examination of changes in Hb-based indices over time in 
populations benefitting from a major anti-malaria intervention would comprise an 
important test of the usefulness of Hb metrics based endemicity monitoring in the 
context of rapidly changing malarial epidemiology in Papua New Guinea or 
elsewhere. 
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4.1 Abstract 
Objectives  
The management of febrile children in malaria endemic areas has evolved and 
the following approach has been proposed: febrile children should be tested for 
malaria [rapid diagnostic test (RDT) or blood slide (BS)], and receive effective 
malaria treatment only if positive. There are safety concerns about withholding 
antimalarial drugs from children with negative tests. More generally, there is 
limited evidence on the safety and feasibility of this strategy, as well as no 
evidence of ACT effectiveness as unified treatment in areas with mixed 
endemicity [Plasmodium falciparum (Pf) and P. vivax (Pv)]. The present study 
explores the feasibility of this approach in Papua New Guinea (PNG), a highly 
endemic country for both Pf and Pv.  
Design  
longitudinal prospective study 
Setting  
Outpatient clinics, Madang and Sepik provinces, Papua New Guinea 
Participants  
1605 infants 3 months old enrolled and followed prospectively for up to 2 years 
Main Outcome Measures  
Rates of re-attendance and occurrence of serious adverse events/complications 
Results   
Among 7211 febrile episodes, 5670 fulfilled the inclusion criteria (fever and/or 
history of fever in the past 48h, no malaria treatment within 4 weeks, no previous 
fever within 2 weeks, no critical illness and no malaria treatment if RDT neg at 
D0). The mean duration of symptoms was 2.7 days (95%CI 2.6-2.8). 3942 (70%) 
had a negative RDT. Among them, 133 (3.4%) re-attended the clinic within 7 
days for fever of which 29 (0.7%) had an associated parasitaemia detected by 
RDT or microscopy. Of the 133, 1 died of lower respiratory tract infection (LRTI) 
with negative RDT & BS. 23 (0.6%) infants re-presented with a serious adverse 
event: two had LRTI with low densities Pv on BS, 2 were diagnosed as Pv 
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malaria based on RDT but BS were negative, 15 had LRTI and 3 had alternative 
diagnoses. Of these, 22 were cured and 1 died while admitted for possible 
meningitis (RDT and BS negative).  
There were 1728 children with positive RDT results. All infants were treated with 
artemether-lumefantrine. 30 (1.7%) re-attended within 7 days for fever, none died 
and 5 (0.3%) developed a serious adverse event, all with a likely diagnosis of 
malaria.  
Conclusion  
This study provides solid evidence that rapid diagnostic testing for malaria and 
treatment with ACT for positive cases is safe and feasible in infants leaving in 
areas with high endemicity for both Pf and Pv infections. 
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4.2 Introduction 
In many countries, patients are treated presumptively for malaria when 
presenting with febrile illnesses. This is because (1) no diagnostic tools are 
available (microscopy or rapid diagnostic tests), (2) health workers do not trust 
the results of these tests(Reyburn, Mbakilwa et al. 2007; Zeno, Bienvenu 
Sodiomon et al. 2009) or (3) there are scarce data on the safety of withholding 
antimalarial drugs in patients with a negative test for malaria. This is especially 
true in children under five, in whom presumptive antimalarial treatment has been 
promoted by the World Health Organization (WHO) (WHO 2009) for decades.  
The situation has evolved and more tools and data are now available for the 
management of suspected malaria episodes, in particular in Sub-Saharan 
Africa(D'Acremont, Lengeler et al. 2009). First, community awareness in endemic 
areas of the importance of early attendance at a health facility when a child is 
febrile has improved.(Sanjana, Barcus et al. 2006) Second, reliable and 
affordable Rapid Diagnostic Tests for malaria (RDT) are now widely 
available.(Bell, Wongsrichanalai et al. 2006; Shillcutt, Morel et al. 2008; WHO 
2008; Drakeley and Reyburn 2009) Third, safe and highly efficacious treatments 
for malaria (artemisinin-based combination therapies, ACT) are available in 
almost all endemic countries. A review by Douglas et al. (Douglas, NM. et al. 
2010) looking at the appropriateness of a single ACT-based strategy for both 
Plasmodium falciparum (Pf) and Plasmodium vivax (Pv) in co-endemic regions, a 
so-called unified treatment, concluded that it might be a reasonable option where 
Pv is resistant to chloroquine. However, these conclusions are based on a small 
number of highly controlled efficacy trials, and data are lacking on the 
effectiveness of this strategy in routine settings. Last, one recently published 
study has demonstrated the safety of withholding antimalarial drugs in children 
with negative RDT under five in Tanzania, where Pf  is the predominant 
species.(d'Acremont, Malila et al. 2010 ) 
The safety and effectiveness of diagnosis-based treatment of malaria has not 
been investigated in infants. Moreover, it is not clear whether withholding 
antimalarial treatment in young children with fever and a negative RDT is safe in 
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different epidemiological contexts, especially in areas with a high prevalence of 
Pv infections; it is well known that many RDT perform poorly for the diagnosis of 
this species.(Sun Hyung, Myung-Hyun et al. 2008; WHO 2008; Ashley, Touabi et 
al. 2009; Meena, Joshi et al. 2009) More data are thus needed to ensure that the 
new WHO policy of only prescribing antimalarials to children with confirmed 
parasitemia is safe in all settings(WHO 2010). It must be a priority in terms of 
clinical management of febrile illnesses as it is well recognized that presumptive 
treatment for malaria may delay the management of other potentially life 
threatening diseases and promote the development of resistance to antimalarial 
drugs.(Reyburn, Mbakilwa et al. 2007)  
Papua New Guinea, located in the South Pacific, is a tropical country highly 
endemic for malaria in costal areas, with malaria incidence rates in small children 
higher than 1 episode/year/child in most regions, Pv accounting for at least half 
of all infections (Mueller, Bockarie et al. 2003) (Senn et al, personal 
communication). As part of a large trial of intermittent preventive treatment in 
infants (IPTi), a passive case detection surveillance system was implemented 
and all sick study participants presenting spontaneously at the study clinics with 
fever or history of fever were screened with RDT for Pf and non-Pf malaria 
infections and treated with ACTs only when the test was positive. The 
standardized approach to case management employed offers an excellent 
opportunity not only to investigate the safety of withholding antimalarial drugs in 
febrile patients with a negative RDT result in a situation where Pv infections are 
very common, but also to assess the appropriateness of using a unified 
treatment for malaria (i.e. using an ACT indiscriminately for both Pf and Pv). 
 
4.3 Methods 
Background & study sites 
This work was carried out alongside a large 3-arm drug trial of intermittent 
preventive treatment for malaria (IPTi) including more than 1500 children 3–27 
months old from 2006 to 2010 (www.ClinicalTrials.gov: NCT00285662). Children 
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were randomly assigned to a treatment course of sulfadoxine/pyrimethamine 
(single dose, 25/1.25mg/kg) with 3 days of either 10mg/kg of amodiaquine (SP-
3AQ) or 4 mg/kg of artesunate (SP-3AT), or to a placebo group. The doses were 
given every 3 months during the first year of life, along the immunization 
schedule. This trial took place in two different settings: 
Mugil (Madang province): the main study site, at which 1125 study participants 
were enrolled, is situated 60km north of Madang town. It is a rural area served by 
one health center and three small aid posts. It is highly endemic for malaria with 
an incidence rate of clinical malaria (fever + positive blood slide or RDT) of 0.94 
episodes / child / year, Pv accounting for two thirds of all infections (unpublished 
results of IPTi trial).  
Maprik: a secondary study site where 480 study participants were enrolled. It is 
also a rural area, located in the East Sepik Province, about 400 km from 
Madang. It is served by two sub-health centers (Kunjingini and Kaugia) and one 
aid post. The incidence rate of malaria is low: 0.13 episode / year / child, Pf 
accounting for two thirds of all episodes (unpublished results of IPTi trial). 
Because of this low malaria incidence, the study was prematurely stopped at this 
site in May 2008.   
 
Data collection (passive case surveillance) 
A passive case detection surveillance system had been established for 20 years 
in Maprik (Genton, D'Acremont et al. 2008) and 10 years in Mugil (Michon, Cole-
Tobian et al. 2007) for studies who took place before the IPTi trial. The same 
infrastructures were used for IPTi and when their child was sick, all parents of 
study infants were asked to visit one of the health facilities. All study patients 
were reviewed by study nurses working in collaboration with the health centers or 
aid posts. A standard case report form was filled for each illness episode that 
included all relevant signs and symptoms as well as the clinical management. 
When presenting with fever or history of fever in the past 48 hours, children were 
screened with an RDT for Pf and non-Pf malaria infections (ICT Combo®, South 
Africa) and only treated with artemether-lumefantrine (AL, Coartem®, Novartis, 
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Switzerland) if the test was found positive (oral quinine was administered if the 
last episode was less than 4 weeks prior to attendance). All study nurses were 
trained to perform and interpret the RDT. Two thick and thin blood slides (BS) for 
malaria microscopy and a blood sample for PCR were also collected. 
Additionally, parents had the possibility to attend voluntarily the mobile clinics 
that were visiting the different villages on a monthly basis to deliver the 
immunization and IPTi interventions. On the rare occasions when infants visited 
a health facility after hours (when the study clinics were closed), they were 
managed according to the national guidelines by the staff on duty. Usually blood 
samples were not taken and management was done based on clinical criteria. A 
review was made by study nurses on the following day. 
During the 3-monthly regular visits (at time of immunization and IPTi treatment), 
the health books were reviewed and all medical attendances outside the study 
clinics were recorded (including date, diagnosis and treatment). If a child died at 
home, a verbal autopsy was performed whenever possible.  
All procedures followed the Good Clinical Practice (GCP) guidelines, and all 
parents signed an informed consent form when enrolling their child in the IPTi 
study. The IPTi protocol was also approved by the Medical Research Advisory 
Committee of Papua New Guinea (MRAC number 05/20). 
 
Study design and procedures 
The present work makes use of morbidity data of the IPTi trial cohort to perform 
safety assessment of children who had an RDT performed as part of a passive 
case detection visit. 
We applied the following inclusion criteria:  
• Children 3-27 months enrolled in the IPTi study in PNG 
• History of fever in the previous 48 hours and/or temperature > 37.5° 
• No positive RDT result in the previous 4 weeks 
• No consultation for history of fever/temperature > 37.5° in the past 2 
weeks 
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• No antimalarial drugs prescribed on the day of consultation if RDT 
negative on the day of consultation 
• No severe illness requiring admission or referral (danger signs/symptoms) 
One or more illness episodes could occur for each child enrolled in the study. 
For all children with above mentioned inclusion criteria, we determined whether 
they re-attended any of the study clinics in the following 7, 28 and 42 days. Upon 
re-attendance, we investigated whether or not they still had fever, and examined 
the clinical and paraclinical outcomes. These were classified as death, Serious 
Adverse Event (SAE) or non-severe adverse event (AE) ambulatory. The result 
of the new RDT performed upon re-attendance was cross-checked by a research 
BS for all AE, SAE and deaths. For the children who had died or had been 
admitted elsewhere or after hours, we recorded the presumptive diagnosis, 
management and treatment from the health book or records from the health 
center.  
 
Serious Adverse Event (SAE)/complication 
Any illness episode was defined as an SAE/complication if it resulted in hospital 
admission or was life-threatening (one or more danger signs/symptoms was 
present as defined by PNG National Guidelines, or the study clinician considered 
the event to be life-threatening on the basis of a medical review) or it fulfilled the 
hematological criteria for an SAE, according to the standardized IPTi consortium 
guidelines (internal document, www.ipti-malaria.org) for Grading Severity of 
Adverse Events (examples: disability such as cerebral palsy following a severe 
malaria infection  or hemoglobin below 5 g/dl). 
 
Interpretation of blood slide (BS) and RDT results 
Children enrolled in the IPTi who experienced a febrile episode had an RDT 
performed to decide on treatment and also a BS for research purpose (not use 
for clinical management). Thick films were examined by light microscopy (LM) for 
100 fields (under 100X oil immersion lens) before being declared infection-
negative. Parasite species in positive films were identified and densities recorded 
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as the number of parasites per 200 white blood cells (WBC). Densities were 
converted to the number of parasites per ml of blood assuming 8,000 WBC per 
ml (population average WBC count [3]). The BS’s were read by two experienced 
microscopists. In case of discrepancies of readings (absence/presence of 
parasite, or more than one log difference for parasite densities), a third 
independent read was performed. In case the readings were still discrepant, 
results were compared with PCR results and a 4th read was performed for the BS 
having a different result from the PCR.  
It is well known that discrepancies between BS readings and RDT results can be 
important due to the fact that the two tests detect different components (antigens 
for RDT and whole parasites for microscopy). Therefore we designed a matrix to 
interpret the combination of BS and RDT upon re-attendance (see table 4.1). 
According to this matrix, we defined 4 categories of malaria status upon re-
attendance: 1) negative = BS & RDT negative, BS or RDT negative and 
corresponding BS or RDT absent, 2) Definite malaria = BS & RDT positive, 3) 
Probable malaria = BS positive and RDT negative or absent, 4) Possible malaria 
= RDT positive and BS negative or absent. Similarly, we defined the presence of 
specific parasites: definite Pf / Pv / Pm / Po, probable Pf / Pv / Pm / Po, Possible 
Pf / Pv / Pm / Po. Mixed infections were allocated to each present species. For 
example a BS and an RDT indicating mixed infection for Pf and Pv was classified 
as Definite Pf and definite Pv.  
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Table 4-1: Matrix of interpretation of BS and RDT results upon re-attendance 
 
 
Neg Pf Pv poss mixed no RDT
Neg Def Neg Poss Pf Poss Pv Poss Pf & Poss Pv Prob Neg
Pf Prob Pf Def Pf Prob Pf and poss Pv Def Pf and poss Pv Prob Pf
Pv Prob Pv Prob Pv and poss Pf Def Pv Def Pv & Poss Pf Prob Pv
Pm Prob Pm Prob Pm and poss Pf Def Pm Def Pm & Poss Pf Prob Pm
Mix Prob Pf and Prob Pv Def Pf & prob Pv Def Pv and Prob Pf def Pf and def Pv Prob Pf and Prob Pv
No BS Poss neg Poss Pf Poss Pv Poss Pf and Poss Pv no results
no results
Neg
Def malaria
Prob malaria
Poss Malaria
RDT rslt
BS 
results
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Data analysis 
All data were doubled entered using FoxPro software as for the IPTi main trial. 
All data management & analyses were performed using STATA software (10.0). 
Re-attendance rates within 7, 28 and 42 days for the different outcomes (SAE, 
death and mild diseases) were obtained for children fulfilling inclusion criteria. 
The risk of symptomatic malaria among participating children may have been 
lessened by the prophylactic effect of the IPTi intervention. To avoid this potential 
bias, we excluded from the analysis the children who received an IPTi treatment 
dose prior to the next attendance. We did also compare children in the treatment 
group versus those in the placebo group for the rates of re-attendance of SAE’s.  
All rates are displayed with a confidence interval of 95%. Differences between 
rates were assessed using a chi square test. 
 
4.4 Results 
General description of the cohort 
Between June 2006 and May 2010, 1605 children 3-27 months were enrolled 
and followed-up in the IPTi randomized controlled trial (Madang=1125 and 
Maprik=480). 1512 (94%) children presented at least 1 illness episode 
(Madang=1053 and Maprik=459). The morbidity surveillance reported a total of 
8944 illness episodes (Madang=5978 and Maprik=2966) (see figure 4.1 & 4.2), 
of which 7223 were febrile (Madang=5249, Maprik=1974). The average number 
of febrile episodes per child was 4.8. 13 deaths and 371 SAEs were reported 
during the observation period. The mean duration of symptoms before 
attendance was 2.7 days (95%CI 2.6-2.8) in febrile children.  
We included in our analysis 5670 febrile episodes (Madang= 4103, Maprik = 
1567) fulfilling the inclusion criteria. 1899 occurred in children enrolled in SP-3AQ 
group, 1888 in the SP-3AT group and 1883 in placebo group. 3942 (70%) of the 
infants had a negative RDT at inclusion. 2512 (61%, 95%CI, 60 - 63) were 
negative in Madang (high endemicity) and 1430 (91%, 95%CI, 90 - 93) in Maprik 
(low endemicity). 1728 (30%, 95%CI, 29 - 32) had a positive RDT for any species 
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of which 1289 were confirmed by BS. Table 4.2 displays the correlation between 
positive RDT result and BS results. According to RDT results, 19% (95%CI, 17 - 
21) were positive for Pf, 37% (95%CI, 35 - 39) were possibly mixed infections (Pf 
and Pv, Po or Pm) and 44% (95%CI, 42 - 46) were non-Pf infections. Median 
duration of symptoms was similar for children with negative and positive RDT (2 
days, IQ ranges of 1-3 and 1-4 respectively).   
 
Table 4-2: Corresponding BS results for all children with positive RDT 
results (total = 1728) 
Pf non-Pf Pf  +/- mixed infection
Negative 96 111 76
Pf 37 10 326
Pv 159 583 116
Pm 0 8 0
Mixed infections (Pf & Pv ) 5 3 42
No BS 29 43 84
RDT results
BS results 
(research read)
 
 
About 20% of children did not undergo blood collection while presenting with an 
SAE. Reasons included admission after hours when no study staff was present, 
the SAE occurred at home (especially death), or the parents refused the 
bleeding. 
 
Clinical and parasitological outcomes upon re-attendance within 7 and 28 days 
following a negative RDT result 
Figures 4.1a displays the outcome within 7 days of febrile episodes for children 
with a negative RDT result. Among the 3942 children with febrile episode and a 
negative RDT result, 172 (4.4%) re-attended the clinic within 7 days, of whom 
133 (3.4%) had a history of fever and/or temperature >37.5°. 29 out of 3942 
(0.7%) children with negative RDT at D0 re-attended the clinic with a parasitemia 
identified by RDT and/or BS. Among the 133 children who re-attended with fever, 
1 died probably of severe respiratory infection (as per clinical assessment); 
malaria was ruled out by both RDT and microscopy at initial and subsequent 
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attendance. 23 children (0.6%) presented with an SAE, the median duration 
between initial negative RDT and SAE being 2 days (IQ range 1 - 4). 
 
Figure 4-1: Flow-charts showing the clinical and parasitological outcomes 
upon re-attendance within 7 days following a negative RDT 
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 Table 4.3 describes these SAEs in detail. Six children with an SAE had neither 
an RDT nor a BS performed. This was mainly due to the fact that they were 
admitted during the night at the health facility when no study staff was present. 
For these children, the likely diagnosis was made based on clinical records 
matched with treatment records. Out of the 23 patients re-attending with an SAE, 
two children were clinically diagnosed as LRTI, and also had low density Pv 
parasitemia (<1000 parasites/µl), but none received antimalarials; and two other 
children had a positive RDT for Pv but the BS were negative. One other child 
died, one week after admission while being treated for a LRTI, probably of a 
meningitis (RDT and microscopy were both negative at initial and subsequent 
visits).  
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Table 4-3: Details of SAE's at re-attendance within 7 days following a negative RDT for malaria 
RDTm at re-
attendance
Blood slide at 
re-attendance
Antibiotics 
received 
Antimalarial 
received Likely diagnosis* comments
1 Neg Neg yes no LRTI Died 7 days later of Meningitis
2 Neg Neg yes no LRTI
3 Neg Neg yes no LRTI
4 Neg Neg yes no Malnutrition + LRTI
5 Neg Neg yes no LRTI
6 Neg Neg yes no Gastroenteritis 
7 Neg Neg yes no LRTI + Febrile fits 
8 Neg Neg yes no LRTI
9 Neg Neg yes no LRTI
10 Neg Neg yes no LRTI
11 Neg Neg yes no LRTI
12 Neg Neg yes no LRTI
13 Pos Neg no yes  LRTI
14 Pos Neg yes yes LRTI + Gastroenteritis 
15 not done Neg yes yes LRTI
16 Neg Pos ( Pv 960/µl) yes no  LRTI + Anemia + parasitemia (Pv) received Co-trimoxazol
17 not done Pos ( Pv 360/µl) yes no LRTI + parasitemia (Pv)
18 not done Not done yes yes Skin abscess at injection site
19 not done Not done yes no LRTI + Febrile fits 
20 not done Not done yes no LRTI
21 not done Not done yes no LRTI
22 not done Not done yes no Tuberculosis received anti-TB treatment
23 not done Not done yes no LRTI
* Likely diagnosis is based on the review of clinical records matched with RDTm & blood slide results and the treatment received 
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If we looked at the cumulative re-attendance pattern from 0 to 28 days (see 
figures 4.2), 725 infants visited the clinic, 573 had fever, 47 had a SAE and one 
died. Out of the 47 admissions, the recorded clinical diagnoses were as follow 
(up to three different diagnoses per child were recorded): 31 LRTI, 10 malaria 
(according to BS and/or RDT results: 3 definite malaria, 5 possible and 2 
negative. Detail species results are displayed in figure 4.2), 8 neurological 
syndromes (febrile fits and/or meningitis), 4 gastro-intestinal diseases, 5 anemia, 
2 otitis, 2 URTI, 1 skin infection, 5 other diagnoses.  
 
Figures 4.3 displays the outcome of 1728 out of 5664 febrile episodes(30%)  for 
children who re-attended the clinic within 7 days following a treatment with AL for 
a positive RDT result. 45 (2.6%) children re-attended the clinic and 30 (1.7%) still 
had fever. Only 5 infants experienced an SAE in the next 7 days following a 
positive RDT result, none died. Table 4.4 shows the details for all SAEs. The 
median duration between a positive RDT and an SAE was 2 days (IQ range was 
1 - 4). 
When we extend the observation period following a positive RDT to 28 days (see 
figures 4.4), we observed that 178 infants out of 1728 (10.3%) re-attended the 
clinic for an ongoing or new fever episode. 162 were non-severe cases. Among 
the 16 who experienced an SAE (up to 3 different diagnoses were recorded per 
child), 7 were diagnosed with malaria, 9 with a lower respiratory tract infection, 8 
had neurological syndromes (such as febrile fits or meningitis), 3 had anemia and 
3 had others diagnoses. One of the children with an SAE died the day after its 
admission, with the dual diagnosis of LRTI and possible severe malaria. Indeed, 
this child had a severe respiratory distress syndrome on admission with a 
possible diagnosis of malaria (positive RDT result but negative BS).  
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Figure 4-2: Flow-charts showing the clinical and parasitological outcomes 
upon re-attendance within 28 days following a negative RDT 
 
 
Clinical and parasitological outcome upon re-attendance within 7 and 28 days 
following a positive RDT result 
 
7223 Febrile episodes 
3942 (100%) 
 Negative RDT 
8944 illness episodes 
1728  
Positive RDT (See Fig 2) 
5670  
febrile episodes 
meeting the criteria 
 
1 
Died 
Neg RDT 
and BS 
 
725 (18.4%) 
Re-attendance within 28 days 
573 (14.5%) 
with fever 
525  
Non-severe events  
Malaria status*:  
71 Definitive (54 def Pv, 7 prob 
Pv, 9 poss Pv, 9 def Pf, 1 prob Pf, 
21poss Pf, 1 def Pm) 
24 Probable (22 prob Pv, 2 prob 
Pf) 
28 Possible (24 poss Pv,11 poss 
Pf) 
386 Neg  
16 No BS or RDT 
 
Final outcome 
 525 cured 
47 
SAE 
Malaria status*:  
3 Definitive (3 def Pv, 1 poss Pf) 
2 Probable (2 prob Pv) 
9 Possible (4 poss Pv, 3 poss Pf) 
30 Neg  
7 No BS or RDT 
  
Final outcome 
 1 died of meningitis (BS 
and RDT neg)   
46 cured 
 
* Malaria status: 
definitive = BS & RDT 
positive, probable = BS 
positive only,  
Possible = RDT 
positive only (see app. 
table 1). Presence of Pf 
and Pv includes also 
mixed infections  
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Figure 4-3: Re-attendance within 7 days following an initial positive RDT 
result 
 
 
 
1728 (100%)   
Positive RDT 
19%(Pf) 44%(non-Pf) 37% (Pf or mix)  
45 (2.6%) 
Re-attendance within 7 days 
30 (1.7%) 
With fever 
5 
SAE 
 Malaria status*: 
0 Definitive  
0 Probable 
2 Possible (1 poss Pv, 2 poss Pf) 
1 Neg  
2 No BS or RDT 
 
25 
Non-severe events 
Malaria status*: 
4 Definitive (1 def Pv, 1 prob Pv, 2 
poss Pv, 2 def Pf, 1 poss Pf) 
0 Probable  
11 Possible (2 poss Pv, 11 poss Pf)  
8 Neg  
2 No BS or RDT 
 
3940 (70%) 
Negative RDT  
(see fig 1) 
7211 Febrile episodes 
8931 illness episodes 
5664  
febrile episodes 
meeting the criteria 
 
Final outcome 
 25 cured 
  
Final outcome 
5  cured 
  
* Malaria status: 
definitive = BS & 
RDT positive, 
probable = BS 
positive only,  
Possible = RDT 
positive only (see 
app. table 1). 
Presence of Pf and 
Pv includes also 
mixed infections  
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Table 4-4: Details of SAE's at re-attendance within 7 days following a positive RDT for malaria 
RDTm at re-
attendance
Blood slide at 
re-attendance
Antibiotics 
received 
Antimalarial 
received Likely diagnosis* comments
1 Not done Not Done Yes Yes malaria, febrile fits
2 Pos (poss mix) Not Done No Yes malaria + febrile fits
3 Pos (Pf ) Not Done No Yes malaria Coartem to Quinine 
4 Not done Neg Yes Yes malaria +/- febriel fits Coartem to Quinine 
5 Not done Not Done Yes Yes Malaria + LRTI
LRTI = Lower Respiratory Tract Infection
 
Table 4-5: Crude rates of re-attendance for children having clinical malaria confirmed by RDT and BS and treated 
with AL presenting with a new clinical malaria due to the same species (PCR uncorrected for re-infections). Def = 
definitive, Prob = probable, Poss = possible 
Day 0
 malaria 
episodes Def Prob Poss 
Neg or 
other 
species
No BS 
and 
RDT
Def Prob Poss 
Neg or 
other 
species
No BS 
and 
RDT
Def Prob Poss 
Neg or 
other 
species
No BS 
and 
RDT
Pv 831* 0 1 (0.1%)
2
(0.2%)
7
(0.8%)
2
(0.2%)
8 
(1%)
6
(0.7%)
5
(0.6%)
71
(8.5%)
3 
(0.4%)
55 
(6.6%)
17
(2%)
20
(2.4%)
98
(11.8%)
3
(0.4%)
Pf 458* 1(0.2%) 0
5
(1%) 0
1
(0.2%)
6
(1.3%) 0
32
(7%)
7
(1.5%)
1
(0.2%)
15
(3.2%) 0
44
(9.6%)
32
(7%)
1
(0.2%)
* Are included only infections confirmed by both RDT and BS + the inclusion criteria of the study: no positive RDT in the past 2 weeks, no fever 
episode in the past 4 weeks, treatment with AL and no critical illness
Re-attendance 0 to 7 days 
N (%) 
Re-attendance 0 to 28 days
N (%)
Re-attendance 0 to 42 days 
N (%)
Definite = BS and RDT positive, Probable = BS positive (RDT neg or absent), Possible = RDT positive (BS neg or absent), Negative = BS and 
RDT neg
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Figure 4-4: Re-attendance within 28 days following an initial positive RDT 
result 
 
 
Re-attendance within 7, 28, 42 and 63 days following Pv and Pf infections 
Table 4.5 and figure 4.5 detail the rates of re-attendance following Pv and Pf 
malaria episodes confirmed by BS and RDT (definite cases) and treated with AL. 
1728 (100%)   
Positive RDT 
19%(Pf) 44%(non-Pf) 37% (Pf or mix)  
213 (12.3%) 
Re-attendance within 28 days 
178 (10.3%) 
With fever   
16 
LT events (SAE) 
Malaria status*: 
1 Definitive (1 prob Pv, 1 def Pf) 
0 Probable  
6 Possible (4 poss Pv, 4 poss Pf)  
7Neg 
2 No BS or RDT 
 
162  
Not LT events (outpatient) 
  Malaria status*: 
25 Definitive (12 def Pv, 7 prob Pv, 6 
poss Pv, 8 def Pf, 8 poss Pf) 
3 Probable (2 prob Pv, 1 prob Pf) 
42 Possible (6 poss Pv, 40 poss Pf)  
89 Neg  
3 No BS or RDT 
 
3940 (70%) 
Negative RDT  
(see fig 1) 
7211 Febrile episodes 
8931 illness episodes 
5664  
febrile episodes 
meeting the criteria 
 
Final outcome 
14 cured 
1 died (Pos RDT (Pf) and Neg BS)  
 
*Mama, with IPTi, your 
child will get less malaria 
* Malaria 
status: 
definitive = BS 
& RDT positive, 
probable = BS 
positive only, 
 Possible = 
RDT positive 
only (see app. 
table 1). 
Presence of Pf 
and Pv 
includes also 
mixed 
infections  
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Only re-attendance with the same species is considered, which gives a proxy for 
clinical treatment effectiveness at 7, 28 and 42 days. 831 definite infections with 
Pv and 458 with Pf were included in the analysis. When considering all malaria 
episodes confirmed by blood slide upon re-attendance (at least the BS is 
positive), the rate of re-attendance with Pv was 0.1% within 7 days, 1.7% within 
28 days, 8.6% within 42 days and 12.2% within 63 days. Comparatively the rates 
for Pf were: 0.2%, 1.3%, 3.2% and 5.7%.    
   
 Figure 4-5: re-attendance rates with positive BS within 7, 28 and 42 days 
for each species (clinical treatment failure rate) 
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Potential effect of IPTi treatment on rates of re-attendance 
No difference was observed in the rates of re-attendance whether the children 
did receive an IPTi treatment or not in the 6 weeks preceding the fever episode 
(maximum duration of IPTi post-treatment effect). More specifically, the rate of 
re-attendance for SAE among 573 children with a negative RDT who came back 
within 4 weeks for fever was similar in those who got an IPTi dose in the past 6 
weeks with 7.7% (34/444) compared to 10% (13/129) in those who didn’t 
(p=0.38).  
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Finally, no serious adverse event that could be related to AL as assessed by 
research and routine health staff was observed. 
 
4.5 Discussion 
We investigated the safety of managing febrile infants with antimalarials based 
on results of RDT. The combination of screening for malaria using RDT, and 
standard treatment of malaria parasitemia with ACT proved to be safe and 
effective in areas with a high endemicity for both Pf and Pv.  
Although this study was conducted alongside a randomized controlled trial, no 
active follow-up of study participants was performed and only spontaneous 
attendance to one of the study clinics or patrols was used to record illness 
episodes. Such passive case detection may reflect health seeking behavior in 
routine practice in a setting such as PNG.   
Almost 6000 febrile episodes were included in our analysis and one third of them 
were associated with malaria parasitemia according to the RDT results. No child 
died or had an SAE because he/she was not treated with artemether-
lumefantrine when the RDT was negative. Among the patients with a negative 
RDT, less than 4% re-attended one of the study clinics within 7 days with 
persistent fever and only 0.6% (23) were admitted. Less than 1% of children with 
an initial negative RDT re-attended within 7 days with parasitemia identified by 
RDT or BS (none had definite malaria based on a positive RDT result and BS). 
This represents the most conservative estimate of possibly missed malaria 
cases. Indeed, this includes not only recrudescence and relapses, but also new 
infections and coincidental parasitemia (most of them had clear alternative 
diagnosis). Two were admitted with a possibly missed diagnosis of malaria one 
day after the initial visit (two low densities Pv on BS, one with RDT negative 
result and one without RDT result) during the initial outpatient visit. All these 
illness episodes were treated appropriately and recovered without sequelae. It is 
however not possible to tell whether these two cases were truly missed, or if they 
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experienced a new occurrence of malaria, or whether it was coincidental infection 
not responsible for the febrile episode.  
One child died presumably of a severe pneumonia (malaria was ruled out by 
RDT and microscopy). These figures provide good evidence that withholding 
antimalarial drugs from children below 2 years with a negative RDT result is a 
safe strategy. Indeed, most of the children experiencing an SAE within 7 days 
following a negative RDT had been already diagnosed with a LRTI during the first 
visit, but as their conditions worsened, admission was required.  
These data are especially reassuring since RDT are known to lack sensitivity for 
Pv infections.(WHO 2008) Fortunately, new generation tests are becoming 
available with sensitivities for Pv as high as those for Pf.(Maltha, Gillet et al. 
2010) These findings provide for the first time evidence of the safety of 
withholding antimalarial drugs in infants in a setting highly endemic for Pv based 
on the results of RDT only.  They also confirm those of another study performed 
in Africa where Pf is the predominant species(d'Acremont, Malila et al. 2010 ). 
 
About 1800 malaria cases were diagnosed based solely on the RDT results. All 
patients of the cohort diagnosed with malaria were treated with artemether-
lumefantrine. At the time of the trial, this ACT was not used in PNG and the first 
line treatment was a combination of sulfadoxine-pyrimethamine and 
amodiaquine. Therefore we had limited data in the country on the effectiveness 
and s*afety of this treatment. The present work explores the outcome of children 
diagnosed with malaria using an RDT and treated with artemether-lumefantrine 
in routine practice. We found that the rate of re-attendance for fever within 7 days 
following a positive RDT was very low (less than 2%). This suggests that 
artemether/lumefantrine was effective at clearing the initial parasitaemia. In the 
28 days following initial diagnosis the rate of re-attendance was 10%, but less 
than 1% of children experienced SAEs, and only 4% of these re-attending 
children had malaria parasitemia.  
Because Pv infection can be followed by relapses from hepatic hypnozoites in 
addition to the recrudescences and re-infections that can occur with Pf, we 
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compared the rates of re-attendances in children with Pv and Pf. Only 1.7% of 
children who were initially diagnosed with Pv came back with a BS positive for Pv 
within 28 days, while this rate was 1.3% for Pf species. By day 42, we found re-
attendance rates of 8.2% for Pv and 3.2% for Pf. These figures do not take into 
consideration illness episodes where only the RDT was positive upon re-
attendance, as it can remain positive weeks after a treatment for malaria 
because of the circulating. Similarly to re-attendance rates for children with a 
negative RDT result, these findings are conservative estimates as they include 
relapses, recrudescences, new infections and coincidental infections. These re-
attendance rates are lower than those previously reported in PNG, Indonesia or 
Africa (Mukhtar, Gadalla et al. 2007; Ratcliff, Siswantoro et al. 2007; 
Karunajeewa, Mueller et al. 2008; Bell, Wootton et al. 2009; Schoepflin, Lin et al. 
2010), This is certainly due, at least partly, to the fact that these studies were 
designed to assess efficacy of AL rather effectiveness and included therefore 
systematic screening of parasitemia on defined days rather than spontaneous 
attendance with illness. The present findings provide unique information on the 
effectiveness of this combination in real conditions of use, as well as on its 
safety. The effectiveness of AL against late clinical failures may be further 
improved by adding a single dose of primaquine to the regimen, as was recently 
shown in a study in Myanmar(Smithuis, Kyaw et al. 2010). These data indicate 
that a unified antimalarial treatment policy of AL for both Pf and Pv is a 
reasonable option in a setting where resistance of Pv to chloroquine is 
high(Douglas, NM. et al. 2010).(Marfurt, Mueller et al. 2007)    
Previous studies in Africa showed that clinicians did not always treat children 
based on malaria test, results and tended to give antimalarials even to children 
with negative results.(Reyburn, Mbakilwa et al. 2007; Bisoffi, Sirima et al. 
2009)More recent pilot programs of RDT implementation in Zanzibar and 
Tanzania showed an excellent adherence to a policy of prescription based on 
positive test results. This strategy led to a dramatic reduction of antimalarial 
consumption(Williams, Causer et al. 2008; Msellem, Martensson et al. 2009). All 
these studies were quite heterogeneous in terms of setting and design which 
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may explain the different results. One of the main contributors to the success in 
the most recent studies was a comprehensive training program, which led to a 
true change in clinicians’ behavior.  The very low rate of AL administration in 
children with a negative test result in the present trial is also probably the 
consequence of proper training. Certainly, the research context also helped the 
clinicians to follow the recommendation of antimalarial treatment based on 
documented diagnosis. 
One of the limitations of our study is the use of a passive case detection system 
which leaves patients free to attend or not the health facilities when sick. This 
type of surveillance may miss some malaria episodes, especially when many 
participants live quite far from the health facility. Also, patients may attend 
another health facility than that of the study when sick. This should have been a 
rare event in our study since the clinics were usually the closest facility and care 
was free of charge for the study children. Some children may have also received 
from time to time non-prescribed antimalarial drugs or so-called ‘over the counter 
medication’ in case of fever for example. However, treatments delivered outside 
the health system are not widely available in the study areas. In spite of these 
methodological issues, we can be sure that none of the children died from, or 
was disabled by malaria, since all children were followed up after their illness 
episode  
In conclusion, this study provides solid evidence that the management strategy 
for febrile infants in rural outpatient clinics including a screening for malaria using 
RDT and unified treatment with ACT for malaria infected children is feasible and 
safe in a setting of high endemicity for Pf and Pv. 
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5.1 Abstract 
 
Background 
Intermittent Preventive Treatment of malaria in infants (IPTi) is one of the most 
promising preventative interventions to reduce the burden of malaria in one of the 
highest risk groups in endemic countries. The concept is to deliver antimalarial 
treatment to infants at regular intervals, alongside the expanded program of 
immunization, regardless of the parasitemia. This intervention has been exclusively 
investigated in Africa where Plasmodium falciparum (Pf) is the predominant species. 
The potential benefits of this intervention in areas with significant levels of non-Pf 
infections (mainly Pv) is not known.  
 
Methods 
 Between June 2006 and June 2010 we conducted a 3 arm randomized controlled 
trial (part of the IPTi consortium) to investigate the efficacy of IPTi with 
sulfadoxine/pyrimethamine (SP, single dose) associated to 3 days of either 
amodiaquine (SP-AQ3) or artesunate (SP-AS3) compared to placebo in Papua New 
Guinea (PNG), a country highly endemic for both Pf and Pv.  
Results: 1125 infants 3 months old were enrolled in the IPTi trial. 4 children were 
excluded form the analysis because they did not take any of the study drugs. The 
intention-to-treat (ITT) relative risk (RR) 3-15 months of age was 0.72 (95%CI, 0.57 - 
0.90) on all malaria episodes with SP-AQ3 and 0.88 (95%CI, 0.70 - 1.10) with SP-
AS3, overall p=0.017. Using SP-AQ3, the RR was 0.63 (95%CI, 0.45 - 0.88) on Pf 
and 0.78 (95%CI, 0.60 - 1.01) on Pv. In as-to-protocol (ATP) analysis for SP-AQ3, 
the RR was 0.49 (95%CI, 0.34 - 0.71) for Pf and 0.69 (95%CI, 0.52-0.91) for Pv. 
The RR for anemia with SP-AQ3 was 0.75 (95%CI, 0.58 - 1.01) in the ITT analysis 
and 0.59 (95%CI, 0.42 - 0.82) in the ATP analysis. No rebound effect was observed 
during the second year of life. Few deaths were observed in the treatment arms 
compared to placebo: placebo=8, SP-AQ3=1 and SP-AS3=3. No serious adverse 
events related to study drugs were observed.  
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Conclusion  
This study established the first evidence on the efficacy of IPTi for the prevention of 
malaria and anemia in a region highly endemic for both Pf and Pv and provides an 
essential proof-of-principal that IPTi is an appropriate strategy for the prevention of 
Pv malaria, if an effective, long half-life drug is used such as SP-AQ3. Policy makers 
should therefore consider this intervention in areas outside Africa where the burden 
of non-Pf infections is important. Given the levels of resistance to SP and AQ in 
many parts of the Asia-Pacific and America, further studies are needed to 
investigate other combinations with long acting drugs with a better efficacy in 
particular against P. vivax.  
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5.2 Introduction 
Malaria and anemia are major causes of morbidity and mortality in children in 
tropical countries(WHO 2010). Several preventive strategies have proven to be 
efficient at reducing this burden such as insecticide-treated bed nets(Lengeler 
2004)indoor residual spraying(Pluess, Tanser et al. 2010) or prompt diagnosis and 
treatment with artemisinin combination treatments(Sinclair, Zani et al. 2009; WHO 
2010). Additionally, the preventative administration of a full treatment course of 
antimalarial drugs at fix intervals regardless of illness episodes, named intermittent 
preventive treatment (IPT), has shown to reduce the morbidity related to malaria in 
different contexts(Greenwood 2004; Gosling, Cairns et al. 2010 May). This strategy 
is already widely used in pregnant women (IPTp), with a positive effect on delivery 
outcomes (Rogerson, Chaluluka et al. 2000; Briand, Cottrell et al. 2007; Crawley, 
Hill et al. 2007; Menendez, D'Alessandro et al. 2007). More recently, this kind of 
intervention has shown to be efficient when given to infants at time of vaccination 
(IPTi) or to older children in areas where malaria transmission is highly seasonal 
(IPTs)(Cisse, Sokhna et al. 2006; Greenwood 2006; Munday 2007; Clarke, Jukes et 
al. 2008; IOM 2008; Kweku, Liu et al. 2008; Meremikwu, Donegan et al. 2008; WHO 
2008; Aponte, Schellenberg et al. 2009). 
In the past 10 years, eight randomized control trials have investigated IPTi in 
different African countries with various drug regimens. Sulfadoxine-pyrimethamine 
(SP) dispensed as a single dose 3 or 4 times during the first year of life is the most 
studied drug and has shown to have a protective efficacy against clinical malaria 
episodes of 30% (ranging from 20% to 59%). It also reduces the risk of anemia by 
21%(Aponte, Schellenberg et al. 2009). In all but one trial the preventative effect of 
the IPTi dose was restricted almost exclusively to the first 5 weeks after an 
individual IPTi dose with little effect thereafter(Aponte, Schellenberg et al. 2009). 
While IPTi with SP retains efficacy in areas with moderate resistance(Mayor 2008; 
Griffin, Cairns et al. 2010), in areas with very high resistance levels, SP appears to 
fail to prevent malaria(Gesase, Gosling et al. 2009; Gosling, Gesase et al. 2009). 
Based on this evidence WHO is now recommending IPTi as suitable malaria control 
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intervention in areas of high malaria burden and low to moderate SP resistance 
(WHO 2010). 
Two recent clinical trials have investigated alternative drug regimens that included 
as least 1 long-half life antimalarial such as mefloquine (125 mg single dose), a 
combination of SP (stat) plus 3 days of artesunate (AS) or amodiaquine plus AS (3d) 
for the use as IPTi. All these treatments have protective efficacies ranging from 26-
38%(Gosling, Gesase et al. 2009; Odhiambo, Hamel et al. 2010) and were 
comparable to those in earlier SP trials. While mefloquine showed the highest effect 
(38%), the tolerability of mefloquine was poor with 8% of the children vomiting the 
drug after its administration. A shorter acting drug, dapsone/chlorproguanil however 
failed to significantly reduce both the burden of malaria and anamiea (Gosling, 
Gesase et al. 2009; Odhiambo, Hamel et al. 2010). This indicates that IPTi works 
mainly through a prophylactic effect achieved by long acting drugs (prevention of 
new infections) rather than through a therapeutic effect (cure of existing parastiemia) 
(May, Adjei et al. 2008).  
 
All IPTi studies have been exclusively carried out in Africa where Plasmodium 
falciparum (Pf) is the predominant parasites and P. vivax (Pv) is virtually absent due 
to the high prevalence of Duffy negativity (Rosenberg 2007). In highly endemic 
areas of the SW Pacific,(Genton, D'Acremont et al. 2008; Lin, Kiniboro et al. 2010) 
SE Asia (Tjitra, Anstey et al. 2008) and the Americas (Alexandre, Ferreira et al. 
2010), Pv is however a major source of morbidity including severe illness and death 
in particular in young children. An intervention specifically targeting infants like IPTi 
may thus have significant benefits in these areas. Unfortunately, to-date, nothing is 
known about IPTi efficacy in non-African settings with a high burden of non-Pf 
infections, where IPTi might be considered as part of national malaria control 
strategies. African results cannot be easily extrapolated to Pv co-endemic areas 
both due the difference in the biology of Pf and Pv, in particular its ability to relapse 
from long-lasting liver-stages and the ability of Pv to quickly acquired resistance to 
SP (Tjitra, Anstey et al. 2008). 
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In order to determine the efficacy of IPTi in reducing the burden of malaria and 
anaemia in a Pf and Pv co-endemic setting we therefore undertook an randomized, 
placebo-controlled trial of IPTi with two different drug regimens combining a long 
acting drug (SP) with either 3 days of another drug with long half-life (AQ) or 3 days 
of a short acting drug (AS) in an area of Papua New Guinea (PNG) that is a highly 
endemic country for both Pf and Pv. 
 
5.3 Methods 
Trial design, sites and study participants 
We undertook an individually randomized, double blind, placebo-controlled trial of 
two different regimes (sulfadoxine/pyrimethamine (stat) with either 3 days of 
amodiaquine (SP-AQ3) or 3 days of artesunate (SP-AS3)) of IPTi. The study took 
place from the 6th of June 2006 to the 16th of June 2010. All drugs were given at 
routine vaccination time points at 3, 6 & 9 months and Vitamin A supplementation at 
12 months following the PNG national expanded program of immunization (EPI).The 
efficacy of the intervention was assessed for a 12 months period from enrolment to 
a primary assessment time point at 15 months of age.  Afterwards children 
continued to be monitored every 3 months for up to 12 additional months (see table 
1) 
 
The study was carried out on the north coast of mainland Papua New Guinea (PNG) 
in the Mugil area of Sumkar District, Madang Province. The study site included 20 
villages situated in an approximate 400 km2 area between the coastline and the 
foothills (<400 m) of Adelbert Range, 30-60 km north of Madang town. The Madang 
north coast receives an ample amount of rainfall all year round (3000-4000mm / 
year) with a short dry season from June to September. The 20 study villages are 
serviced by 2 major health centres (Mugil and Alexishafen) and several aid posts. 
Both Health centers are responsible to deliver the Expended Program of 
Immunization (EPI) program in surrounding villages through monthly outreach 
clinics. 
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Free distribution of long-lasting insecticide treated nets (ITN) by the national malaria 
program only started at the end of 2008. Until then, a majority of the population in 
the study site was using untreated nets. 
 
Originally, the study was started as a two-site study with a second site in Maprik 
(East Sepik Province). However, an interim analysis performed at mid-study found 
that the incidence of malaria was dramatically different between the two sites 
(approximately 0.2 episode/child/year for both Pf and Pv in Maprik compared to 1.0 
in Mugil) restricting the comparability of the two sites. Consequently, the study was 
terminated in Maprik (enrolments ceasing in May 2008). Data from the Maprik cohort 
was only included in the safety analyses. The Data and Safety Monitoring Board 
(DSMB) was informed and agreed on the changes made.  
 
The study was carried out in accordance with Good Clinical Practice (GCP) 
guidelines as required by the International Conference on Harmonization (ICH) GCP 
E6 and monitored by an independent external monitor. An independent DSMB 
composed of 2 clinicians and one statistician was also constituted. The study was 
approved by the PNG Medical Research Advisory Committee (MRAC number 
05.20). The trial was registered on www.clinicaltrials.gov (number NCT00285662) 
and formed part of the IPTi consortium (www.ipti-malaria.org) (Schellenberg, Cisse 
et al. 2006). 
 
Randomization, blinding and treatment allocation 
The inclusion criteria were: 1) permanent resident of the area, 2) aged 2-4 months 
old, 3) no disability, 4) no chronic illness, 5) no allergy to study drugs, 6) Hb>5g/l 
and 7) weight for age > 60%. The children meeting these criteria were randomly 
allocated to receive placebo, SP-AQ3 or SP-AS3 treatment group using a pre-
assigned list. In order to assure blinding of the trial, either treatments or placebo 
were randomly assigned to 4 different treatment codes each, resulting in a total of 
12 treatment codes. The randomization list was produced by an independent 
statistician and held by the DSMB. Opaque envelops with consecutive ID containing 
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allocated treatment codes were prepared in advance for the field staff. Only when a 
child met the inclusion criteria, he/she was allocated to the next available ID number 
and the corresponding treatment code by opening the next envelope.  
 
AS & SP or placebo (IPCA Ltd, India) and AQ or placebo (Kimapharma, Ghana) 
were pre-packaged in individual blisters. Study drugs and placebo were assigned to 
the respective treatment codes by an independent technician using the allocation list 
produced by the independent statistician. Quality of drugs and correct code 
allocation was cross-checked by testing drug content in a random sample of tablets 
at the school of Medicine & Pharmacology, University of Western Australia.  
 
Clinical Study Procedures 
The three different treatment regimens were a single dose of SP (25mg sulfadoxine 
and 1.25mg pyrimethamine/kg) combined with 3 days of AQ at 10mg per kg (SP-
AQ3) plus 3 days of AS placebo; a single dose of SP plus 3 days of AS at 4mg per 
kg (SP-AS3) plus 3 days of AQ placebo or matching placebos for all three drugs. 
The tablets were split (quarters or halves) according to the weight (kg) of each child. 
These two treatments arms correspond to the first and second lines of treatment of 
the PNG national standard guidelines for malaria until 2011 when 
artemether/lumefantrine (AL) will be adopted as first and DHA-piperaquine as 2nd 
line treatment. 
 
The intervention was delivered four times during the first year of life alongside the 
Expanded Program of Immunization (EPI). The first IPTi treatment dose was 
delivered at enrollment at 3 months of age along with the third dose of immunization 
against poliomyelitis (OPV), hepatitis B (HBV), diphtheria/pertussis/tetanos (DPT) 
and Haemophilus influenza type b (Hib, introduced in 2007).The second IPTi dose 
was administered at 6 months of age along with first doses of measles vaccine and 
vitamin A. The third IPTi dose was given at 9 months of age along with second dose 
of measles vaccine.  Finally the fourth and last IPTi dose was delivered at 12 
months of age along with the second dose of vitamin A.   
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The drugs were crushed and mixed with water and sweet syrup (Golden Crush 
Cordial ® Papua New Guinea) for easy administration with spoon or syringe. The 
first day dose was administered by a study staff during the clinic. The child was 
monitored closely and if he/she vomited within the next 30 minutes the dose was 
repeated. The 2nd and 3rd doses were given by the carer at home without direct 
supervision. To assess adherence and potential drug adverse reactions, a 
community reporter in each village was tasked to visit each child every day that a 
study treatment dose was given.  
Children were recruited into the IPTi study alongside monthly outreach maternal and 
child health clinics (MCH), which were run by specifically trained study nurses jointly 
with medical staff of both health centres under the supervision of two study 
physicians.  
 
Enrollment of study participants 
The parents or guardians of potential study participants were contacted during 
routine EPIclinics when the child was 1-2 months of age. The study was explained in 
details to the parents through both individual and community awareness meetings 
and an information brochure and consent form in English and in the local language 
(Pidgin) was given to the parent to take home for further discussion.  
 
The child who met the inclusion criteria was formally enrolled during the next clinic 
when the child was 3 months of age (more or less 1 month) and after parents gave 
their written consent  
In total, up to 9 visits were scheduled. Upon enrollment at 3 months of age, a 
concise medical history including bed net use, possible disabilities and presence of 
acute illness was performed. A brief physical examination was done including 
measurement of weight (with weight for age reporting) and spleen size. Table 5.1 
summarizes the different visits performed all along the trial. 
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Table 5-1: Study schedule of the IPTi trial with immunizations and blood collection time points 
 
 
Type of Visit
2 3 6 9 12 15 18 21 24 27
Pre-screening
IPTi treatment IPTi 1 IPTi 2 IPTi 3 IPTi 4
Primary efficacy assessment
Follow-up 
Final assessment
Passive case detection
OPV3 OPV4
HBV3
DPT2 DPT3
Meas 1 Meas 2
Vit A Vit A
During schedulded visits
 blood collection from finger prick 500µl 250µl 250µl 1 ml 250µl 250µl 250µl 250µl 1ml
Hb level & spleen measurment 
Age (months)
Immunization
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Throughout the study period, a passive case detection system was maintained at 
the Mugil study health centre outpatient clinic as well as at three aid posts within 
the study area to assure a continuous morbidity surveillance of study 
participants. The parents of study participants were encouraged to attend these 
study clinics free of charge for clinical management whenever their child was 
sick. Each illness episodes was assessed by study staff using a standard case 
report form. In case of history of fever in the past 48 hours or an axillary 
temperature > 37.5°, rapid malaria diagnostic tests (RDT, ICT Combo®, South 
Africa) was performed, two blood smears and 250 microliters of whole blood 
collected and Hb level measured using a portable Hemocue 201® machine 
(Angelholm, Sweden). Treatment decision was based solely on RDT results with 
only RDT positive infants treated with artemether/lumefantrine (Coartem®), 
irrespective of the species. The children with moderate to severe anemia (Hb < 
8g/dl) received iron supplementation at the dose of 5mg/Kg of ferrous sulphate 
for 6 weeks. All other illnesses were treated according to the standard treatment 
guidelines of PNG. Children presenting any danger signs or symptoms were 
referred to the health centre for admission and treatment. If study participants 
attended after hours, they were attended to by the health centre nurses directly. 
In this case, study staff recorded the reason of admission with clinical 
presentation and treatment allocation (when ever available) the next day. A finger 
prick could be done if necessary to check for malaria parasites and Hb levels. 
Usually, the health center staff did not have the capacity to perform any blood 
test such as malaria rapid diagnostic test at the time of admission and treatments 
were delivered on presumptive diagnosis. 
 
All illness episodes were considered as adverse events and were graded by the 
study clinicians according to the severity from 1 (less severe) to 3 and serious 
adverse event (SAE: life-threatening or death). Hospital admissions that did not 
fulfill the criteria of severity were considered as grade 3. Causality of AE was also 
assessed by the study clinicians as: not related, unlikely, possible and certain. All 
SAE and AE possibly or certainly related were reported to the DSMB. Grade and 
causality were assessed using guidelines adopted by the IPTi Consortium. 
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Laboratory procedure 
Malaria diagnosis 
All blood slides were read independently by two expert microscopists. In case of 
discrepancies, a third read was performed by another microscopist and the two 
concordant reads of the three were considered as the final result.  Thick blood 
films were examined by light microscopy (LM) for 100 thick-film fields (under 
100X oil immersion lens) before being declared infection-negative. Parasite 
species in positive films were identified and densities recorded as the number of 
parasites per 200 white blood cells (WBC). Densities were converted to the 
number of parasites per ml of blood assuming 8,000 WBC per ml (population 
average WBC count [3]). Slides were scored as LM-positive for an individual 
Plasmodium species, if the species was detected independently by at least two 
microscopists. Parasites densities were obtained by calculating the geometric 
mean between the two reads. A third read was performed if the first two slides 
readings were discrepant (different species or more than one logarithm 
difference in parasites densities).Additionally, if the final slides readings (after 2 
or 3 reads) were discrepant compared to PCR results(positivity and species), 
they underwent a 3rd/4th read by a senior microscopist and this last read was kept 
as the final BS result. 
Blood samples were collected from finger pricks in tubes coated with 
Ethylenediaminetetraacetic acid (EDTA) and/or in plain tubes to obtain serum 
depending on the visit.  Upon arrival in the laboratory, samples were separate 
into plasma/serum and cell pellet. Plasma and serum were stored at -80°C until 
further use. DNA was extracted from cell pellets using the QiaAMP 96 extraction 
kit (Qiagen) and the 96-well Genomic DNA Extraction Kit (Favorgen).  
The presence of each of the four human malaria species was also assessed in 
all blood samples using a semi-quantitative post-PCR, ligase detection 
reaction/fluorescent microsphere assay (LDRFMA) ((McNamara, Kasehagen et 
al. 2006))). This assay combines PCR amplification of the small subunit (ssu) 
ribosomal RNA gene (491–500 bp fragments) using genus specific primers, 
followed by a multiplex species-specific ligation detection reaction (LDR). LDR 
products are then incubated with a solution of streptavidin-phycoerythrin and 
specific fluorescent microspheres. The fluorescent signals are collected through 
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a Bioplex reader (Bio-Rad®). The design and sensitivity of this assay has been 
described previously. Mix of serial dilutions of clones of P. falciparum, P. vivax, 
P. malariae and P. ovale 18s RNA fragments were used as controls of reactions, 
as well as two pools of P. falciparum or P. vivax positive samples obtained from 
field isolates. The threshold of positivity of the reactions for each specie was 
determined monthly using the mean value obtained for the negative controls (for 
each specie), plus 3 times the value of its standard deviation. Samples with low-
positive values for one specie (< threshold + 5 times the standard deviation) were 
double-checked and considered as positive only if the result was confirmed. 
 
Molecular marker of drug resistance typing 
A subset of asymptomatic infections with Pf or Pv were typed for molecular 
markers of antimalarial resistance using two post-PCR LDRFMA. Markers of Pf 
SP drug resistance included mutations in pfdhfr (dihydrofolate reductase gene – 
codons 51, 59, 118, 164) and pfdhps (dihydropterate synthase gene – codons 
436, 437, 540, 581, 613); markers of Pf 4-aminoquinoleine drug resistance 
included mutations in pfcrt (chloroquine transporter gene – codons 72 to 76) and 
pfmdr1 (multidrug resistance 1 gene – codons 86, 184, 1034, 1042, 1286). The 
protocol published by Carnevale et al (Carnevale, Kouri et al. 2007) was 
optimized towards a simultaneous amplification of five fragments of these genes 
(pfdhfr, pfdhps, pfcrt and two fragments of pfmdr1) in a multiplex nested PCR, 
with newly designed primers for the five gene fragments (see additional files for 
sequences). A single LDR was performed with 32 allele-specific primers (see 
additional files for sequences). Threshold of positivity Markers of Pv SP drug 
resistance included mutations in pvdhfr (codon 57 to 61, 117, 173), pvdhps 
(codons 382-383, 553, 647) and to 4-aminoquinoleines, pvmdr1 (codon 976).The 
analysis was conducted as described elsewhere. 
 
Sample size calculations 
Based on a predicated incidence rate of 1.2 episodes / child/year (0.7 for Pf and 
0.5 for Pv), a power of 90% and alpha = 0.025, a sample size of 250 children per 
arm was estimated to be necessary to find at least a 28% reduction in the 
incidence of all malaria episodes, 30% reduction in incidence of Pv episodes and 
35-37% reduction in incidence of Pf. Assuming a drop out of participants of 20% 
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in conjunction with a fall in incidence of malaria of 30 to 50% due to insecticide-
treated bed nets (ITN) introduction through the national program in November 
2008, a final adjusted samples size of 366 children per arm or 1100 children in 
total has been calculated. 
 
Statistical methods 
The analysis was performed both by Intention to treat (ITT) and also according to 
protocol (ATP). The ITT population includes all randomized children in Mugil. 
Following the intention-to-treat principle, subjects were analyzed according to the 
preventive treatment they were assigned to at randomization. In the ATP 
analysis, the population includes all randomized subjects that received at least 3 
IPTi treatments (each given with 4 weeks after the schedules treatment time 
point) and were under passive surveillance for the entire 12 months period. 
 
The primary objective of the trial was determination of protective effect of the two 
IPTi regimens. The primary outcome was measured as the incidence of 
symptomatic malariadue to any Plasmodium species from 3 - 15 months of age. 
Secondary outcomes included 1) the specific incidences of symptomatic malaria 
due to Pf or Pv from 3 to 15 months of age, 2) the incidence of symptomatic 
malaria (any, Pf and Pv) from 15 - 27 months (i.e. ‘rebound’), 3) the incidence of 
moderate-to-severe (Hb < 8 g/dl) and severe anaemia (Hb<5 g/dl) from 3 to 15 
months and 15 to 21 months, 4) the prevalence and density of malaria 
parasitemia at 15 and 21 months and 5) the prevalence of splenomegaly at 15 
and 27 months. 
 
Symptomatic malaria was defined as (history of fever and/or axillary temperature 
>37.5° and a positive blood smear or a positive RDTm, confirmed by positive 
PCR). The incidences between the groups are compared using poisson 
regression models with gamma random effects at the intercept (negative 
binomial regression) to take into account possible extra-poisson variation due to 
frailty at individual level. Analysis were adjusted by sex, genotype, number of 
IPTi treatments received, season of enrolment (wet vs dry) and site (grouped by 
12 recruitment zones). The time at risk was calculated starting the date of 
enrollment until the date defined according to the analysis, or withdrawn from the 
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study. An arbitrary period of 28 days was excluded after each episode. The same 
methodology was used for the evaluation of the incidence of moderate-to-severe 
(Hb < 8 g/dl) and severe anemia (Hb<5 g/dl). For the analysis of Hb 
concentration, the mean and standard deviation are presented by group. 
Difference between groups was evaluated using Ordinary Least Square 
Regression, adjusting by sex, genotype, number of IPTi treatments received, 
season of enrolment and site. 
 
For the analysis of prevalence of anemia and splenomegaly, the number of 
subjects that accomplish the definition, percentage and the population at risk is 
presented by group. Comparison between groups was analyzed using logistic 
regression adjusting by sex, genotype, number of IPTi treatments received, 
season of enrolment and site. The risk of malaria in the 35 days following the 
administration of each of the treatment dose was investigated by calculating 
incidence rates and hazard ratios using a cox regression model.  
The analyses were performed in Stata version 11. (Stata statistical software, 
College station, TX, USA). 
 
Role of the founding source 
The sponsor of the study has no role in the design and conduct of the study. All 
collected data are stored at the PNG IMR in Madang.  
 
5.4 Results 
From June 2006 to June 2010, 1125 infants 3 months old were enrolled, 
randomized and followed-up in the trial in Madang area (Figure 5.1).  Four were 
retrospectively excluded from the analysis as they were already receiving 
antimalarial treatments at the time of all IPTi visits and therefore didn’t receive 
any IPTi treatment dose. 374 were allocated to SP-AQ3 group, 374 to SP-AS3 
group and 373 to placebo group (Figure 1). A total of 1079 (96%) completed 
follow-up to 15 months, whereas 857 (76%) completed the primary 6 months and 
372 (33%) the extended 12 months post-treatment follow-up. At the Maprik site, 
480 children were enrolled from July 2006 to May 2008.  
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Figure 5-1: IPTi Study flow diagram 
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The baseline characteristics of all Madang study infants were similar across the 3 
treatment arms (Table 5.2). No significant imbalances were observed between 
the 3 groups. In the final multivariate models gender, village of residence, ITN 
use in the past 2 weeks and season of recruitment were included.A total of 939 
children received 3 or 4 IPTi treatments were thus included in the ATP population 
with no significant imbalances between groups. 
 
Table 5-2: Baseline Characteristics of the study participants 
PLACEBO AQ-SP AR-SP
N 373 374 374
Girls 192 (51.5%) 166 (44.4%) 187 (50%)
Biranis 18 (4.8%) 20 (5.4%) 18 (4.8%)
Megiar 20 (5.4%) 17 (4.6%) 22 (5.9%)
Aronis Garup Wasabamal Zizzi 41 (10%) 35 (9.4%) 42 (11.2%)
Basken Dimer 77 (20.6%) 74 (19.9%) 72 (19.3%)
Bunu Kusen Mugil 38 (10.2%) 54 (14.4%) 54 (14.4%)
Matukar Wasab 38 (10.2%) 31 (8.3%) 24 (6.4%)
Dylup 20 (5.4%) 29 (7.8%) 22 (5.9%)
Karkum 16 (4.3%) 8 (2.1%) 20 (5.6%)
Mirap 17 (4.6%) 23 (6.2%) 31 (8.3%)
Sareng 30 (8%) 21 (5.6%) 23 (6.2%)
Taldig CCI 41 (11%) 48 (12.8%) 33 (8.8%)
Rempi 17 (4.6%) 14 (3.7%) 13 (3.5%)
308 (82.8%) 299 (80%) 305 (82%)
303 (81.2%) 301 (80.5%) 301 (80.5%)
96 (15) 99 (18) 98 (16)
Weight (Kg) 5.9 ( 0.8) 6.0 ( 0.9) 6.0 ( 0.8)
Haemoglobine (g/dl) 9.5 ( 1.0) 9.5 ( 1.2) 9.5 ( 1.1)
All species 14 (3.8%) 30 (8%) 24 (6.4%)
Pf 7 (1.9%) 13 (3.5%) 9 (2.4%)
Pv 7 (1.9%) 17 (4.5%) 15 (4%)
α-thalassemia
αα/αα 53 (17.4%) 63 (19.6%) 53 (16.9%) 
αα/α- 134 (44.1%) 134 (41.7%) 143 (45.5%)
α-/α- 108 (35.5%) 112 (34.9%) 103 (32.8%)
Unknown 9 (3%) 12 (3.7%) 15 (4.8%)
Gerbich blood group  
wt/wt** 171 (56.3%) 192 (59.8%) 201 (64%) 
wt/∆ex3 86 (28.3%) 92 (28.7%) 77 (24.5%)
∆ex3/∆ex3 35 (11.5%) 24 (7.5%) 26 (8.3%)
Unknown 12 (4%) 13 (4.1%) 10 (3.2%)
SAO
wt 263 (86.5%) 273 (85.1%) 275 (87.6%) 
sao 34 (11.2%) 44 (13.7%) 30 (9.6%)
Unknown 7 (2.3%) 4 (1.3%) 9 (2.9%) 
Data are means (SD) and n(%)
** wild-type
 Red blood cells polymophysms
Slept under bednet last two weeks 
Recruitment during rainy season (September-June)
Village areas
Prevalence of 
parasitemia at baseline 
(light microscopy)
Mean Age at enrollment (days) 
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Protective efficacy (PE) 
The incidence of clinical malaria between the first dose at 3mth and 15 mth was 
0.85 per year-at-risk overall and 0.22 and 0.68 for P. falciparum and P. vivax, 
respectively. In ITT analyses, PE against all cases of malaria was 29% ([95%CI, 
0.10, 0.43], p = <0.001) in the SP-AQ3 group and 12% ([95%CI, -0.11, 0.30], p = 
0.12) in the SP-AS3 group. The PE was higher against P. falciparum than P. 
vivax in both groups (Table 5.3 & 5.4): In the SP-AQ3 group, Pf incidence was 
reduced by 35% ([95%CI, 0.09, 0.54], p = 0.012) and Pv incidence by 
23%([95%CI, 0.00, 0.41], p = 0.048). In the SP-AS3 group on the other hand a 
significant reduction was found only for incidence of P. falciparum (IRR = 0.69, 
95%CI, 0.49, 0.96] p = 0.027) for but not P. vivax episodes (IRR = 0.96, [95%CI, 
0.94, 1.24] p = 0.758). 
The strength of protection increased when only children with ≥3 IPTi treatments 
were considered (i.e. APT analyses, Table 5.4). Regular administration of SP-
AQ3 reduced malaria episodes by 38% overall ([95%CI, 0.20, 0.52] p < 0.001) 
and 49% ([95%CI, 0.26, 0.65] p < 0.001) and 31% ([95%CI, 0.09, 0.49] p = 
0.010) for P. falciparum and P. vivax malaria episodes, respectively, whereas 
administration of SP-AS3 resulted in a 23% reduction in all malaria episodes 
([95%CI, 0.01, 0.40] p = 0.041) and a 46% ([95%CI, 0.22, 0.62] p = 0.001) and 
12% ([95%CI, -0.12, 0.34] p = 0.355) for P. falciparum and P. vivax episodes.  
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Table 5-3: efficacy results of IPTi 3-15 months (ITT) 
 
 
95% 95%
(PYAR) Conf. Interval Conf. Interval
Placebo 362 337.3 1.07 1 - 1.07 1 - 0.017
AQ-SP 280 352.1 0.80 0.71 ( 0.57, 0.90) 0.80 0.72 ( 0.57, 0.90)
AR-SP 336 346.9 0.97 0.88 ( 0.70, 1.11) 0.97 0.88 ( 0.70, 1.10)
Placebo 100 356.1 0.28 1 - 0.28 1 - 0.012
AQ-SP 67 366.6 0.18 0.65 ( 0.46, 0.91) 0.18 0.63 ( 0.45, 0.88)
AR-SP 71 365.4 0.19 0.69 ( 0.49, 0.96) 0.19 0.68 ( 0.49, 0.94)
Placebo 282 342.9 0.82 1 - 0.82 1 - 0.130
AQ-SP 234 355.4 0.66 0.77 ( 0.59, 1.00) 0.66 0.78 ( 0.60, 1.01)
AR-SP 283 350.5 0.81 0.96 ( 0.74, 1.24) 0.81 0.96 ( 0.75, 1.24)
Placebo 169 351.1 0.48 1 - 0.48 1 - 0.110
AQ-SP 132 362.6 0.36 0.75 ( 0.56, 1.01) 0.36 0.75 ( 0.56, 1.01)
AR-SP 133 361.2 0.37 0.75 ( 0.56, 1.01) 0.37 0.77 ( 0.58, 1.04)
Placebo 12 362.1 0.03 1 - 0.03 1 - 0.906
AQ-SP 10 370.4 0.03 0.81 ( 0.33, 1.97) 0.03 0.82 ( 0.33, 2.00)
AR-SP 11 369.6 0.03 0.89 ( 0.37, 2.13) 0.03 0.9 ( 0.38, 2.15)
p-value from Negative binomial regression model using Likelihood Ratio Test
Treatment effect adjusted by:sex, village areas, slept under bednet last two weeks and season at recruitment
All malaria 
episodes
Pf infections
Severe 
malaria
Anemia (Hb 
< 8g/dl)
Pv 
infections
p-valueRR
Group
Time At 
RiskNumber 
of cases Incidence 
per PYAR
0.108
0.090
0.894
Adjusted valuesUnadjusted values
0.018
0.020
Incidence 
per PYAR RR p-value
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Table 5-4: Efficacy results of IPTi 3-15 months (ATP) 
 
95% 95%
(PYAR) Conf. Interval Conf. Interval
Placebo 302 285.84 1.06 1 - 1.06 1 - 0.0008
AQ-SP 212 310.45 0.68 0.62 ( 0.48, 0.80) 0.68 0.62 ( 0.48, 0.79)
AR-SP 250 300.04 0.83 0.77 ( 0.60, 0.99) 0.83 0.77 ( 0.61, 0.99)
Placebo 83 301.58 0.28 1 - 0.28 1 - 0.0001
AQ-SP 45 321.71 0.14 0.51 ( 0.35, 0.74) 0.14 0.49 ( 0.34, 0.71)
AR-SP 47 314.14 0.15 0.54 ( 0.38, 0.78) 0.15 0.54 ( 0.38, 0.78)
Placebo 235 290.41 0.81 1 - 0.81 1 - 0.033
AQ-SP 180 312.79 0.58 0.69 ( 0.52, 0.91) 0.58 0.69 ( 0.52, 0.91)
AR-SP 218 302.32 0.72 0.88 ( 0.66, 1.16) 0.72 0.88 ( 0.67, 1.16)
Placebo 143 297.21 0.48 1 - 0.48 1 - 0.0048
AQ-SP 92 318.92 0.29 0.59 ( 0.42, 0.82) 0.29 0.59 ( 0.42, 0.82)
AR-SP 101 310.39 0.33 0.66 ( 0.47, 0.92) 0.33 0.69 ( 0.50, 0.96)
Placebo 11 306.412 0.036 1 - 0.036 1 - 0.6545
AQ-SP 7 324.153 0.022 0.6 ( 0.22, 1.66) 0.022 0.62 ( 0.23, 1.71)
AR-SP 9 316.767 0.028 0.79 ( 0.30, 2.05) 0.028 0.81 ( 0.32, 2.09)
p-value from Negative binomial regression model using Likelihood Ratio Test
Treatment effect adjusted by:sex, village areas, slept under bednet last two weeks and season at recruitment
RR p-value
Adjusted values
Severs 
malaria
Anemia 
(<8g/dl)
Pv 
infections
Pf 
infections
All malaria
RR p-value
0.001
Incidence 
per PYAR
0.6115
Time At 
RiskNumber 
of casesGroup
Unadjusted values
0.0002
0.0325
0.0037
Incidence 
per PYAR
 
 
  
87
IPTi with both SP-AQ3 and SP-AS3 also provided protection against moderate-
to-severe anaemia (Hb < 8 g/dl, Table 5.3 & 5.4). In the ITT population, the 
incidence of anaemia was reduced by 25% for both SP-AQ3 ([95%CI, -1, 44] p = 
0.054) and SP-AS3 (([95%CI, -1, 44] p = 0.062). In the ATP population (i.e. ≥3 
IPTi treatments) the protective efficacy increased to 41% ([95%CI, 18, 58] p = 
0.002) in the SP-AQ3 and 34% ([95%CI, 8, 53] p = 0.013) in the AS-AS3 group. 
The study shows also a reduction of the risk of moderate-to-severe anemia (hb < 
8g/dl) by 25% with SP-AQ3 in the ITT analysis (p=0.11) and 41% in the ATP 
analysis (p=0.005). 
Few cases of severe anemia (< 5g/dl) were observed during the study. In the ITT 
analysis, there were 8 severe anaemia in the placebo group, 2 in the SP-AQ3 
group and 4 in the SP-AS3 group (p=0.12). In the ATP analysis, there were 7 
cases in the placebo, 1 in SP-AQ3 group and 2 in the SP-AS3 group (p=0.04).  
Adjustment for sex, place of residency, season of recruitment and use of bed 
nets in the past two weeks did not significantly alter estimates of PE (figure 5.2).   
 
Figure 5-2: Summary of IPTi preventive efficacy of malaria at 15 months of 
age (all RR were adjusted for sex, place of residence, season of enrolment 
and use of bed nets in the past 2 weeks) 
 
 
 
Graph 5.1 shows the Kaplan-Meier survival curves for the time to the first or only 
malaria episode 3 to 15 months in ITT and ATP analysis for any species, Pf and 
Pv infections. Hazard ratios (HR) were as follow for SP-AQ3 in the ITT analysis: 
0.85 [95%CI 0.69, 1.05] for all species, 0.60 [95%CI, 0.42, 0.84] for Pf and 0.92 
(95%CI, 0.73, 1.16) for Pv. In the ATP analysis, HR for SP-AQ3 were 0.79 
(95%CI, 0.62, 0.99) for all species, 0.50 (95%CI, 0.34, 0.74) for Pf and 0.82 
(95%CI,0.63, 1.06) for Pv. 
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Graph 5-1: Kaplan-Meyer survival curves of the IPTi protective efficacy 
using either SP/AQ or SP/AS on all malaria episodes, on Pf and on Pv 
 
Post-dose efficacy 
SP-AQ3 had slightly lower protective efficacy in the 35 days following the 
allocation of each IPTi treatment doses against Pf (72% [95%CI, 39 – 87], p < 
0.001) than Pv (83% [95%CI, 70 – 90], p < 0.001), whereas SP-AS3 was more 
efficacious against Pf (82% [95%CI, 53 – 93], p<0.001) than Pv (58% [95%CI, 36 
– 73], p<0.001). (Table 5.5) 
 
Post-intervention risk 
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The incidence of clinical malaria between 15 and 21 mths was 1.09 per year-at-
risk overall and 0.43 and 0.70 for P. falciparum and P. vivax, respectively. No 
evidence of a ‘rebound effect’ was observed in the 6 mths following the end of 
the intervention at the age of 15 mths (p=0.79 between all three groups in the ITT 
analysis). Similarly, no significant differences in incidence of P. falciparum 
malaria, P. vivax malaria and anaemia were observed (Table 5.6).  There was 
also not indication of a rebound effect in the subset of children that were followed 
up to 27mths (p=0.99 between all 3 groups in the ITT analysis). 
 
Prevalence of parasitaemia during follow-up 
The prevalence rates of both P. falciparum and P. vivax increased from 1.5% and 
8.5% at 6mth to 3.0% and 15.8% at 15mth and 4.4% and 20.3% at 21mth, 
respectively, when detected by microscopy (Figure 5.3). At 15 months, the 
prevalence of P. falciparum was significant lower in the two treatment arms (p = 
0.037) but not at any other time point. No significant differences in P. vivax 
prevalence were found between treatment arms. Only 2 P. malariae and no P. 
ovale infections were detected by light microscopy 
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Table 5-5: protective efficacy in the 35 days following each treatment dose 
 
Time At Risk 95%
(PYAR) Conf. Interval
Placebo 4 27.7 0.14 1 - 
AQ-SP 1 29.1 0.03 0.24 ( 0.03, 2.13)
AR-SP 2 29.0 0.07 0.48 ( 0.09, 2.61)
Placebo 4 27.6 0.15 1
AQ-SP 3 29.0 0.10 0.71 ( 0.16, 3.18)
AR-SP 8 28.7 0.28 1.92 ( 0.58, 6.38)
Placebo 3 27.3 0.11 1 -
AQ-SP 2 29.6 0.07 - -
AR-SP 0 27.4 0.00 -
Placebo 27 26.4 1.02 1 - 
AQ-SP 3 29.7 0.10 0.1 ( 0.03, 0.32)
AR-SP 7 27.2 0.26 0.25 ( 0.11, 0.57)
Placebo 9 26.9 0.34 1 - 
AQ-SP 2 28.4 0.07 0.21 ( 0.05, 0.97)
AR-SP 2 26.8 0.08 0.22 ( 0.05, 1.03)
Placebo 23 26.2 0.88 1 - 
AQ-SP 5 28.4 0.18 0.2 ( 0.08, 0.53)
AR-SP 7 26.7 0.26 0.3 ( 0.13, 0.69)
Placebo 11 25.6 0.43 1 - 
AQ-SP 3 28.0 0.11 0.25 ( 0.07, 0.90)
AR-SP 1 26.4 0.04 0.09 ( 0.01, 0.68)
Placebo 28 24.9 1.13 1 - < 0.0001
AQ-SP 5 27.9 0.18 0.16 ( 0.06, 0.41)
AR-SP 13 25.6 0.51 0.45 ( 0.23, 0.87)
Pf infections
Pv infections < 0.0001
p-value
Pf infections 0.3383
Group Numbner 
of cases
Incidence 
per PYAR HR
After dose 4 at 12 
months
Pf infections 0.0029
Pv infections
After dose 3 at 9 
months
After dose 2 at 6 
months
After dose 1 at 3 
months
Pf infections 0.027
Pv infections 0.0002
Pv infections 0.2669
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Table 5-6: Incidence of malaria per treatment arm within 6 and 12 months following the end of the intervention ITT) 
 
Time At Risk 95%
(PYAR) Conf. Interval
All malaria Placebo 171 149.0 1.15 1 - 
AQ-SP 164 155.5 1.05 0.92 ( 0.70, 1.22)
AR-SP 167 157.2 1.06 0.92 ( 0.70, 1.21)
Pf infections Placebo 65 156.2 0.42 1 - 
AQ-SP 68 162.0 0.42 1.01 ( 0.69, 1.49)
AR-SP 74 163.8 0.45 1.07 ( 0.73, 1.56)
Pv infections Placebo 115 152.9 0.75 1 - 
AQ-SP 112 158.8 0.71 0.96 ( 0.69, 1.33)
AR-SP 106 161.1 0.66 0.89 ( 0.64, 1.24)
Anemia (<8g/dl) Placebo 42 157.7 0.27 1 - 
AQ-SP 44 163.4 0.27 0.98 ( 0.62, 1.57)
AR-SP 45 165.4 0.27 1.02 ( 0.64, 1.62)
0.9391
0.7715
Group Numbner of 
cases
Incidence 
per PYAR RR p-value
0.7925
0.988
15-21 months
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Figure 5-3 Prevalence of parastiemia during follow-up visits 
 
 
Safety 
A total of 6,165 adverse events and 275 severe adverse events were observed 
during the intervention period (3-15mth) with no significant difference between 
treatment arms (Table 5.7). None of them was found to be study related. One 
child in the placebo group experienced a non-severe (grade 1) skin rash a few 
days following administration of the second IPTi dose. 
 
In total, thirteen deaths occurred among study participants. One was excluded 
from the analysis because he/she did not receive any IPTi treatment dose. Nine 
occurred in Madang and three in Maprik. Out of the twelve remaining, nine 
occurred during the intervention period. Of these, seven occurred in the placebo, 
two in the SP-AS and none in the SP-AQ3 group. An additional thee deaths (one 
in each group) were observed during post-intervention follow-up (p=0.03) The 
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likely diagnosis as per available clinical and paraclinical data were: one severe 
Pv malaria (density of 12’200/µl) with severe anemia (Hb=5g/dl)and possible 
lower respiratory tract infection (severe respiratory distress and cough), four 
lower respiratory tract infections, three dehydrations and malnutrition, one 
tuberculosis, one meningitis and two with unknown diagnosis. 
 
Adherence and levels of drug resistance 
Adherence to study drugs was assessed by field workers visiting the parents at 
home on every day that an IPTi dose should have been given and reported an 
adherence rate of more than 90% (data not shown) 
 
Prevalence of molecular markers of drug resistance 
The presence of mutations related to SP and AQ drug resistance in Pv was 
assessed on 105 randomly selected asymptomatic infections. (Pf data no 
available at this time) 
Of 105 Pv infections, 53 were monoclonal based on the genotyping of pvdhfr, 
pvdhps and pvmdr1. Five isolates (9.4%) were displaying wild type pvdhfr 
haplotype (F57-S58-T61-S117-I173), 20 (37.7%) a double mutant haplotype 
(57L-58R-T61-S117-I173), one (1.9%) a triple mutant haplotype (57L-58R-T61-
117T-I173) and 27 (50.9%) a quadruple mutant haplotype (57L-58R-61M-117T-
I173). All the isolates displayed the same haplotype for pvdhps: S382-C383-
A553-647P. 36 isolates (67.9%) displayed the pvmdr1 976F mutation. Twenty 
(37.7%) isolates carried the quintuple mutant haplotype pvdhfr 57L-58R-61M-
117T-I173 / pvmdr1 976F associated with AQ-SP resistance. 
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Table 5-7: Incidence of adverse events, serious adverse events, severe anaemia, hopital admission and deaths for 
Madang and Maprik at different time points 
 
 
Time At Risk 95%
(PYAR) Conf. Interval
Placebo 2035 512.07 3.97 1 - 0.9935
AQ-SP 2078 519.52 4 1 ( 0.91, 1.09)
AR-SP 2052 518.31 3.96 1 ( 0.91, 1.08)
Placebo 82 517.2 0.16 1 - 0.8408
AQ-SP 99 524.68 0.19 1.11 ( 0.78, 1.56)
AR-SP 94 523.47 0.18 1.07 ( 0.76, 1.52)
Placebo 7 517.407 0.014 1 -
AQ-SP 0 524.953 0 - -
AR-SP 2 523.723 0.004 - 
Incidence per 
PYAR
3-15 months
cases RR
Deaths
Serious adverse events
All adverse events
p-value
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5.5 Discussion 
This study in PNG infants provides the first evidence for the efficacy of IPTi with 
SP-based regimens for the prevention of malaria and anaemia in a non-African 
population exposed to high levels of non-falciparum malaria. IPTi with 
combination of SP plus 3 days of AQ resulted in a 28% decrease in all malaria 
episodes and a 25% decrease in episodes of moderate-to-severe anaemia (Hb < 
8g/dl). Efficacy increased in children that received at least 3 doses of IPTi during 
the 1st year of life (38% for any malaria and 41% for anaemia, respectively). In 
line with local resistance patterns and pharmacokinetic properties SP-AS3 was 
found to be inferior to SQ-AQ3 (see below for detailed discussion). Overall, the 
efficacy of IPTi SP-AQ3 in PNG infants is comparable to the 30% efficacy 
observed in African infants receiving IPTi with SP (Aponte, Schellenberg et al. 
2009). Both IPTi treatments were well tolerated and safe. The present data thus 
provide essential proof-of-principle evidence for the safety & efficacy of IPTi 
outside Africa. 
 
Prevention of malaria 
Overall, IPTi with AS-AQ3 was more efficient in preventing P. falciparum than P. 
vivax malaria (ITT 37% vs 22%, ATP 51% vs 31%). This was not unexpected. 
African IPTi studies demonstrated that the IPTi efficacy is almost exclusively due 
to the post-treatment prophylactic effect of the drugs given with the preventative 
effect of IPTi SP almost entirely due to a reduction of malaria in the first 5 weeks 
after treatment (May, Adjei et al. 2008; Aponte, Schellenberg et al. 2009). 
Consequently, only IPTi with long- but not short-half live drugs were effective in 
reducing the risk of malaria in infancy (Gosling, Gesase et al. 2009; Odhiambo, 
Hamel et al. 2010). In line with the African results, in the present study both SP-
containing regimens had similarly high protective effect against P. falciparum for 
the first 35 days (72-82%), resulting in an overall efficacy of IPTi against P. 
falciparum that was towards the higher end of those found in African studies 
(37% vs 30%, (Aponte, Schellenberg et al. 2009; Gosling, Gesase et al. 2009; 
Odhiambo, Hamel et al. 2010)).  
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Although a similar post-treatment prophylactic effects was observed in relation to 
the risk of P. vivax malaria with SP-AQ3 preventing 83% of P. vivax episodes in 
the 1st 35 days following treatment, the overall efficacy of IPTi against P. vivax 
malaria was lower in the SP-AQ3 and absent in SP-AS3 arm. The main reasons 
for this are the ability of P. vivax to relapse from long-lasting liver-stages(Krotoski 
1989) and higher levels of SP resistance in P. vivax.  
 
P. vivax strains from New Guinea are thought to relapse very frequently (Craige, 
Alving et al. 1947) and following drug treatment P. vivax blood-stage infections 
are therefore re-established very rapidly. In a concurrently conducted in-vivo drug 
trial PNG children 0.5-5 yrs treated with SP-chloroquine (3d) and SP-AS3, 65% 
and 49% respectively had recurrent parasitaemia and 22% and 18% a recurrent 
clinical episode by day 42 (Karunajeewa, Mueller et al. 2008).Consequently, 
even if an IPTI is able to both clear pre-existing infections and effectively prevent 
primary infections during 1st 5 weeks, the first relapse will occur at time when 
drug levels have dropped below the levels required for prevention of re-infection. 
Even though PNG children acquire immunity to P. vivax very rapidly (Lin, 
Kiniboro et al. 2010), infants are unlikely to have acquire significant immunity in 
the 1st year of life and are at risk of clinical disease from both new and relapsing 
infection during the interdose period.  
 
As SP was never used as a mono-therapy in PNG, there are no estimates of SP 
in-vivo resistance for either P. falciparum of P. vivax. However, well-validated 
molecular makers of SP resistance exist for both parasites. In P. falciparum the 
quintuple Pfdhfr 51-59-108 / Pfdhps 436-547 is associated with a high degree of 
drug resistance (Picot, Olliaro et al. 2009) while in P. vivax 57L-58R-61M-117T 
quadruple mutation (irrespective of pvdhps mutations) has been associated with 
increased risk of treatment failure (Hawkins, Joshi et al. 2007; Marfurt, de 
Monbrison et al. 2008). The high frequency of the quadruple pvdhfr mutation but 
complete absence of quadruple/quintuple pfdhfr/pfdhps in infection from iPTI 
children, therefore indicated that while SP retained a substantial efficacy against 
P. falciparum, its efficacy against P. vivax was likely to have been severely 
compromised.  
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Although chloroquine resistance P. vivax was first described in PNG(Rieckmann, 
Davis et al. 1989), there is a significantly higher level of 4-aminoquinoline 
resistance present in P. falciparum compared to P. vivax. AQ resistant P. 
falciparum was first detected in the early 1980s (Tulloch 1980) and within 10yrs 
reached >35% RII & RIII resistance (Mueller, Bockarie et al. 2003). The almost 
complete fixation of the SVMNT pfcrt haplotype and the pfmdr1 86Y mutation 
that were associated with AQ resistance among the Pf isolates(Marfurt, Muller et 
al. 2008) from the IPTI children demonstrated the continued very high level of AQ 
resistance. There are only limited data on AQ resistance in P. vivax from PNG. In 
a study in 90’, 14% (12/88) of infections (any species) treated with AQ did not 
show an adequate response, but only one Pv out of 18 was RII resistant 
(Genton, Baea et al. 2005). In 2003/04, although SP-AQ3 was 100% clinically 
effective, recurrent parasitaemia was observed in 12% of children treated 
(Marfurt, Mueller et al. 2007) with the pvdhfr 57L-58R-61M-117T / pvmdr1 976F 
quintuple mutation associated with treatment failure (Marfurt, de Monbrison et al. 
2008). The relatively low level of 976F mutations in P. vivax infection observed in 
IPTi children thus indicated that AQ retains good clinical efficacy against P. vivax 
infection in PNG.  
 
The differential efficacy of IPTi SP-AQ4 and SP-AS3 for the prevention of P. 
falciparum and P. vivax malaria are therefore well explained by the above 
resistance patterns and the pharmacokinetic properties of the different drugs 
used. Given the high level of AQ resistance and the very short half life of AS 
(Karunajeewa, Ilett et al. 2004), the efficacy to IPTi for the prevention of P. 
falciparum is therefore likely to be due to the preventative efficacy of SP. The 
high level of preventative efficacy for 35 days is well in line with the terminal 
elimination half-life (t1/2β) of 15.6 and 9.1 days for pyrimethamine and 
sulphadoxine, respectively in PNG infants(Salman, Kose et al. 2011). With SP 
unlikely to be efficacious against P. vivax, the success of IPTi intervention thus 
relies on the efficacy of the partner drug. Whereas P. vivax parasites are 
efficiently cleared by SP-AS3, the short half-life of AS provides no post-treatment 
prophylactic effect and recurrent P. vivax infections are very common 
(Karunajeewa, Mueller et al. 2008).  AQ on the other hand has a half-life of ~9 
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days (Stepniewska, Taylor et al. 2009) and a 3day course should therefore 
effectively suppress sensitive parasites for 4-5 weeks. The differences in efficacy 
between IPTi SP-AQ3 and SP-AS3 for prevention of P. vivax malaria confirm the 
observation from African studies that only combinations including efficacious long 
acting drugs such as SP, AQ or mefloquine are efficient in preventing P. 
falciparum malaria (Gosling, Gesase et al. 2009; Odhiambo, Hamel et al. 2010). 
In addition, the lack of any protective effect of SP-AS against P. vivax but not P. 
falciparum adds further evidence that while SP can retain a considerable effect of 
low to moderate levels of resistance (Griffin, Cairns et al. 2010), it looses its 
prophylactic activity at very high levels of resistance (Gosling, Gesase et al. 
2009).  
 
Prevention of anemia, severe illness and death 
Besides reducing the burden of malaria episodes, IPTi also reduced the risk of 
moderate-to-severe (Hb < 8 g/dl, 25% in the ITT and 34-41% in the ATP 
analyses, respectively) and severe anemia (Hb < 5gl). Probably because of the 
small number of cases, the observed decrease of risk didn’t reach statistical 
significance. These effects are in line with previous findings on the prevention of 
anemia in Africa(Aponte, Schellenberg et al. 2009) and highlight the important 
contribution of P. vivax infections to anemia related morbidity in highly endemic 
areas(Genton, D'Acremont et al. 2008). 
 
No difference was observed between the groups in number of SAE’s (i.e. all 
cause admissions plus severe illness). But surprisingly, a significantly lower 
death rate was observed in the 2 treatment-arms compare to the placebo-arm. 
Even though this finding is very encouraging, it has to be interpreted with caution. 
Only 11 deaths occurred during the intervention period with most children dying 
at home. The cause of death therefore had to be established by verbal autopsy 
(VA). Based on VA’s and available clinical records, a majority of children might 
have died of severe lower respiratory tract infections. Since Sulfadoxine, being a 
sulfonamide drug, has a well demonstrated suppressive effects on bacterias 
(Schürmann and al. 2002), it is thus possible that IPTi with SP might provide 
some level of protection against invasive bacterial infections such as 
streptococcus pneumoniae.  
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Safety of SP-AQ3 and SP-AS3 
IPTi with both SP-AQ3 and SP-AS3 was very safe. More than 4’000 doses of SP 
and 6’000 doses of AQ & AS were given and no study drug related AEs were 
observed. As in earlier studies, no significantly increase in risk of malaria or 
anemia was recorded after completion of 12 months of IPTi, indicating that IPTi 
does not impair the acquisition of immunity to both P. falciparum and P. vivax 
and lead to a rebound in malaria risk. These data are very reassuring in regards 
to a possible use of these drug combinations in PNG and add the safety data of 
pooled analysis IPTi SP safety from African studies(Aponte, Schellenberg et al. 
2009).  
 
The use SP as prophylaxis has been criticized because of the potential risk of 
severe skin reaction of Stevens-Johnson syndroms (White 2005) but by now 
>5600 children have been treated with SP-containing IPTi regimens in well 
control clinical trials and not a single drug related severe dermatological event 
was observed (Aponte, Schellenberg et al. 2009; Gosling, Gesase et al. 2009; 
Odhiambo, Hamel et al. 2010). On the other hand IPTi with mefloquine while 
highly effective was not well tolerated with high rates of vomiting (Gosling, 
Gesase et al. 2009). Given that SP has now been used for several years in 
pregnant women with good acceptability and tolerability, in the absence of novel 
drug regimens for IPTi, the combination of SP and AQ is the best, currently 
available option for IPTi in PNG. 
 
Adherence, acceptability and implementation  
The size of the difference in IPTi efficacy between “as to protocol” (ATP) analysis 
and intention to treat (ITT) population indicates that if the intervention is 
implemented, it will be important to achieve both high coverage and high 
adherence to the treatment to achieve a good efficacy. 
 
In both SP-AQ3 and SP-AS3 only the first dose was given as directly observed 
treatment (DOT). Parents were then counseled on the importance of giving the 
remaining two doses at home. With this approach a very high rates of 
compliance (more than 90%) was achieved. As a result, appropriate drug levels 
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were measured in random sample of study participants on the day after the last 
IPTi dose (AQ or AS) was administered by parents (Senn et al, personal 
communication). Acceptability by parents and health workers of IPTi was 
excellent and the administration of IPTi alongside EPI IPTi did not have negative 
impacts on attitudes to EPI, EPI adherence or existing malaria prevention 
practices(Pell, Straus et al. 2010).  
 
Finally, cost-effectiveness was also investigated in PNG and has shown 
encouraging results similarly to what has been found in Africa(Conteh, Sicuri et 
al. 2010)(PNG data not yet available). Therefore, and in line with what was 
described in Africa(Armstrong Schellenberg, Shirima et al. 2010), the IPTi 
intervention seems well suited for implementation in rural and remote settings of 
PNG and both its acceptability and adherence is likely to be very good.  
 
5.6 Conclusions 
This study established the first evidence on the efficacy of IPTi for the prevention 
of malaria and anemia in a region highly endemic for both Pf and Pv and 
provides an essential proof-of-principal that IPTi is an appropriate strategy for the 
prevention of Pv malaria, if an effective, long half-life drug is used. Policy makers 
should therefore consider this intervention in areas outside Africa where the 
burden of non-Pf infections is important. Given the levels of resistance to SP and 
AQ in many parts of the Asia-Pacific and America, further studies are needed to 
investigate other combinations with long acting drugs with a better efficacy in 
particular against P. vivax.  
 
In the PNG context, the combination of SP-AQ3, two long-acting drugs with well 
match half-lives and good activity against either P. falciparum (SP) or P. vivax 
(AQ) is an appropriate drug choice for IPTi and its introduction into the national 
standard treatment guidelines should be considered. If implemented, it will be 
important to assure that children receive at least three IPTi doses in the 1st year 
of life to assure optimal protection against malaria and malarial anemia. The 
replacement of AQ and SP by arthemeter-lumefantrine as the national 1st line 
treatment will reduce the selection pressure for resistance against AQ and SP 
  
101
and it can thus be expected that the (prophylactic) efficacy of two drugs will be 
retained or as seen in Africa following withdrawal of chloroquine possible even 
improve (Laufer, Thesing et al. 206). Appropriate monitoring of prophylactic 
efficacy of AQ, SP as well as possible novels drugs such as DHA-piperaquine 
should therefore accompany IPTi introduction in PNG. 
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6.1 Abstract 
Background 
No studies have looked at the appropriateness of Integrated Management of 
Childhood Illnesses (IMCI) guidelines in the context of the introduction of malaria 
rapid diagnostic tests (RDT) and Intermittent Preventive Treatment in infants 
(IPTi), a so-called IMCI+.  
Methods 
Making use of the passive case detection of the IPTi trial in Papau New Guinea, 
the appropriateness of IMCI+ on the incidence of disease and case management 
(diagnostic and treatment) was assessed in PNG young children along an IPTi 
randomized control trial. 
Results 
1605 children 3-27 months were enrolled and 8944 illness episodes reported. 
Incidence rates (episodes/child/year) were: 0.85 for LRTI (95%CI,0.81-0.90), 
0.62 for malaria (95%CI,0.58-0.66), 0.72 for GI (95%CI,0.65 -0.93) and 0.08 for 
otitis (95%CI,0.07-0.09). Introduction of RDTs led to high accuracy of malaria 
diagnosis compared to expert computer-generated algorithm ( 0.99). Clinical 
diagnosis of LRTI (=0.47), gastro-enteritis (=0.52) and otitis (= 0.52) 
were significantly less accurate (p < 0.001). According to IMCI+, 6% didn’t 
received antibiotics when they should have and 19% received antibiotics when 
they shouldn’t have. Re-attendance rates within 14 days following LRTI was 9% 
when children received antibiotics compare to 8% when they didn’t receive 
(p=0.44), rates for gastroenteritis were respectively 8% and 9% (p=0.51) . No 
differences were found in the incidence of non-malarial illnesses between the 
placebo and IPTI intervention arms (AQ -SP and AS-SP).  
Conclusion 
IMCI+ results in a high accuracy of malaria diagnosis, while the syndromic 
diagnosis of LRTI is insufficiently accurate to adequately guide treatment. 
Inappropriate use of antibiotics is common. However, their usage seems not to 
change the outcome of children with LRTI and GI. Better strategies for the 
identification of diseases that require antibiotics are needed. Although effective in 
  
105
preventing malaria, IPTi had no impact on other common causes of morbidity in 
infancy. 
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6.2 Background  
Worldwide, the leading causes of death in children under five years (excluding 
peri-natal mortality) are pneumonia, diarrhoea and malaria. These three diseases 
are responsible for an estimate of 5 millions of deaths yearly with more than 90% 
of them occurring in Africa and countries with limited resources(Bryce, Boschi-
Pinto et al. 2005).At a community level and in outpatient settings, data are 
scarce, but the few available studies reported that acute respiratory infections, 
diarrhoea and malaria are similarly responsible for a high burden of morbidity in 
developing countries, the poorest people suffering the most. (Velema, Alihonou 
et al. 1991; Roca, Quinto et al. 2006; Deressa, Ali et al. 2007; Animut, Mekonnen 
et al. 2009; Feikin, Olack et al. 2011) 
For decades, a high importance was given to malaria as a cause of fever, which 
has lead to an overestimation of its burden and at the same time an 
underestimation of other diseases. (Reyburn, Mbatia et al. 2004; Gwer, Newton 
et al. 2007) This is still the case in many countries where malaria prevalence is 
measured through presumptive diagnosis only. Nowadays, case management 
strategy of sick children under five in developing countries is usually based on 
clinical presentation of diseases (syndromes) rather than on aetiologies as 
recommended by the World Health Organization (WHO) who developed the 
Integrated Management of Childhood Illness (IMCI)(WHO 2007) guidelines for 
this purpose. For example, cough or difficult breathing associated to tachypnoea 
defines a lower respiratory tract infection (LRTI), which includes pneumonia of 
bacterial and viral origins. The estimation of the burden of diseases in developing 
countries is usually based on data using these syndromic definitions of diseases. 
In order to get a precise estimate of the burden of syndromic diagnosis in a 
specific setting, it is crucial to have detailed records of the signs and symptoms 
of patients attending the clinic at health facilities. Unfortunately, these data are 
often missing and as a consequence there is only limited information on the 
incidence of major classes of diseases in young children in tropical countries. 
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Another well-known problem with the syndromic approach is the overlap of signs 
and symptoms between different diseases, e.g. malaria and 
pneumonia.(O'Dempsey, McArdle et al. 1993; Kallander, Nsungwa-Sabiiti et al. 
2004). This has important implications for the treatment of these two diseases. It 
remains unclear how much of this overlap of signs/symptoms is related to 
children commonly being infected with both malaria parasites plus one 
respiratory pathogen rather than the overlap in the clinical picture of the 
individual diseases (O'Dempsey, McArdle et al. 1993; Kallander, Nsungwa-Sabiiti 
et al. 2004), Gaining a better understanding of the interaction between both 
diseases in the context of primary health facilities in tropical countries is 
important for assuring appropriate treatment of both diseases.  
. 
Although the IMCI strategy has been used for many years, few studies 
investigated the adequacy of its use in routine practice in terms adherence to 
IMCI recommendations, quality of care and effect on health outcomes. If most 
experts agree that the introduction of IMCI has improved the quality of care at 
limited costs(Armstrong Schellenberg, Bryce et al. 2004), IMCI has it own 
limitations and improving quality of training of health staff is probably not 
sufficient to achieve a high quality of care (Pariyo, Gouws et al. 2005). Besides 
the above mentioned problem of overlapping signs and symptoms of major 
disease classes,, the absence of diagnostic tools, the staff-dependant application 
of the charts, the availability of resources and the need to take into account the 
local epidemiology of diseases may all result a in low specificity of IMCI 
algorithms (Shah and Sachdev 1999; Factor, Schillinger et al. 2001; Armstrong 
Schellenberg, Bryce et al. 2004; El Arifeen, Blum et al. 2004; Animut, Mekonnen 
et al. 2009; Horwood, Vermaak et al. 2009; Horwood, Voce et al. 2009). 
 
The advent of sensitive and easy to use, malaria rapid diagnostic tests (RDTs) 
has the potential to improve the management of febrile patients by providing 
objective documentation of malaria episodes. Indeed, in regions where 
microscopy is unavailable, this strategy has the potential to reduce to prescription 
of antimalarial drugs and improve the treatment of febrile illnesses unrelated to 
malaria as it was shown in some studies(Skarbinski, Ouma et al. 2009; Ansah, 
Narh-Bana et al. 2010; d'Acremont, Malila et al. 2010 ; D'Acremont, Kahama-
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Maro et al. 2011).With increasing evidence that deciding on antimalarial 
treatment based on parasitological evidence is safe even in young children, there 
is strong case for including the use of RDTs into IMCI guidelines. 
 
In addition, novel preventive interventions such as Intermittent Preventive 
Treatment for malaria in infants (IPTi) have demonstrated to be efficient to 
reduce the burden of malaria in endemic areas. Given its close link with the 
Expanded Program of Immunization (EPI), IPTi could be easily implemented 
through and monitored within the IMCI guidelines.  
 
No studies have evaluated the overall benefits for children’ health and health 
system of integrating diagnostic tools such as RDT for malaria or IPTi 
interventions to IMCI strategies as an intervention that could be termed as 
‘IMCI+’. 
 
Similarly to other tropical countries, PNG is suffering a high burden of malaria on 
costal areas and pneumonia is the leading cause of admission in children under 
five years in the Highlands.(Shann, Gratten et al. 1984; Duke T, Michael A et al. 
2002; WHO 2005) Case management of sick children is almost only syndromic-
based using guidelines based on IMCI recommendations. In outpatient settings, 
few diagnostic tools are available and even microscopy or RDT are rarely 
available in health facilities to confirm malaria infections. Thus, presumptive 
treatments with antimalarial and/or antibiotics are prescribed to cover common 
diseases such as pneumonia, malaria or otitis. In PNG, no data are available on 
the incidence of diseases and on the performances of the IMCI strategy in 
outpatient settings.  
 
A randomized controlled trial of Intermittent Preventive Treatment for malaria in 
infants (IPTi) was carried out from 2006 to 2010 in two regions of Papua New 
Guinea endemic for malaria. The aim of the trial was to investigate the 
prophylactic efficacy of a fixed regimen of antimalarial drugs provided four times 
during the first year of life for the prevention of malaria and anemia (see chapter 
5). As part of the trial, a passive case detection system was set up to record 
illness episodes in all study participants aged 3 to 27 months old. All illness 
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episodes were managed in accordance with the PNG standard treatments 
guidelines (local IMCI), except for malaria, where treatment was guided by RDT 
instead of using presumptive or syndromic diagnosis. This study therefore 
provides a unique opportunity to investigate the appropriateness of using an IMCI 
approach to guide case management of common illnesses in young children in 
the context of introduction of malaria RDT use and IPTi implementation, the so-
called IMCI+. In addition, it can also provide important estimates of the burden of 
common syndromes/diseases as well as information on the potential effect of the 
IPTi intervention on other diseases than malaria. 
 
6.3 Methods  
The study was carried out along the IPTi randomized controlled trial performed in 
PNG and all data were collected within this cohort of patients. 
 
Study sites and population 
The study was carried out in two sites on the north coast of mainland Papua New 
Guinea (PNG) in Mugil, Madang Province and in the Wosera, East Sepik 
Province. Each study site included approximately 20 villages (total 40 villages). 
The 40 study villages are serviced by 4 major health centres: 1) Mugil and 
Alexishafen in Madang area. 2) Kunjingini and Kaugia in Wosera. Several aid 
posts were also used for the morbidity surveillance. The enrolment and follow-up 
were performed from the 6th of June 2006 to the 16th of June 2010; 1605 infants 
were recruited in the trial. All IPTi preventive treatments were given at time of 
routine vaccination time points at 3, 6 & 9 months and Vitamin A supplementation 
at 12 months following the PNG national expanded program of immunization 
(EPI).  
The study was carried out in accordance with Good Clinical Practice (GCP) and 
monitored by an independent external monitor. The study was approved by the 
PNG Medical Research Advisory Committee (MRAC number 05.20). The trial 
was registered on www.clinicaltrials.gov (number NCT00285662) and formed 
part of the IPTi consortium (www.ipti-malaria.org).Parents or carers were asked 
to fill a written consent form prior to enrolment of their child in the trial. 
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Children enrolled in the trial were randomly allocated to receive placebo or two 
different antimalarial drug regimes [sulfadoxine/pyrimethamine (single dose) with 
either 3 days of amodiaquine (SP-AQ3) or 3 days of Artesunate (SP-AS3)].The 
primary objective of the trial was the determination of protective effect of the two 
IPTi regimens on malaria episodes. Children were recruited into the IPTi trial 
alongside monthly outreach maternal and child health clinics (MCH). In total, 
participants were seen actively every 3 months (up to 9 scheduled visits in total) 
to receive the study drugs or to have blood collected for malaria parasites 
identification. 
 
Clinical procedure for sick study participants 
Throughout the trial, a passive case detection system was maintained at the four 
study health centres outpatient clinics as well as at four aid posts to assure a 
continuous morbidity surveillance of study participants. The passive 
surveillance’s records were used to perform the present study.  The parents of 
study participants were encouraged to attend these study clinics free of charge 
for clinical management whenever their child was sick. Even when children came 
for scheduled visits (to receive the IPTi intervention), he/she was assessed for 
sickness only if the mother spontaneously reported that the child was sick. 
 
Each illness episode was assessed by study staff using a standard case report 
form (See appendix 1). Management of sick children followed the PNG standard 
treatment guidelines except for malaria and anemia where a specific procedure 
was adopted to guarantee the best possible care to study participants. Indeed, in 
case of history of fever in the past 48 hours or an axillary temperature > 37.5°, a 
rapid diagnostic test for malaria [RDT (ICT Combo®) South Africa] was performed 
and Hb level measured using a portable Hemocue 201® machine (Angelholm, 
Sweden). Malaria treatment decision was based on RDT results with only infants 
with positive results treated with artemether/lumefantrine (Coartem®, Novartis, 
Switzerland), irrespective of the species. The children with moderate to severe 
anemia (Hb< 8g/dl) received iron supplementation at the dose of 5mg/Kg of 
ferrous sulphate for 6 weeks. Pulse oxymetry was also assessed in sick study 
participants from 2007 onwards. It was recommended to clinical staff that they 
should consider admitting the child if value drop below 94%. All other illnesses 
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were treated according to the standard treatment guidelines of PNG, which is 
based on IMCI (See appendix 2). Children were also assessed for danger signs 
or symptoms and referred to the health centre for admission when necessary 
(see appendix 1 for criteria). If children attended after hours, they were taken 
care by the regular health centre nurses staff. As they did not have the capacity 
to perform any blood test such as malaria rapid diagnostic test at the time of 
admission, treatment was delivered on presumptive diagnosis only. On site study 
nurses recorded their presumptive diagnosis and provided treatment. All records 
were cross-checked by the study clinicians who confirmed the likely diagnosis. 
Both study nurses and clinicians could record as many as 3 different diagnoses 
for each episode.  All illness episodes were graded by the study clinicians 
according to the severity. Detailed trial procedures for malaria & anemia and the 
main features of the PNG standard treatments are displayed in appendix 2. 
 
Laboratory procedure 
A blood sample was collected from finger prick at the same time as malaria and 
anemia were assessed. These samples were firstly used to perform a blood slide 
for research read (not used to guide malaria treatment) and secondly samples 
were stored to undergo in-depth malaria analysis (acquisition of immunity, drug 
resistance pattern and host/parasites genotyping).  
 
Definition of syndromes and diseases 
For the present study, we defined four major syndromes (based on signs and 
symptoms only) and one disease (documented with diagnostic test) with different 
levels of severity according to IMCI+:  
1. Respiratory infections (syndromes) 
 Acute Respiratory tract Infections (ARI)  
 Upper Respiratory Tract Infection (URTI) 
 Lower Respiratory Tract Infection (LRTI) 
• Severe LRTI 
2. Gastro-enteritis (GI, syndrome) 
• Mild GI 
• Moderate to severe GI 
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3. Malaria (disease confirmed by RDT) 
• Uncomplicated malaria 
• Severe Malaria 
4. Otitis 
 
Table 6.1 describes the criteria applied to the different syndromes and diseases 
with their corresponding treatment as recommended by the national treatment 
guidelines in detail.  
 
For this study, a definition for malaria based on clinical signs and symptoms plus 
RDT results was used in order to give estimates of its burden in PNG. In-depth 
investigations of the safety of using RDT for the diagnosis of malaria and the 
treatment with artemether/lumefantrine for all species is presented in chapter 4 
(Senn et al, in preparation) 
  
113
Table 6-1: Definition of syndromes or diseases (including the use of RDT 
for malaria) 
Criteria Standard treatment 
Cough and/or difficulties in breathing
Cough and/or difficulties in breathing
AND
RR<50 (<1Y) RR<40 (>1y)
AND
No respiratory distress (chest indrawing, cyanosis, 
nasal flaring)
Paracetamol
Cough and/or difficulties in breathing
AND
RR>50 (<1Y) RR>40 (>1y)
Cough and/or difficulties in breathing
AND
RR>50 (<1Y) RR>40 (>1y)
AND
No respiratory distress (chest indrawing, cyanosis, 
nasal flaring)
Amoxicillin 5 
days 
Cough and/or difficulties in breathing
AND
RR>50 (<1Y) RR>40 (>1y)
AND
Respiratory distress (chest indrawing, cyanosis, 
nasal flaring)
Crystapen im or 
chloramphenicol 
im 10 days, 
admit
Diarrhoea and/or vomit
Diarrhoea and/or vomit
AND
no dehydration (slow skin pinch, sunken eyes)
more hydration + 
breast feed
Diarrhoea and/or vomit
AND
dehydration (slow skin pinch, sunken eyes)
ORS or iv fluid +/- 
admit
Fever and/or history of fever in past 48h
AND
positive RDT (any species)
Fever and/or history of fever in past 48h
AND
positive RDT (any species)
AND
No danger signs
Artemether/lume
fantrine 
(Coartem) 3 
days
Fever and/or history of fever in past 48h
AND
positive RDT (any species)
AND
At least one danger signs
Artemether im + 
sulfadoxyne/Pyri
methamine + 
admit
All GI
Moderate to Severe 
GI
Mild GI
Severe malaria
Uncomplicated 
malaria
All malaria
Otitis
Respiratory infections
Gastro-enteritis (GI)
Table 1: Definition of syndromes or diseases  (including the use of RDT for malaria)
Malaria
Acute Respiratory 
Infection (ARI)
 mild LRTI 
Upper Respiratory Tract 
Infection (URTI)
All Lower Respiratory Tract 
Infection (all LRTI)
Moderate to Severe 
LRTI
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Study procedure 
Illness episodes were included in the study if they fulfilled the following inclusion 
criteria: 
• IPTi study participant 
• No illness episode in the past 2 weeks (to avoid counting the same 
episode twice) 
Illness episodes were firstly classified according to syndromic or disease 
definitions described above in a standardised fashion using IMCI criteria and 
based on the morbidity records. Episodes not fitting any of the above definitions 
were categorized as “other diagnosis”. This provided an ‘objective’ measure of 
the prevalence rates of the morbid episodes in the outpatient clinics. 
The severity of the morbid episodes was also assessed by the study clinicians. A 
serious advers event (SAE) was defined as a illness episode with potential life-
threatening features such as respiratory distress or severe pallor. At least one 
danger sign or symptom need to be present in order to be classified as SAE (as 
per IMCI, see 10-step check-list, annex 2). A child with criteria for SAE was not 
necessary admitted.  
Health care in Papua New Guinean outpatient settings is based on IMCI. In order 
to provide appropriate treatment, it is of importance that health staffs apply strict 
IMCI criteria for diagnosis. Comparing diagnosis as recorded by health workers 
and standardised post-hoc computerized diagnosis allowed estimating how well 
the IMCI+ version was adhered to. In addition, the prescription of antibiotics was 
evaluated in detail as a proxy of adherence to the IMCI guidelines by health staff. 
The impact of antibiotics prescription on health outcomes was investigated by 
calculating the rate of re-attendance within 14 days and the outcome upon re-
attendance (death, serious adverse events or mild diseases) for specific 
syndromes according to the use of antibiotics. Indeed, as syndromes were not 
necessary correctly identified by health staff, a certain number of children did not 
receive antibiotics when they should have and the other way round.  
Finally, we were also able to investigate the effect of IPTi on the major 
syndromes by comparing incidence rates between treatment arms during the 
intervention period (3-15 months). 
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Statistical analysis 
All data were doubled entered using FoxPro software. Data analyses were 
performed using STATA software (10.0). In order to describe the spectrum of 
common syndromes & diseases in an outpatient setting, prevalence rates were 
calculated based on definitions described above (ARI, URTI, LRTI, malaria, GI 
and otitis) . More than one diagnosis was possible for each illness episode. 
Overlap of signs and symptoms of the main syndromes are presented as Venn 
diagram based on a model developed by Rodgers et al 
(www.cs.kent.ac.uk/people/staff/pjr). Incidence rates and incidence rate ratios 
were calculated using a negative binomial regression model. In order to avoid 
counting a single illness episode more than once, children were considered not 
at risk of the same type of illness category in the two weeks prior to clinic 
attendance. Following an illness episode, a child was not excluded from time at 
risk in order to capture a possible interaction between malaria and respiratory 
infections. Concordance of health workers’ diagnosis and that of the 
standardized definitions was assessed by using kappa test. 
6.4 Results  
Baseline characteristics 
1605 children 3 months old were enrolled and followed-up for up to 24 months 
between June 2006 and June 2010 in the IPTi randomized controlled trial 
(Madang=1125 and Maprik=480). 1512 (94%) children presented at least 1 
illness episode (Madang=1053 and Maprik=459). The morbidity surveillance 
reported a total of 8944 illness episodes (Madang=5978 and Maprik=2966). 371 
Serious Adverse Events (SAE) and 13 deaths occurred during the study. Overall, 
2903 illness episodes occurred in the placebo group, compared to 3038 in the 
AQ-SP group and 3002 in the AR-SP. Table 6.2 describes the baseline 
characteristics of the patients. No significant differences in the demographic 
characteristics of the children enrolled into the different treatment allocation 
groups were observed. 
Table 6.3 displays the dangers signs/symptoms, clinical and para-clinical 
features of all illness episodes with full records available. As shown, 81% of the 
illness episodes presented with fever/history of fever and 77% had cough.  No 
significant difference was observed between the different treatment groups. 
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Table 6-2: Baseline Characteristics of the study participants 
 
N 
Weight (Kg)
Haemoglobin (g/dl)
% (N) % (N) % (N) % (N)
Girls 47.9 768 51.1 274 44.2 237 48.2 257
86.5 1384 87.3 466 85.4 457 86.8 461
82.2 1320 83.2 446 81.7 438 81.8 436Recruitment during rainy season (Sep-Jun)
Mean Age at enrollment (days) 
* Most of bet nets are untreated (national program started end of 2008)
96
5.8 (5.8 - 5.9)
97
9.5 (9.4 - 9.5)
Mean numb. of illness episodes/child (range) 8.1 (0 - 20)
Slept under bednet last two weeks *
PLACEBOtotal
5.8 (5.7 - 5.8)
536 536
8.4 (0 - 28)
1605
9.5 (9.4 - 9.6)
5.9 ( 5.8 - 5.9)
8.7 (0 - 24)
9.5 (9.4 - 9.6)
8.3 (0 - 28)
IPTi treatment arm AR-SP
533
9.5 (9.4 - 9.6)
5.9 (5.8 - 5.9)
9797
AQ-SP
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Table 6-3: Clinical and paraclinical features of all illness episodes per treatment arms with no previous visit in the past 14 
days 
% (N) tot % (N) % (N) % (N)
with 
records
unable to eat 0.8 62 7980 0.6 16 0.9 25 0.8 21
Vomit everything 0.6 46 7978 0.6 16 0.5 13 0.6 17
Uncsonscious /drowsy 1.5 119 7975 1.4 35 1.6 43 1.5 41
Respiraotry distress 2 159 7971 1.7 44 2.4 66 1.8 49
Fits 1 76 7971 1.1 29 0.9 24 0.9 23
Inability to sit up 0.2 15 7972 0.1 3 0.3 7 0.2 5
Neck stifness 0.1 11 7969 0.1 3 0.11 3 0.2 5
Severe Dehydration 0.7 56 7970 0.5 14 0.7 18 0.9 24
Pale with HR>160 or oedema 0.3 21 7966 0.5 12 0.2 5 0.2 4
Fever (temp>37.5° / hist of fev) 81.4 6505 7987 82.2 2140 80.8 2194 81.3 2171
palor 2.6 205 7840 3.1 78 2.2 59 2.6 68
cough 76.8 6110 7954 77.2 2001 77.6 2096 75.6 2013
Difficulties in breathing 15.5 1228 7921 15.6 402 16.1 433 14.8 393
Running nose 46.1 3647 7905 44.7 1153 47.2 1268 46.5 1226
Diarrhoea 21.1 1679 7941 20.7 535 22 595 20.7 549
Abdominal pain 2.8 218 7921 2.8 71 2.7 73 2.8 74
Vomit 10.6 838 7929 11.1 287 10 270 10.6 281
Ear pain 0.7 52 7928 0.6 16 0.6 17 0.7 19
Skin rash 0.3 13 5184 0.2 4 0.2 3 0.3 6
Skin abscess 1 80 7932 1.2 31 1 26 0.9 23
Pus out of the ear 2.5 199 7882 2.4 62 2.7 71 2.5 66
Mean temperature 37.4 37.5 37.4 37.4
Median heart rate (range) 134 (45-220) 134 (45-208) 134 (54-205) 134 (58-220)
Median resp rate (range) 40 (20-90) 40 (20-90) 40 (20-88) 40 (20-90)
Mean weight 8.6 8.5 8.6 8.6
mean pulse O2 (range) 98.3 (68-100) 98.4 (73-100) 98.3 (84-100) 98.2 (68-100)
Mean Hb level 9.6 9.5 9.6 9.7
Para-clinical features
Main signs and symptoms 
Danger signs
all illnesses Placebo AQ-SP AR-SP
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Prevalence of syndromes and diseases following IMCI+ criteria 
A total of 7739 illness episodes had complete records available and 6975 fulfilled 
the inclusion criteria (no illness episode in the past 2 weeks). Based on 
standardised definitions of syndromes/diseases (more than one disease per 
illness episode is possible) 76.5% of episodes (5335/6975, 95%CI 75.5 - 77.5) 
were diagnosed as ARI, including 44.7% URTI (3116/6975, 95%CI 43.5 - 45.8) , 
30.1% mild  LRTI  (2102/6975, 95%CI 29.0 - 31.2) and  1.7% moderate to severe 
LRTI (117/6975, 95%CI 1.4 - 2.0). 25.6% had GI (1788/6975, 95%CI, 24.4-29.9), 
including 24.9% mild GI (1740/6975, 95%CI 23.9 - 26.0) and 0.7% moderate to 
severe GI (48/6975, 95%CI 0.5 - 0.9). 25.1% had malaria (1750/6975, 95%CI, 
23.8- 26.4), including 23.6% uncomplicated malaria (1643/6975, 95%CI 22.6 - 
24.6) and 1.5% severe malaria (107/6975, 95%CI 1.2 - 1.8). 2.8% had otitis 
(199/6975, 95%CI 2.5 - 3.2) and 10.2% (710/6975, 95%CI 9.5 - 10.9) couldn’t be 
classified in one of these syndromes. In this category, there were mainly running 
nose as single symptom (which cannot be classified as URTI according to PNG 
guidelines), skin infections and fever without any other accompanying symptom. 
Figure 6.1 shows the Venn diagram of the overlap of signs and symptoms 
among the 4235 illness episodes presenting at least one of the three main 
syndrome or disease (LRTI, gastro-enteritis and malaria). 32% of the illness 
episodes fulfilled the definition for more than one syndrome/disease. Figure 6.2 
shows the same Venn diagram for severe diseases only (LRTI, malaria and GI). 
In this case, only 12% had an overlap of signs and symptoms. 
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Figure 6-1 Venn diagram showing the overlap of signs and symptoms 
among 4235 illness episodes with at least one of the three main syndromes 
 
 
Figure 6-2: Venn diagram showing the overlap of signs and symptoms 
among 244 illness episodes with at least one of the three main severe 
syndromes 
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Correlations (Kappa) between standardised syndromes/diseases and the 
diagnosis as stated by health staff were 0.42 for URTI, 0.47 for LRTI and 0.52 for 
both gastro-enteritis and otitis but 0.99 for malaria.  
 
As shown in table 6.4, no difference in prevalence rates of different syndromes 
was observed when events are stratified by season of occurrence (dry season is 
short from mid July to Mid October) 
 
Table 6-4: prevalence rates for the four major diseases stratified by season 
(dry season= mid July- until mid-Ocotber) 
 
prevalence prevalence
LRTI 0.32 0.30 0.34 0.32 0.31 0.33
 MALARIA 0.25 0.23 0.27 0.25 0.24 0.26
 GI 0.27 0.25 0.3 0.25 0.24 0.26
OTITIS 0.026 0.018 0.034 0.029 0.025 0.034
CI 95% CI 95%
Dry  Wet
 
 
Incidence rates for the syndromes and disease 
With an incidence of 2.05 episodes / child / yr. (95%CI, 1.98-2.12), ARI was the 
most common syndrome in children 3-27 months old. Of these, URTI accounted 
for the highest burden with an incidence rate (IR) of 1.2 (95%CI 1.17 - 1.22) 
followed by LRTI with an IR of 0.85, (95%CI, 0.81 - 0.90). IR of GI was 0.72 
(95%CI, 0.65 - 0.93). IR of malaria was 0.62 (95%CI, 0.58 - 0.66) and IR of otitis 
was 0.08 (95%CI, 0.07 - 0.09).  
Table 6.5 shows the different incidence rates with confidence intervals for the 
major non-severe syndromes stratified by age categories in months (3-9, 9-15, 
15-21 and 21-27). IR for LRTI and GI are rapidly decreasing with age while the 
IR for malaria is increasing and no age pattern is observed for otitis (figure 6.3). 
On average, children experienced 0.13 (95% CI, 0.12 - 0.14) severe 
episodes/child per year with severe LRTI accounting for a higher burden (IR = 
0.05, 95%CI, 0.04- 0.06) than severe malaria (IR = 0.04, 95%CI 0.03 - 0.05) and 
severe GI (IR = 0.02, 95%CI 0.016 - 0.032). 
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Table 6-5: incidence rates (episodes/year/child) for the four major syndromic diseases 
 
 
incidence incidence incidence incidence
LRTI 0.99 0.95 1.50 0.97 0.92 1.02 0.8 0.76 0.85 0.48 0.44 0.52
 MALARIA 0.52 0.49 0.56 0.69 0.65 0.73 0.73 0.69 0.77 0.58 0.54 0.63
 GI 0.98 0.94 1.03 0.84 0.8 0.89 0.53 0.49 0.57 0.45 0.41 0.49
OTITIS 0.09 0.07 0.10 0.08 0.06 0.09 0.09 0.07 0.10 0.06 0.05 0.08
3-9 months 9-15 months 15-21 months 21-27 months
CI 95%CI 95%CI 95%CI 95%
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Figure 6-3: Incidence rates according to age categories for the main syndromes / diseases:  respiratory 
infections (fig 3a), GI (fig 3b) and malaria (fig 3c) 
 
 
 
 
Figure 3a: Respiratory infections 
(ARI = URTI + mild LRTI + severe LRTI)
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Figure 3c: Malaria
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Figure 3b: Gastroenteritis 
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Adherence and safety of IMCI+ 
Out of the 6975 illness episodes fulfilling the inclusion criteria with complete 
records, 53.6 % were treated by antibiotics (at least one of amoxicillin, co-
trimoxazole, i.m. penicillin, i.m. ceftriaxone or erythromycin) and 25.1% received 
antimalarial drugs (97.6 % for RDT confirmed episodes). 
 
The overall appropriateness of antibiotics was evaluated in 6389 illness episodes 
for which clear recommendations exist in the PNG national guidelines (Figure 
6.4). According to these data, 25% of children were not treated appropriately. i.e. 
6% did not receive antibiotics when they should have and 19% received 
antibiotics when they should not have.  
 
Figure 6-4: Appropriateness of antibiotics use according to the IMCI 
recommendations 
 
 
Among children with a clinical diagnosis of URTI 53.4% (1330/2493) received 
(inappropriately) antibiotics (excluding other reasons for receiving antibiotics) and 
66.5% (1351/2031) of mild syndromic LRTI received (appropriately) antibiotics 
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(excluding severe cases). When children had a diagnosis requiring no use of 
antibiotics (all except LRTI, otitis, skin infection, meningitis, or gastro-enteritis 
lasting more than 7 days) the prescription drop from 56% if RDT was negative to 
16% when it was positive (p<0.001). When children presented with criteria for 
both LRTI and malaria, only 39.3% of antibiotics were prescribed. In contrast, 
when they had a single diagnosis of LRTI (without malaria), the prescription of 
any antibiotics raised to 76.5% (p<0.001). Among children with a diagnosis of 
severe LRTI 96.6% (113/117) received any kind of antibiotics, 75.2% (88/117) 
received i.m. or i.v. antibiotics as per national guidelines and 49.6 % (58/117) 
were admitted. 55% (437/795) patients with mild gastro-enteritis received 
(inappropriately) antibiotics (excluding other reasons to give antibiotics). Finally 
90.9% (179/197) children with otitis received (appropriately) antibiotics. 
Re-attendance rate within 14 days following  a clinical diagnosis of mild LRTI (as 
per syndromic definition) was 9% when treated with antibiotics compare to 8% 
when they did not receive any antibiotics  (p=0.44). For mild malaria, even 
though not significant (p=0.14), a lower number of children came back within 14 
days if they received antibiotics, with a re-attendance rate of 4% vs 6% when 
they did not receive antibiotics. For gastroenteritis, no difference in re-attendance 
rates was observed (p=0.51) whether they received antibiotics or not with 8% vs 
9%, respectively. Figure 6.5 displays the re-attendance rates and outcomes 
within 14 days following the initial consultation for mild LRTI, uncomplicated 
malaria and mild GI according to the prescription of antibiotics.  
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Figure 6-5: Re-attendance rates within 14 days and outcomes for the most 
common mild syndromes according to the prescription of antibiotics or not 
 
  
 
Protective efficacy of IPTi treatments against ARI, all LRTI, severe LRTI & GI 
infections  
The incidence rates of all illness episodes over the entire intervention period (3-
15 months) were: 3.37 (95%CI, 3.21 - 3.53) in the placebo group, 3.37 (95%CI, 
3.22 - 3.54) in the SP-AQ3 group and 3.31 (95%CI, 3.15 - 3.47) in the SP-AS3 
group. Incidence rate ratios (IRR) were similar for both treatment arms with 1.0 
(95%CI, 0.92-1.09, p=0.67) for SP-AQ3 and 0.98 (95%CI, 0.90 - 1.07, p=0.99) 
for SP-AS3  
Incidence rates for ARI 3-15 months (intervention period) were: 2.59 (95%CI, 
2.46 - 2.74) in the placebo, 2.63 (95%CI, 2.50 - 2.78) in the SP-AQ3 group and 
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2.54 (95%CI, 2.41 - 2.68) in the SP-AS3 group. IRR were similar with 1.01 
(p=0.78) for SP-AQ3 and 0.98 (p=0.63) for SP-AS3.  
Incidence rates for all LRTI 3-15 months were very similar in all groups with 0.97 
(95%CI, 0.89 - 1.06) in the placebo group, 1.00 (95%CI, 0.92 - 1.09) in the SP-
AQ3 group and 0.98 (95%CI, 0.90 - 1.07) in the SP-AR3 group. IRR were 1.03 
(p=0.64) and 1.01 (p=0.87) for AQ -SP and AS-SP respectively.  
Incidence rates for severe LRTI 3-15 months were 0.09 (95%CI, 0.06 - 0.12) in 
the placebo group, 0.11 (95%CI, 0.09 - 0.15) in the SP-AQ3 group and 0.12 
(95%CI, 0.09 - 0.15) in the SP-AR3 group. The IRR were superior to 1 between 
the treatment arms and placebo with IRR of 1.34 (p=0.18) and 1.35 (p=0.18) for 
AQ -SP and AS-SP respectively.  
For GI (severe included), the incidence rates 3-15 months were similar in all 
groups with: 0.94 (95%CI, 0.86 - 1.02) for placebo, 0.92 (95%CI, 0.84 - 1.0) for 
SP-AQ3 and 0.89 (95%CI, 0.81 - 0.99) for SP-AS3. IRR were not significantly 
different between treatment arms and placebo with IRR of 0.99 (p=0.85) for SP-
AQ3 and 0.95 (p=0.51) for SP-AS3. 
The efficacy results of IPTi on malaria are described in detail in chapter 5. The 
following results were shown: The incidence of clinical malaria between the first 
dose at 3 months and 15 months was 0.85 per year-at-risk overall and 0.22 and 
0.68 for P. falciparum and P. vivax, respectively. In the intention-to-treat 
analyses, the protective efficacy against all cases of malaria was 29% ([95%CI, 
0.10, 0.43], p = <0.001) in the SP-AQ3 group and 12% ([95%CI, -0.11, 0.30], p = 
0.12) in the SP-AS3 group. 
 
6.5 Discussion  
Morbidity in PNG infants 
This study gives for the first time a comprehensive prospective picture of the 
morbidity of young infants in PNG in routine practice as measured through IMCI 
criteria augmented by malarial RDT. With almost 8000 standardized illness 
records, this study therefore provides an important insight into to the distribution 
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of common syndromes encountered in PNG. More than 80% of illnesses 
episodes presented with fever. Respiratory infections were the most common 
syndromes with 75% of all illness records having criteria for ARI (cough and/or 
difficulties in breathing) and one third having WHO’s criteria for a LRTI 
(pneumonia or bronchiolitis). One quarter each was diagnosed with malaria 
and/or gastroenteritis. Acute media otitis was much less frequent with only 3%. 
Only 10% of the children did attend the clinic without any of these syndromes.  
 
Among the 3 main diseases, the overall incidence rate in children 3-27 months 
was the highest for LRTI with 0.9 episode /child /year followed by gastroenteritis 
(0.7) and malaria (0.6).This is somewhat higher compared to findings in African 
countries. However, direct comparisons are difficult due to different reporting 
methodology and case definitions (Roca, Quinto et al. 2006; Feikin, Olack et al. 
2011). We observed important variation across age groups. Indeed, the 
incidence of LRTI was decreasing rapidly with age, being twice higher in infants 
3-9 months (1.0) compare to children older than 15 months (0.5). A very similar 
pattern was observed for the incidence of gastroenteritis with a rapid decrease 
from 1.2 in young infant to 0.4 in children 2 years old. On the other hand, the 
incidence of malaria was increasing with age from 0.5 in infants 3-9 months to 
0.7 in children 15-21 months to decrease again in older children. It is possible 
that the decrease of malaria incidence observed in older children might be due, 
at least partly, to the introduction towards the end of trial of ITN in the study area. 
This effect is however difficult to measure as no records are available on which 
children receive ITN and which not. Nevertheless, these figures illustrate nicely 
the different patterns of exposure to specific pathogens and provide and highlight 
the high susceptibility of the younger infants to respiratory and gastrointestinal 
infections.  
 
Syndromic approach: the problem of accurate diagnosis 
The syndromic approach towards diseases management is widely used and 
recommended by WHO through the IMCI strategy (and used in the PNG 
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standard treatment guidelines)(WHO 2000). In the present trial, medical staff 
were asked to follow IMCI recommendations to decide on treatment except for 
malaria where treatment was provided only if a RDT was positive for any of the 
Plasmodium species (instead of presumptive treatment). As expected, we 
observed that the overlap of signs and symptoms is important as one third of 
illness episodes fulfilled the criteria of at least two of the three main syndromes 
(LRTI, malaria and gastro-enteritis). The overlap is less important for severe 
diseases where only 12% of episodes had signs/symptoms for at least two 
diseases/syndromes. This reflects the lack of specificity of diagnosis based 
exclusively on signs and symptoms, especially for LRTI and for such diseases. 
This should theoretically lead to an overuse of drugs. For example, children with 
fever/cough/positive RDT (malaria) / tachypnoea are classified as having both 
malaria and pneumonia and thus receive antimalarials and antibiotics.  
The diagnosis of LRTI is more complex than that of malaria as no reliable and 
easy-to-use tests are validated to identify respiratory infections that require the 
use of antibiotics such as bacterial pneumonia. It has been recently recognized 
that LRTI are often associated with virus detection and that there is a complex 
and yet not clear interplay between virus and bacteria in the development of 
pneumonia (Don, Fasoli et al. 2005; Berkley, Munywoki et al. 2010). Considering 
the dramatically high burden of respiratory illnesses, especially in very young 
children, the development of more accurate diagnostic strategies able to identify 
children with pneumonia requiring antibiotics should be on the top list of priorities 
(Lim, Steinhoff et al. 2006).The potential benefits of the use of RDT to document 
viral pathogens such as RSV or Influenza need be investigated. Beyond the 
aetiology of respiratory infections, it would be also valuable to develop tests able 
to identify children with potential severe (invasive) diseases, which require 
specific supportive care. In that regard, inflammatory markers such as pro-
calcitonin or C-reactive protein (CRP) or other proteins  and promising analysis of 
exhaled gases need to be considered(Schmidt, Bhandari et al. 2010). 
We observed only a moderate agreement (kappa = 0.47) for the diagnosis of 
LRTI between the clinical judgment of health workers and a standardize post-hoc 
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diagnosis (applying signs of symptoms as recorded on forms). This discordance 
might be partly due to the use of stethoscopes along the study by nurses not 
familiar with this tool which may have led to an overestimation of abnormal 
sounds and hence clinical diagnosis of LRTI. Similarly, when standardized 
criteria were applied for the clinical diagnosis of gastroenteritis and otitis, the 
agreement with the clinical judgement of health workers remained limited. In 
contrast, the agreement for malaria was almost perfect (kappa=0.99) which is 
certainly due to the systematic use of RDT that provides objective results. It is 
also true that the present work was carried out alongside a malaria drug trial and 
strong emphasis was put on this disease and its diagnosis & management.  
Finally, the syndromic approach for clinical diagnosis is clearly insufficient for 
some common diseases. For example, dengue fever, with its potential severe 
outcome, is responsible for almost 10% of fever episodes in coastal PNG in a 
recent study(Senn, Luang-Suarkia et al. 2011) but is not considered by IMCI 
guidelines. Similarly urinary tract infections are only seldom identified by this 
mean. 
 
Adherence to IMCI+ 
One of the aims of this assessment was to study how IMCI translates into routine 
practice if used in conjunction with RDT and IPTi. We investigated two aspects: 
1) how accurate is the clinical judgment of health workers (see above) and 2) are 
drugs (mainly antibiotics) appropriately prescribed? The prescription of antibiotics 
can be considered as a proxy for guidelines’ adherence. We observed a high rate 
of prescription in our cohort as more than half of cases were treated with 
antibiotics when only a maximum of 40% should have received antibiotics 
according to guidelines. This is high compared to other similar settings where it 
was estimated that approximately 20% of patient should receive antibiotics when 
diagnosis was made by highly skilled clinicians based on IMCI criteria.(Horwood, 
Voce et al. 2009; D'Acremont, Kahama-Maro et al. 2011) This might reflect the 
relative inaccuracy recognition of signs & symptoms by health staff. For example, 
it is likely that tachypnoae is not often properly identified due to wrong respiratory 
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rate estimation. We observed indeed, that despite the official recommendation of 
counting over 1 minute and most of respiratory rate were even numbers (Senn & 
Rarau pers. Comm.) suggesting that health workers are not counting over one 
minute. Similarly it was sometimes observed that one single respiratory cycle 
(inspiration and expiration) was counted as two. All these observation might 
contribute to overestimate fast breathing and consequently the prescription of 
antibiotics. This is especially a concern as tachypnoea is corner stone of LRTI 
identification in IMCI. 
Overall, we observed that 1 patient out of 4 was not treated according to the 
recommendations (received antibiotics when he/she should not have and vice 
versa, see figure 6.4). When looking at prescriptions of antibiotics for respiratory 
infections, it is surprising to observe that half of children with criteria only for 
URTI (excluding other potential reasons for receiving antibiotics) still received 
anti-bacterial chemotherapies. On the other hand, we observed that only two 
third of children with objective criteria for a mild LRTI received antibiotics. This 
might be explained by the strong emphasis put in the study on malaria. Indeed, 
when the diagnosis of malaria was made, most of the children received only 
antimalarial drugs even if they also met criteria for a mild LRTI (we already 
mentioned that the overlap of signs and symptoms for both diseases was 
important, around 15%). One might argue that such a high rate of non-adherence 
to standard IMCI recommendations might also leave a lot children with potential 
bacterial pneumonia untreated and hence poor outcome. However, we observed 
that it is in fact not the case. Indeed, first the rate a re-attendance following a visit 
for mild LRTI was similar irrespective of the use of antibiotics (9% if they received 
antibiotics and 8% if they did not). This is well in line with findings in Pakistan 
where the use of amoxicillin was not found to have any benefits on pneumonia as 
defined by WHO(Hazir, Nisar et al. 2011). Second when the children looked 
more severely ill with danger signs such as chest indrawing, almost all children 
were treated with antibiotics (mostly intra-muscular). The absence of difference in 
the re-attendance rate is probably due to the fact that the vast majority of mild 
LRTI had a viral aetiology rather than bacterial and the lack of specificity of the 
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present criteria to identify true pneumonia. In a sub-sample of these children, 
RDT made on nasal swabs revealed that more than half of children with criteria 
for LRTI were positive for at least one of the four most common respiratory 
viruses (Influenza A&B, Adenovirus and Respiratory Syncytial Virus). Similar 
findings have also been published in other countries.(Berkley, Munywoki et al. 
2010). Being a malaria drug trial, the present study was not suitable for 
investigating the prescription habits of health workers for malaria as specific 
guidelines were used (only patients with positive RDT results were treated using 
artemether/lumefantrine). However, this study provides still good evidence that 
the introduction of RDT associated to adequate training of health staff led to a 
reduction of antibiotics prescription. Indeed, sick study participants with 
signs/symptoms of LRTI and a positive RDT had significantly less antibiotics 
prescribed compared to those with a positive RDT (76% vs 39%). 
 
Impact of IPTi on morbidity  
Even if the study was not aimed at assessing the efficacy of IPTi on the overall 
morbidity and for ARI, we could estimate its impact on these outcomes. The 
efficacy of IPTi on malaria is well documented in Africa (Aponte, Schellenberg et 
al. 2009) and similar efficacy results were also found in PNG within the present 
cohort of patients with an overall reduction of the risk of malaria of about 30% 
(Senn et al, submitted for publication). However, out of the same cohort of 
patients, we do not observe any reduction of the overall morbidity following the 
IPTi intervention. Indeed, the incidence of illness episodes was similar in all trial 
arms as well as the mean number of illness episodes. More specifically, no 
protective efficacy was observed on mild LRTI in infants 3-15 months (duration of 
the IPTi intervention) as incidence rates were similar. There was some weak 
evidence for severe LRTI to be more frequent in the two treatment arms 
compared to the placebo group. Again, the study was not designed to assess the 
efficacy of IPTi on the morbidity; however, it seems important to take into account 
this apparent lack of impact of the IPTi intervention on the overall morbidity to 
assess the true benefit of this intervention.  
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These data are important to consider from a public health perspective. If it is 
clear that IPTi has a proven effect on malaria (see chapter 5); however, the fact 
that no benefit is observed on the overall morbidity and on severe 
illnesses/hospitalisations is a strong limitation to its  implementation nationwide. 
Indeed, what would be the interest for health authorities to invest resources in an 
intervention that is neither going to improve the overall health status of children 
nor going to decrease the workload of health workers because the children are 
going to be as often sick as before?   
 
Limitations of the study 
This study has some limitations. Firstly, being a drug trial, the clinical 
management of malaria episodes was performed in ideal conditions (i.e. 
treatment of only RDT positive cases). However, for all other diseases, the 
recommendation made to the study nurses was identical to the national standard 
treatment protocols. Secondly, the increased training and monitoring of all clinical 
activities that was done as part of the trial may have led to an improvement in the 
overall quality of care. It was indeed recently shown that intensive training in 
conjunction with monitoring of adherence to guidelines has the potential to 
improve quality of care, at least in rural hospital.(Ayieko, Ntoburi et al. 2011) It 
seems therefore essential to put a strong emphasis on improving the training of 
routine staff with regular updates, especially if RDTs’ should be implemented in 
the PNG standard treatment guidelines.  
Third, because this study was carried out alongside a drug trial, it is possible that 
parents of sick study participants were more likely to attend the clinic. This may 
have resulted in a higher incidence rates of LRTI compared to other regions, 
such as Kenya where an incidence of 0.3-0.5 episode/child/year was reported in 
children under five(Feikin, Olack et al. 2011) (compared to 0.9 in our cohort). 
However, being a passive case detection, only truly sick study participants were 
seen at the clinic. Finally, it is possible that the fact that the diagnostic of malaria 
was based on RDT makes the comparison of incidence rates with other 
syndromes (LRTI, otitis, GI) more difficult. Indeed, as syndromes were 
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exclusively based on signs and symptoms, it is possible their incidence rates are 
slightly overestimated compared to the one of malaria. 
6.6 Conclusions  
The present study provides for the first time a comprehensive picture of the 
burden of common diseases in Papua New Guinean infants. The most common 
diseases in very young infants are respiratory infections followed by 
gastroenteritis and malaria. Whereas malaria is more common in older children 
(>15 months), LRTI and gastroenteritis are rapidly decreasing after one year of 
age. Despite the fact that mild clinical LRTI are often missed by health workers, 
the prescription of antibiotics in children with syndromic LRTI does not seem to 
change their outcomes in terms of re-attendance and complications compared to 
those who did not receive antibiotics. This absence of benefits of antibiotics is 
certainly due the lack of specificity of the present recommendations to 
discriminatively differentiate children with true bacterial LRTI and those with viral 
infections. It is urgently needed to develop better strategies to improve the 
identification of LRTI that require antibiotics or more intensive clinical care.  
 
The use of RDT for malaria seems to have improved significantly the quality of 
diagnosis and is easily implementable within IMCI strategy. On the other hand 
and surprisingly, the present study demonstrated that the IPTi intervention 
neither had an impact on the overall morbidity nor on respiratory infections. 
Policy makers should consider this aspect of IPTi if planning a possible 
implementation of the intervention in PNG  
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7.1 Abstract 
Background 
Building on previous acceptability research undertaken in sub-Saharan Africa this 
article aims to investigate the acceptability of intermittent preventive treatment of 
malaria in infants (IPTi) in Papua New Guinea (PNG). 
Methods 
A questionnaire was administered to mothers whose infants participated in the 
randomised placebo controlled trial of IPTi. Mothers whose infants participated 
and who refused to participate in the trial, health workers, community reporters 
and opinion leaders were interviewed. Men and women from the local community 
also participated in focus group discussions.  
Results 
Respondents viewed IPTi as acceptable in light of wider concern for infant health 
and the advantages of trial participation. Mothers reported complying with at-
home administration of IPTi due to perceived benefits of IPTi and pressure from 
health workers. In spite of patchy knowledge, respondents also demonstrated a 
demand for infant vaccinations and considered non-vaccination to be neglect. 
There is little evidence that IPTi has negative impacts on attitudes to EPI, EPI 
adherence or existing malaria prevention practices. 
Conclusion 
The degree of similarity between findings from the acceptability studies 
undertaken in sub-Saharan Africa and PNG allows some generalization relating 
to the implementation of IPTi outside of Africa: IPTi fits well with local health 
cultures, appears to be accepted easily and has little impact on attitudes towards 
EPI or malaria prevention. The study adds to the evidence indicating that IPTi 
could be rolled out in a range of social and cultural contexts.  
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7.2 Background 
Intermittent preventive treatment (IPT) of malaria involves the administration of 
treatment doses of an anti-malarial drug at predetermined intervals, regardless of 
parasitaemia or symptoms. IPT during pregnancy (IPTp) is linked to ongoing 
routine antenatal care and IPT for infants (IPTi) is delivered through the 
Expanded Programme of Immunization (EPI) (Egan, Crawley et al. 2005). 
 
Various studies in sub-Saharan Africa have shown that IPTi with sulphadoxine-
pyrimethamine (SP) given at the time of routine vaccinations in the first year of 
life reduces the incidence of clinical malaria by between 20% and 59% 
(Schellenberg, Menendez et al. 2001; Chandramohan, Owusu-Agyei et al. 2005; 
Pool, Munguambe et al. 2006; Grobusch, Lell et al. 2007; Kobbe, Kreuzberg et 
al. 2007; Mockenhaupt, Reither et al. 2007), and by 30% across the six sites 
(Aponte, Schellenberg et al. 2009). In addition to the clinical effectiveness of IPTi, 
recent social science research has also demonstrated that in several sites across 
sub-Saharan Africa, IPTi is socially and culturally acceptable (Pool, Munguambe 
et al. 2006; Pool, Mushi et al. 2008; Gysels, Pell et al. 2009). This acceptability 
research, undertaken alongside clinical trials (in Gabon, Kenya, Mozambique and 
Tanzania) and implementation studies of IPTi (in Ghana, Malawi and Tanzania) 
with various drug regimens, also indicated that IPTi does not negatively influence 
attitudes to and uptake of immunization, nor is IPTi misunderstood as 
immunization against malaria. IPTi does not, therefore, influence other preventive 
measures or delay treatment seeking for malaria.  
 
Although the acceptability research published to date provides a comprehensive 
insight into community responses to IPTi delivered in sub-Saharan Africa, there 
are no published data on the acceptability of IPTi outside of sub-Saharan Africa. 
Given that IPTi has the potential to reduce the malaria-related morbidity and 
mortality for infants in other regions with a significant level of malaria mixed 
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endemicity (Plasmodium falciparum and Plasmodium vivax), such as South-East 
Asia or Oceania, it is crucial to ensure that IPTi is socially and culturally 
acceptable in distinct social and cultural settings outside of sub-Saharan Africa.  
 
Building on previous acceptability research undertaken in sub-Saharan Africa 
and in the context of an IPTi trial in Papua New Guinea (PNG), this article aims 
to: 
1. Describe knowledge, perceptions, experiences and responses relating to IPTi 
and EPI of trial participants, community members, and local health care 
providers  
2. Identify and understand the mutual interactions between perceptions of, 
attitudes to and experiences with EPI and IPTi.  
3. Identify and understand local barriers to the acceptance of and long-term 
adherence to IPTi. 
4. Identify wider socio-cultural, national and regional factors that affect, or may 
affect, the implementation or acceptability of IPTi. 
 
Setting 
The acceptability research undertaken in PNG was carried out alongside a 
randomized placebo-controlled clinical trial of IPTi, which was run by the Papua 
New Guinea Institute of Medical Research (IMR) and carried out under the 
auspices of the IPTi Consortium with the financial support of the Bill and Melinda 
Gates Foundation.  The trial tested the following drug regimens: single dose of 
SP associated to three days of either amodiaquine or artesunate given four times 
at three, six, nine and 12 months following the PNG EPI schedule. Each dose of 
the three-dose regimen was given on consecutive days: trial staff gave the first 
dose; the second and third doses were given to mothers to administer to their 
infants the following days. The study drugs were administered in collaboration 
with local health facilities responsible for operating Mother and Child Health 
(MCH) clinics, which, due to the scattered nature of settlements in PNG, deliver 
EPI through monthly village outreach services.  
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Although the trial commenced in two areas of PNG, East Sepik Province and 
Madang Province, in 2008, the East Sepik site was closed due to a lower than 
excepted malaria incidence. The acceptability research therefore focused upon 
Madang Province, a mainly coastal lowland (0-500m) with a high year-round 
malaria transmission rate. The study was carried out about 60km north of 
Madang town. 
 
PNG is renowned for its linguistic and cultural diversity, and in the study area six 
languages coexist. However, this contrasts with the lack of socio-economic 
differentiation in rural areas. In Madang province, subsistence farming of a range 
of crops (including sweet potatoes, greens and tropical fruits) is the main 
livelihood activity. In addition, both men and women migrate to Mandang town, 
which is one of the few urban centres in PNG.  
 
7.3 Methods 
The methods employed in this study were based on those used in the 
acceptability studies carried out in sub-Saharan Africa (Pool, Munguambe et al. 
2006; Pool, Mushi et al. 2008; Gysels, Pell et al. 2009). In PNG, emphasis was 
placed on a questionnaire survey of mothers whose infants participated in the 
IPTi trial. Additional individual in-depth interviews and focus group discussions 
with mothers, health workers, village reporters (community members employed 
by the IPTi trial recording study drug adherence and the occurrence of adverse 
events), opinion leaders and community members were also undertaken in order 
to triangulate findings from the questionnaires. The topics explored in the data 
collection tools were drawn from previous studies and modified to suit the 
context. These topics included, amongst others: knowledge, understanding and 
attitudes regarding vaccination; vaccination behaviour; experiences of 
vaccination; and, knowledge and understanding of IPTi. The behaviour of health 
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workers and participant mothers was also observed during delivery of IPTi and 
field notes taken. 
 
Respondents were drawn from four villages within the IPTi trial recruitment area. 
Initial sampling was based on convenience, e.g. mothers who were willing to be 
interviewed were recruited through study clinics. As the study developed 
theoretical sampling was used: participants were recruited on the basis of the 
research team’s developing understanding of the field and the questions that 
emerged from the ongoing analysis of already collected data. The numbers of 
questionnaires, interviews and FGDs (see Table 7.1), were determined by the 
point of saturation (when no more novel information emerged). Prior to their 
participation, informed consent was obtained from all study respondents in 
accordance with local ethics committee regulations. Interviews were carried in 
Tok Pisin (formerly, Pidgin English) or English, and with the agreement of 
respondents, recorded and transcribed verbatim, and, when necessary, 
translated into English by field workers for analysis.  
 
Table 7-1: Study respondents and data collection tools. 
Type of respondent Data collection tool* N 
Participant mothers  IDI 23 
  QNN 213 
Mother refusers IDI 2 
Health workers  IDI 5 
Village reporters IDI 2 
Opinion leaders IDI 2 
Community members FGD 6 
*IDI: in-depth interview; QNN: questionnaire; FGD: focus group discussion 
 
Qualitative data analysis was carried out employing a Grounded Theory 
approach (Glaser and Strauss 1967), with more abstract generalizations 
emerging from the data based on the coding of emerging themes using QSR 
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Nvivo 2. Descriptive statistics from the qualitative data were generated using 
SPSS 14.0.  
 
Overall ethics clearance for the acceptability research was obtained from the 
Ethics Committee of the Comité Ético de Investigación Clínica of the University of 
Barcelona. Separate local ethical clearance was obtained from the PNG Medical 
Research Advisory Committee and the PNG Institute of Medical Research 
Institutional Review Board (IRB), approval number 0807. 
 
7.4 Results 
Acceptability and adherence 
A number of key factors have emerged from the data that influence the 
acceptability of IPTi in positive or negative ways. These factors relate to local 
attitudes towards infant care and vaccinations, the clinic environment, the IPTi 
regimen and the nature of the clinical trial context. 
 
Local health culture and the routinization of EPI 
The interviews with mothers whose infants participated in the study indicate that 
there is common awareness of and demand for EPI vaccinations. Although the 
mothers were unable to name all the diseases that vaccination prevents (56% 
[119/213] could name some), they knew that vaccination prevented diseases or 
provided protection (91% [194/213]), were positive towards vaccination and often 
distressed by the possibility that their children may miss out on vaccination. 
Although over 20% (47/213) of mothers stated that vaccination provides 
prevention against malaria, it is unclear to what extent this was due to confusion 
with the IPTi study. Vaccinated children were viewed as healthy; indeed keeping 
the child healthy was cited as the reason for vaccinating children by over 40% of 
mothers (87/213). There was debate about whether vaccination provided 
complete or partial prevention for diseases, with general opinion leaning towards 
partial prevention: vaccination gave some protection, but complete prevention 
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depends on other factors; the disease would develop more slowly giving mothers 
chance to go to the clinic; or, the child could be sick again in the future. 
  
Reports of vaccination-related side effects were minimal (2% [5/213] of 
participant mothers reported side effects), and descriptions focused on mild fever 
or passing distress. Although relatives and neighbours were said to complain 
occasionally of children crying after vaccination, mothers were able to dismiss 
these complains and they did not prevent them from vaccinating their children. 
Children receiving multiple injections during a single clinic visit was said to cause 
concern amongst mothers and relatives. Sometimes relatives questioned 
mothers about the number of injections that the child had received and said that 
two was too many. One mother reported getting angry after seeing blood drip 
down her child’s arm after vaccination. 
 
In spite of the concerns about multiple injections, very few mothers reported 
factors preventing them from vaccinating their children (one reported that if she 
was too busy she may be unable to take her children, another that her husband 
could prevent her, one mentioned transport problems and one described how 
she would not be able to go if she was sick). However, in the qualitative 
interviews, other factors mentioned included: health workers reprimanding 
mothers for missing previous appointments; difficulties in meeting the costs 
levied at the clinic; and, laziness.  
 
Although the data suggest that mothers are responsible for the healthcare of the 
children, taking them to the clinic and caring for them in the home, fathers often 
play the role of ultimate decision-maker, to whom women have to seek 
permission to travel to the clinic. Fathers also take a more prominent role in 
emergencies. Whilst respondents did not report that husbands prevented them 
from vaccinating their children, there were scattered reports, offered by mothers, 
of other women’s husbands preventing their wives from participating in the IPTi 
trial. However, one health worker suggested that this might be an easy excuse to 
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avoid refusing directly. The women who participated in the trial reported having 
made the decision to participate with their husbands, who agreed because they 
saw the benefits.  
 
The data revealed only scattered accounts of the use of non-biomedical means 
of preventing disease: two mothers reported using “paw paw” seeds to prevent 
disease, and one mother specifically mentioned preventing malaria; one mother 
referred to herbs more generally; and, a health worker described the use of 
amulets for spiritual protection by members of the local Catholic church. Herbal 
remedies were more popular for curing rather than preventing: respondents 
described a range of remedies for mild diseases such as cough, cold, diarrhoea 
and fever. Mothers, however, preferred that serious diseases be dealt with in the 
clinic. 
 
IPTi drugs, adherence and reasons for refusal 
Two-thirds of mothers interviewed knew that the IPTi trial involved malaria 
prevention (67% [143/213]) and almost three-quarters knew they were 
participating in research (74% [157/213]). However, the vast majority (87% 
[186/213]) were unsure about the names of the drugs used, and only four named 
Fansidar (the brand name for SP) as one of the study drugs. Nevertheless, the 
mothers were almost universally content with their experiences of the trial: the 
IPTi drugs, the outreach clinics and the free treatment. Mothers reported a 
decrease in malaria amongst the participating infants and commented more 
generally on the health of the infants, comparing it favourably with that of other 
children who did not participate. They also reported that study participation had 
brought broader benefits as they travelled less often to the clinic and had more 
time to do other activities such as work. Indeed, mothers commonly enrolled 
more that one of their children in the study. Trial staff were considered diligent 
and caring, compared to other health staff who were rude, slow to deal with 
mothers, and did not give proper care. One mother conceded that this might be 
due to the health workers’ heavy workload. A common concern expressed by 
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respondents was what would happen when the IPTi trial came to an end in the 
area.  
 
Reports of side effects from the IPTi drugs were also rare: two mothers referred 
to the child’s body being weak, but that they quickly recovered; a third, described 
how her child was seen by one of the trial doctors after suffering a reaction to the 
trial drugs. In none of the cases was the mother discouraged from continuing her 
participation. 
 
IPTi was delivered in three doses at four intervals to infants who participated. 
Two doses were left with the mother to give to the child the following days. 
Fifteen percent of mothers (31/213) reported that they sometimes did not give the 
IPTi drug as instructed. The majority, who reported having followed the 
instructions, did so out of the belief that the drugs would help the child and not 
doing so would be akin to neglect or due to pressure from health workers. 
 
Respondents reported that during the trial and particularly the recruitment phase 
there were reports that blood sampled from participants was being sold by the 
local research institute. People with less experience of research, such as men, 
the elderly and the residents of remote villages, were said to spread these 
rumours. Indeed, the majority of participant mothers surveyed reported that the 
blood was used for diagnostic purposes (62% [133/213] referred specifically to 
testing for malaria). One woman, who refused to participate in the IPTi trial, did 
so because she believed that the blood would be used for transfusion, something 
that she disagreed with. Although there were concerns from two participants 
about their children losing blood and 16% (33/213) of mothers were unsure about 
the purpose of the blood sampling, many mothers paid little attention to these 
complains. The majority of the mothers who refused to participate or dropped out 
from the study did so because of the rumours associated with blood sampling 
and not because of IPTi per se. 
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The influence of IPTi on disease prevention 
There is no evidence that IPTi had a negative impact upon EPI adherence. Given 
the support that the staff employed by the clinical trial gave to the local 
healthcare system, in the local clinics and at monthly outreach visits to the 
communities, it is likely that EPI adherence increased during the trial. 
Furthermore, all participant mothers were positive about their participation.  
 
Participant mothers perceived IPTi as offering complete prevention from malaria: 
98% (208/213) of mothers stated that after IPTi their children would not get 
malaria. This finding is however contradicted by the extent of bed net usage: over 
three-quarters (77% [163/213]) of participant mothers reported using bed nets as 
a means of malaria prevention. There was however debate about the 
effectiveness of bed nets. The new bed nets that were being handed out to trial 
participants were considered effective at repelling the mosquitoes, in contrast to 
the less useful older nets. One health worker attributed the popularity of bed 
nets, to previous campaigns of mosquito eradication that had left a strong 
message about the importance of preventing mosquito bites. 
 
7.5 Discussion 
In a similar fashion to acceptability studies undertaken in Africa (Gysels, Pell et 
al. 2009), the data from PNG indicate a general concern about infant health and 
that mothers were generally motivated to comply with prevention practices, 
regardless of whether they fully understood them or not. Although mothers who 
participated in the IPTi trial were often not entirely clear about the diseases that 
vaccinations prevented, they viewed EPI non-compliance as neglect. This was 
based on the general distinction that they drew between the health of un-
vaccinated and vaccinated children. Although references to traditional prevention 
practices were very rare in the PNG data (a finding which differentiates PNG 
from other sub-Saharan African sites (Pool, Munguambe et al. 2006; Pool, Mushi 
et al. 2008; Gysels, Pell et al. 2009)) the observed benefits of vaccination, 
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together with the general concern about infant health, formed a favourable 
context for the acceptance and routinization of both EPI and IPTi.  
 
The presence of the IPTi trial in PNG did not negatively affect participants’ 
attitudes towards EPI vaccinations, nor did it influence their other malaria 
prevention practices, as was the case in the sub-Saharan African sites (Pool, 
Munguambe et al. 2006; Pool, Mushi et al. 2008; Gysels, Pell et al. 2009). 
However, whilst in the sub-Saharan African sites, the preventive healthcare 
practices, including IPTi, were almost always considered as bestowing only 
partial protection, in PNG mothers viewed IPTi as providing complete protection 
from malaria. Although one may expect a decrease in bed net usage to 
accompany this finding, no such reduction was reported. This may be the result 
of the general compliance with preventive practices or to avoid nuisance 
mosquito bites. However, if IPTi were implemented across PNG and delivered as 
part of EPI further research on bed net usage would be useful to confirm this 
finding. 
 
One of the main determinants of acceptability is whether recipients and other 
community members perceive the intervention as performing as they think it is 
supposed to, and whether the benefits are perceived to outweigh the 
disadvantages. In the case of the clinical trial of IPTi in PNG, participant mothers 
understood that IPTi was intended to prevent malaria in infants and they 
identified a positive effect upon the health of participating infants and perceived a 
decrease in malaria incidence. In a similar fashion to the clinical trial sites, where 
acceptability studies have been undertaken (Kenya, north-eastern Tanzania, 
Mozambique and Gabon (Pool, Munguambe et al. 2006; Pool, Mushi et al. 2008; 
Gysels, Pell et al. 2009)) participant mothers and other community members 
viewed the benefits of trial participation, which included the free high-quality 
health care provided by the trial staff at local clinics and during outreach services, 
and the perceived reduction in malaria amongst participating infants as 
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outweighing any concerns about the blood sampling and associated rumours of 
“blood selling”. 
 
Because, in clinical trial settings, it is difficult to isolate the advantages and 
disadvantages linked to trial from those linked to the intervention, it is challenging 
to distinguish what precisely motivates mothers to attend clinic and adhere to 
treatment, and this makes it difficult to assess how they would respond in a more 
routine implementation setting. However, given the similarities with the response 
in the intervention sites in Africa it seems likely that the response in “natural” 
settings will not be very different. In the intervention studies with SP in Malawi 
and Ghana, ‘IPTi was simply an unnoticed addition to an already routinized EPI’ 
(Gysels, Pell et al. 2009). 
 
During the PNG trial of IPTi participants had greater opportunity for non-
adherence than in the other clinical trials of IPTi: mothers were given the two last 
doses of the trial drug to administer themselves at home. Although perhaps 
inflated by desirability bias, the majority of mothers reported having always given 
the doses as instructed, motivated by the benefits they perceived that the 
previous doses had proportioned their child (or children). Although a single dose 
drug regimen for IPTi would be ideal, in order to avoid potential non-adherence, 
the results from this study suggest that if they perceive benefits, mothers are 
prepared to administer drugs for prevention unsupervised. Data from other 
acceptability studies, where health workers sometimes provided IPTi drugs for 
mothers to administer at home, despite being instructed not to, suggest that 
some mothers did give the drugs correctly. Other mothers forgot and some, given 
that they thought the drug was to cool the post-vaccination fever, only gave if the 
child had fever (Pool, Mushi et al. 2008; Gysels, Pell et al. 2009). The latter 
indicates the importance of providing, in addition to the medication, clear, 
relevant information. 
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Respondents’ concerns about the care that their infants would receive when the 
trial ends highlight the broader issue of the feasibility of implementing IPTi in 
PNG and in other countries with resource-poor health systems. Research in sub-
Saharan Africa has, however, shown IPTi to be a cost-effective intervention 
(Conteh, Sicuri et al. 2010) and pilot implementation studies undertaken by 
UNICEF in six African countries indicated that IPTi with SP was a feasible 
intervention, reaching 97% of immunized infants (de Sousa, Salama et al. 2010). 
In spite of these, findings, efforts are required to address the poor coverage and 
timeliness of childhood immunization outside of the urban centres in PNG 
(Toikilik, Tuges et al. 2010). Furthermore, in a third of cases reported in this 
study, non-vaccination was attributed to problems with the health services 
(Toikilik, Tuges et al. 2010), which illustrates the need for investment in the 
provision of MCH outreach services. Although, the data presented provide some 
insight into health workers’ behaviour towards mothers attending MCH for 
immunization and its effect on immunization adherence, this requires further in-
depth study. 
 
The data collected in PNG illustrate additional, striking similarities to those from 
acceptability studies undertaken in sub-Saharan Africa. For example, mothers in 
all sites were familiar with vaccination as prevention yet uncertain regarding 
particular diseases prevented and the nature of the prevention. Also the key 
barriers to attending clinics, mainly distance and transport and treatment costs, 
were common in sub-Saharan Africa and PNG. There were also common 
complaints about (non-trial) health staff that criticize and chastise mothers in the 
clinic (Schwarz, Gysels et al. 2009). The data also suggest that the role of fathers 
in infant care is similar: although fathers play a relatively minor role in day-to-day 
childcare, when more serious matters arise, such as participation in a clinical trial 
or severe illness, they take the role of decision-makers. Even the nature of the 
rumours that circulated around the clinical trial of IPTi in PNG, relating to the 
selling of the blood sampled, resonated strongly with the rumours encountered in 
other trial sites (Pool, Munguambe et al. 2006; Gysels, Pell et al. 2009).  
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Strengths and limitations of the study 
A clinical trial is not the ideal context to investigate the acceptability of any 
intervention as many of the factors that affect a community’s response to the 
intervention itself are influenced by the presence of the trial. However, in the 
case of IPTi in PNG, it was the only way of collecting acceptability data early 
enough to be able to make recommendations for improving access and long-term 
adherence during roll out. Using a range of methods (including direct observation 
of behaviour) and interviewing a range of respondents, enabled the triangulation 
of findings and ensured their reliability. 
 
7.6 Conclusions 
The findings presented complement a broader programme of social science 
research undertaken in sub-Saharan Africa (Gysels, Pell et al. 2009). The 
inclusion of PNG as an additional site for acceptability research enables 
comparisons to be made between this very different social and cultural context 
and the sites in sub-Saharan Africa. The results of the acceptability research in 
PNG are remarkably similar to those from the African sites and this allows 
tentative generalization regarding IPTi implementation beyond Africa. Firstly, IPTi 
seemingly fits well with local health cultures and appears to be accepted easily. 
Secondly, there is little evidence that IPTi has negative impacts on attitudes to 
EPI or EPI adherence. Furthermore, although in PNG mothers described IPTi as 
complete malaria prevention this did not, as in other African sites, influence 
existing malaria prevention and treatment-seeking behaviour. In practical terms, 
the degree of similarity across the sites suggests that IPTi would require minimal 
adjustment in order to be rolled out successfully across diverse social and 
cultural contexts. The generalizability of findings vindicates the overall research 
approach of undertaking small-scale social science studies in many sites.
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8 General discussion  
 
8.1 Rationale 
The aim of the present work was to explore the context and potential benefits of 
implementing an IPTi intervention in PNG. First, it was important to have a good 
understanding of the epidemiology of malaria in PNG. This was the objective of 
chapter 3 where the relationship between malaria endemicity and population Hb 
means & population anemia prevalence was assessed. Second, the 
management of malaria in Papua New Guinean children was for many years to 
treat presumptively all patients with fever. In chapter 4, the effectiveness of 
treating malaria with a unified treatment for Pf and Pv (artemether-lumefantrine,  
AL) based exclusively on RDT results was assessed. Third, if the efficacy of the 
IPTi strategy is well established in African countries with a predominance of Pf 
infections, nothing is known on the potential efficacy of IPTi in regions of the 
world with a high burden of non-Pf infections. This was addressed in chapter 5 
were the efficacy of a single dose of SP associated to 3 days of AQ or AS was 
investigated. Fourth, in order to have a broader picture of the burden of diseases 
in PNG and how would fit an IPTi intervention in this context, we looked in 
chapter 6 at the potential benefits of IPTi on the overall morbidity as well as the 
appropriateness of the IMCI strategy supplemented with RDT to guide malaria 
treatment. Finally, one of the challenges of implementing any new intervention 
such as IPTi is to be sure that it is understood and accepted by the targeted 
population. This is addressed in chapter 7 where a qualitative anthropological 
investigation of the acceptability of IPTi in PNG was undertaken.  
All these different aspects combined give a comprehensive picture of the context 
and potential benefits implementing an IPTi intervention in PNG. 
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8.2 Diseases burden in PNG 
8.2.1 Respiratory infections 
As described in chapter 6, the major contributors to morbidity in PNG are 
respiratory infections as they are the leading cause of illness episodes in children 
under 5 years in PNG with almost one episode of lower respiratory tract infection 
(LRTI) per child per year (syndromic definition: tachypnoea + cough and/or 
difficulties in breathing). This is followed by malaria and gastro-enteritis with 
approximately 0.7 episode / child / year each. The age pattern of these different 
diseases is very different with respiratory infections and gastro-enteritis 
decreasing rapidly as age increases while malaria incidence is increasing with 
age, being the higher between 18 and 21 months (see fig 2 & 3, chapter 6).  
 These estimates based on signs and symptoms, except for malaria, are a bit 
higher than what was described in other settings, even if the present findings are 
consistent with another study carried out in the PNG Highlands in the 90’, where 
an incidence rate of LRTI of more than 1 episode/child/ year in children under 5 
years was described by Smith et al. (Smith, Lehmann et al. 1991) In a recent 
observational study in Kenya, incidence rate of 0.2 to 0.6 was reported for LRTI 
in children below 2 years (Feikin, Olack et al. 2011).  
A number of factors could explain a potential overestimation of ARI and LRTI in 
PNG and need to be considered before concluding that their incidence rates are 
higher in PNG. First, the definitions used might differ slightly from one place to 
the other. Indeed, in PNG for example, a distinction is made between mild (fast 
breathing + cough), moderate (+ chest indrawing) and severe pneumonia (+ 
danger signs such as tachycardia and cyanosis). Thus, a moderate pneumonia in 
PNG corresponds to a severe pneumonia in the WHO classification.  Second, 
one of the main components of the definition of LRTI is tachypnoea. However, 
the estimation of the respiratory rate might vary greatly between observers. More 
generally, a regular training of health workers is required to achieve good clinical 
assessment (Horwood, Vermaak et al. 2009). Third, the reporting system of 
cases might vary greatly from one region to the other. Indeed, in the present drug 
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trial, parents were strongly encouraged to visit the health facilities, free of charge, 
when their child was sick. Regular visits to villages to perform the IPTi 
intervention might have also increased the attendance rate of sick children. 
However, and even considering these potential reasons for an overestimation of 
its burden, LRTI and more generally ARI are leading causes of morbidities in 
young Papua New Guinean, especially below one year.  
Several reasons might explain this high burden of ARI and LRTI observed in 
PNG. First, several surveys performed in PNG showed that Streptococcus 
pneumoniae and Haemophilus influenza (Hib) were highly prevalent as a cause 
of pneumonia (Lehmann 1992; Riley 2002). It is also the only country where a 
polysaccharide vaccine against S. pneumomiae has demonstrated an effect on 
overall mortality with a decrease of 19%. (Riley, Lehmann et al. 1986) Even if 
these studies were mainly performed in Highlander populations of PNG which 
are different from Madang, it is possible that the effect on mortality reflects also a 
higher susceptibility of Papuan children to this pathogen and could explain 
therefore why the burden of LRTI is higher compared to other developing 
countries.  
Nutrition factors might also play a significant role in terms of susceptibility to 
LRTI. Indeed, it was demonstrated that children in PNG and elsewhere with poor 
nutrition status and low birth weights are particularly at risk of LRTI, especially 
infants below 6 months. (Smith, Lehmann et al. 1991; Lehmann and Heywood 
1996; WHO 2011) Due to a poor diet and unfavourable socio-economic factors, 
PNG presents very high prevalence rates of children under 5 years with low 
height-for-age (stunting) and low weight-for-height (wasting) (Mueller and Smith 
1999; Mueller, Vounatsou et al. 2001). Pattern of malnutrition is different across 
the country. In the Highlands, stunting is predominant (>50%) with little wasting, 
while on costal areas (such as Madang), wasting is more common (3-5%) and 
frequently associated with stunting (30-40%).(Norgan 1995) We can therefore 
postulate that these factors contribute to make young children of PNG especially 
susceptible to LRTI and thus increase the overall incidence. Other environmental 
factors such as cooking on fire inside the house (indoor pollution), passive 
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smoking or overcrowding, which are common in PNG, might also contribute to 
the high burden of ARI/LRTI observed.(Armstrong and Campbell 1991; Smith, 
Samet et al. 2000; Suzuki, Thiem et al. 2009) 
8.2.2 Malaria  
For malaria, the story is more complex. Indeed, with approximately 0.7 episode 
per year, PNG can be considered as hyperendemic according to WHO definition 
(WHO 2010). This figure, however, does not reflect the local variations of 
endemicity. The IPTi trial is a very good example. Indeed, originally the study 
was planned on two sites (Mugil in Madang province and Wosera in East Sepik 
province) because they were supposed to be equivalent in terms of malaria 
transmission: same altitude, similar geography & climate (See figure 8.1), rural 
setting, previous report with similar EIR (Mueller, Bockarie et al. 2003). However, 
during the IPTi trial, very different transmission intensities were observed. 
Indeed, the incidence of malaria in children aged 3-15 months was extremely low 
in the Wosera with less than 0.1 episode/child/year (interim analysis of the IPTi 
study, personal communication) compare to 1.07 episode/child/year in Mugil, 
0.28 for Pf and 0.81 for Pv (placebo group, IPTi trial, chapter 5). It is not totally 
clear why the endemicity decreased so rapidly in the Wosera from approximately 
1.3 episodes/child/year in the early 90’ (Shankar, Genton et al. 1999) to less than 
0.1 during the IPTi trial (interim analysis, personal communication), but several 
hypotheses can be formulated. First, a couple of months prior to the beginning of 
the study, a “wild” distribution of ITN by a non-governmental organization (NGO) 
was initiated in the region. Knowing the effectiveness of this control intervention, 
(Lengeler 2004) it is likely that it has contributed to this drop. Second, small 
climate changes (drier, warmer) might have made the environment less 
favourable for malaria transmission. It is often difficult to predict, because even if 
simple climate determinants (rainfalls, temperature) are well recognized factors 
influencing malaria transmission, more complex ecological characteristics 
(deforestation, agriculture or water quality) might also influence the local 
epidemiology of malaria. (Paaijmans, Read et al. 2009; Parham and Michael 
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2010; Stresman 2010) Finally, the Wosera area has been involved for more than 
20 years in various research projects on malaria. This might have been a highly 
efficient intervention for malaria control (but not much cost-effective!), probably 
because almost the entire population was sensitized to the problem of malaria 
and had a better access to malaria interventions than other regions. Apart from 
the ITN intervention, we are not aware of any other intervention such has mass 
drug administration that could have taken place in this region.  
 
Figure 8-1: Typical landscapes of both the Wosera and Mugil areas, the 
original 2 sites planned for the study. 
 
  Wosera      Mugil  
   
 
This example highlights the fact that local endemicity can vary rapidly over a 
relatively short period of time. This demonstrates also the complexity of 
monitoring malaria and the importance of using appropriate tools to measure 
these variations. In regards to that, it might be important to consider anaemia 
prevalence or population Hb mean as additional indicators to the known arsenal 
of metrics such as parasite rate or Pf incidence rate. Monitoring malaria 
transmission variations becomes critical when planning and when prioritizing the 
implementation of control interventions such as ITN, IRS or even IPTi.    
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8.2.3 Gastroenteritis  
Diarrheal syndromes were frequent reasons for OPD visits in our cohort with an 
overall incidence of 0.7 episode/child/ year. These findings are in line with what 
was found recently  in Kenyan infants, where incidence rates of 0.4 to 0.7 were 
described in children under 5 years.(Feikin, Olack et al. 2011) 
However, these figures are much lower than what was observed in PNG 
previously. A study performed in the late 80’ described a much higher burden 
with around 5 episodes per year in the Highlands of PNG in the same age 
group.(Wyrsch, Coakley et al. 1998) WHO reported various incidences from 
developing countries, but generally, they are well over one episode per year, 
even in the Asia-Pacific areas, except Indonesia where an incidence of around 
0.8 was reported in the late 80’. (Kosek, Bern et al. 2003) There are only few 
recent estimates of incidence of diarrhea in developing countries. However, all 
indicate an important decrease of its burden. Reasons are not all well 
established. Main factors that might have impact on diarrhea are: better living 
conditions, better hygiene and better awareness. It is also likely that the reporting 
methods were different and diarrheal episodes were defined differently in the 
past. 
8.2.4 Acute otitis media (AOM) 
Surprisingly, acute otitis media were much less frequently diagnosed compared 
to other syndromes. It is also much lower than elsewhere. Indeed, only 2.8% of 
cases seen in the study clinics had a diagnosis of AOM, which is 10 times less 
than what was reported in Nigeria in a small survey, where 29% of children under 
5 years were diagnosed with AOM in an outpatient clinic.(Amusa, Ogunniyi et al. 
2005) It is also very low compared to what is reported in developed countries, 
where incidence rates of 1.7 to 1.9 episodes/child/year are reported in children 
below 2 years (PNG = 0.06-0.09).(Chonmaitree, Revai et al. 2008; Rovers 2008) 
It is especially surprising considering that OAM usually follows the occurrence of 
upper respiratory tract infections (URTI). As we have seen, URTI are very 
common in PNG, but seems not to be associated with a high burden of AOM. 
  
157
Reasons for this very low incidence are not entirely clear, but it is likely that AOM 
are under diagnosed because of difficulties for the routine health staff to perform 
good quality otoscopies. Moreover the diagnosis is often made only when pus is 
discharging from the ear, which is a sign of a perforated AOM corresponding to a 
minority of all cases. Finally, it is now well established that most AOM heal 
spontaneously without any antibiotics. (Coker, Chan et al. 2010) AOM could 
therefore remain undiagnosed without having important consequences for the 
child. 
 
8.2.5  Burden of diseases and public health implications  
These data show clearly that ARI and LRTI are leading causes of morbidities in 
Papua New Guinea infants. If important resources have been allocated to better 
understand and control malaria in the recent years in PNG, it seems also urgent 
to plan interventions that could impact on the burden of respiratory infections. 
These interventions should aim first at preventing the occurrence of LRTI and 
their complications. In this regard, the recent introduction of Hib vaccine in PNG 
will certainly have a positive impact on the burden of respiratory infections as it 
was shown in resources limited countries. In a second step, the introduction of 
the immunization against S. pneumoniae could be also considered. (Gessner 
2009) Malnutrition, among other factors, increases the risk of respiratory 
infections, especially in infants. Therefore, interventions should also emphasize 
the importance of integrating correction of malnutrition. The same applies to 
other co-factors such as indoor air pollution where prevention should be 
reinforced. Finally the epidemiology of respiratory infections in PNG, especially in 
regards to aetiologies, is still unclear and should be investigated in order to 
improve treatment and prevention strategies.  
The high burden of malaria is also an important problem in PNG. As it will be 
discussed below, it will be important to measure the impact of the recently 
introduced prevention strategies such ITN and ACT to prioritized further 
interventions.  
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Diarrheal syndromes seem to have considerably decreased in the past 20 years, 
which is good news for health authorities. Simple sanitation measures account 
certainly for an important part of this drop and efforts should be maintained to 
promote a better hygiene and safe access to water.  
 
8.3 Main findings about IPTi in PNG 
This work provides the proof of principle that IPTi using a combination of two long 
acting drugs (SP associated with 3 days of AQ) reduced the risk of malaria (all 
species) by 28%. On the other hand, SP associated with 3 days of AS (a short 
acting drug) had only a limited effect on malaria. SP-AQ3 worked better against 
Pf than Pv (ITT 37% vs 22%, ATP 51% vs 31%). It reduced the risk of anemia 
(<8g/dl) by 25% (non-significant in ITT analysis). It had no effect on the overall 
morbidity (RR=1.0, p=0.99), no effect on serious adverse events (RR=1.11, 
p=0.84) but a surprisingly lower risk of death (7 in the placebo group, 2 in the SP-
AS3 group and none in the SP-AQ3 group). Resistance levels for both SP and 
AQ were high in the study area, however different for Pf and Pv.(Marfurt, Mueller 
et al. 2007) Indeed, SP is mainly effective against Pf while AQ is much better for 
Pv. This explains why this drug combination (SP-AQ3), even though suboptimal, 
is complementary in preventing malaria in PNG, highly endemic for both species.  
No serious adverse event related to the study drugs was observed.  
Nevertheless, these encouraging efficacy results are only a first step on the long 
way leading to a successful implementation. The feasibility and appropriateness 
of such an intervention is complex and depends on a lot of different factors. 
Indeed, several factors can be identified that could compromise the benefits of 
the IPTi intervention when implemented in routine practice, which refers to the 
effectiveness. These aspects will need to be considered when health authorities 
might decide on IPTi policy in PNG. Therefore, the following section 8.4 will 
detail the main determinants that could affect the IPTi effectiveness, i.e.  
• the EPI coverage: a key component for IPTi delivery  
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• The endemiciy of malaria in PNG: IPTi is beneficial mainly in areas with 
moderate to high endemicity. This might change rapidly in PNG due to the 
recent introduction of control strategies (ITN and ACT).    
• The effect (or the absence of effect) of IPTi on the overall morbidity: 
This is important to consider from a public health perspective, because it 
will necessarily impact on the health resources needed 
• Drug combinations: The IPTi trial investigated two different drug 
regimens that are not perfect in many aspects such as resistance and 
safety profiles. Therefore, it is important to consider whether other drug 
combinations might be useful to investigate. 
• Acceptability: This aspect of the intervention is also important and was 
investigated along side the trial. 
• Feasibility: This includes, among others, the availability & delivery of the 
drugs, the adherence to the home delivery of drugs and the ease of 
administration of the drugs   
• Cost-effectiveness: This is essential to consider from a public health 
perspective. 
All these factors should be considered one by one for their implications for 
policy decision.  
  
8.4 The determinants of IPTi effectiveness in PNG  
8.4.1 IPTi coverage depends on EPI coverage 
One of the main features of IPTi interventions is to use as much as possible the 
existing health infrastructure. Practically, the trial was set up in collaboration with 
local health facilities responsible to conduct the EPI in their own catchment 
areas. The study teams joined the routine staff during outreach clinics and 
performed the IPTi study while nurses from the health centres were taking care 
of the immunizations as well as of the MCH clinic. Therefore, if one would like to 
implement IPTi in PNG, logistics is not to be one of the main barriers as no 
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supplementary infrastructures will need to be set up. This is one strength of the 
IPTi intervention compared to other types of intermittent preventive strategies 
such IPTc which are stand-alone strategies. The feasibility issue has been 
mentioned in several publications (Beeson, Rogerson et al. 2011; Bojang, Akor 
et al. 2011) and specifically studied for IPTi in an effectiveness trial performed in 
2006 in Tanzania (Willey, Armstrong Schellenberg et al. 2011). They concluded 
that IPTi implementation is feasible using existing health facilities at limited cost.  
One of the key determinants of the effectiveness of IPTi is the level of coverage 
(proportion of children receiving the intervention in real-life settings). Indeed, to 
achieve a reasonable effectiveness, it is important that most of the children get 
the desired four IPTi doses. In the present trial, infants who received at least 3 
doses were better protected compared to those who had less doses (38% 
against all species if the infants get at least 3 doses vs 28% in all infants). 
Similarly, an important difference of efficacy was observed between intention-to-
treat and as-to-protocol analysis, which also reflects the relation of coverage to 
effectiveness. 
Usually, the DPT3 vaccine time point is used to estimate the vaccine coverage 
and to extrapolate potential IPTi coverage (Carneiro, Smith et al. 2010 Nov; 
Willey, Armstrong Schellenberg et al. 2011). The only available data on IPTi 
coverage in routine practice come from Tanzania, where they observed that 72% 
of children received at least 1 IPTi dose and only 22% received all 3 scheduled 
doses. The vaccine coverage ranged from 69% for DPT2 (IPTi-1) to 42% for 
measles (IPTi-3). (Willey, Armstrong Schellenberg et al. 2011) In PNG, vaccine 
coverage is rather low, with similar figures as Tanzania, around 50-60% for DPT3 
and measles 1 (at 6 months of age, IPTi dose 2) to less than 50% for the second 
shot of measles at 9 months (IPTi dose 3). Figures are not known for the last EPI 
time point, when infants receive the second dose of vitamin A supplementation 
(and last dose of IPTi), but it is believed to be very low.  We can thus assume 
that IPTi coverage is likely to be low, which should affect directly its 
effectiveness. This is below the minimal GAVI recommended cut-off of 70% 
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DTP3 coverage required for any new intervention to be implemented within EPI 
(which usually applies to highly effective vaccine). (GAVI 2011)   
It seems therefore of prime importance that, if IPTi is considered for 
implementation, health authorities consider improving EPI coverage. It is also 
unlikely that the introduction of IPTi by itself could improve the coverage of EPI. It 
seems thus not straightforward that with about 30% of efficacy in a highly control 
trial a measurable impact of IPTi on malaria could be observed in real-life 
condition with such a low coverage. 
 
8.4.2 Changes in transmission intensity of malaria in PNG 
As several studies pointed out, the effectiveness of IPTi is increasing as malaria 
endemiciy of malaria increases. (Kobbe, Adjei et al. 2007; Carneiro, Smith et al. 
2010 Nov; Ross, Maire et al. 2011) These studies highlighted also the need to 
monitor closely the endemicity of malaria in order to proper implement IPTi. This 
is another challenge that health authorities will have to face, would they wish to 
implement IPTi in PNG. Indeed, we have seen above how endemicity of malaria 
can change rapidly and almost unnoticeably between two regions (Wosera and 
Mugil). On top of this, very effective interventions such as long lasting insecticide 
impregnated nets (LLINs) and standard treatment with ACT start to be 
implemented at scale in PNG, which is going to greatly affect the endemicity of 
malaria all over the country. In such circumstances, it might be difficult: 1) to 
identify the regions that could really benefit from an IPTi intervention 2) to 
measure the impact attributable to IPTi. 
 
8.4.3 Effect on overall morbidity, severe illnesses and mortality 
One fundamental aspect of any public health intervention is to improve the health 
status of individuals. It is thus important to measure the impact of an intervention 
on the overall morbidity, severe illnesses and mortality (on all illness episodes) 
as it was described by Murray et al. (Murray and Chen 1992), and as it was 
reliably done for ITN. (Lengeler 2004) In the case of IPTi, apart from the effect of 
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the intervention on malaria related morbidities (malaria episodes, anaemia), the 
outcomes of interest are the outpatient attendance rates (overall morbidity), 
hospitalisation/severe illnesses rates and mortality.  
In the previous eight trials described in table 2 (chapter 1), six found no effect on 
the outpatient visits rate or did not reported it. One reported a limited impact 
within one month after IPTi dose 1 and 3 in Ghana (OR= 0.80 [0.68 to 0.96] after 
dose 1 and OR= 0.71 [0.59 to 0.84] after dose 3) and one trial in Mozambique 
reported an impact on outpatient attendance with chest indrawing within one 
month after dose 1(RR=0.57, p=0.025). (Chandramohan, Owusu-Agyei et al. 
2005; Macete, Aide et al. 2006)  None reported a positive impact on the overall 
outpatient attendances during the first year of life. Similarly for 
hospitalisations/serious illnesses, two found a significant impact of 19 and 30%, 
(Schellenberg, Menendez et al. 2005; Macete, Aide et al. 2006), one found a 
limited impact one month after dose 1 (Mockenhaupt, Reither et al. 2007) and 
one found an impact on anemia-related admission only. (Macete, Aide et al. 
2006) Looking at the present IPTi trial in PNG and as described above, no effect 
was found on overall morbidity during the first year life, neither on hospital 
admissions/severe illnesses. Surprisingly, an effect on mortality was found, even 
though the trial was not designed to assess this outcome. None of the other trials 
measured any impact on mortality. 
The findings presented here tend to demonstrate that the reduction of the malaria 
incidence in the treatment arms is not accompanied by a reduction of the overall 
morbidity. Similarly to all other trials performed in African countries, the study 
was not aimed at investigating the effect of IPTi on overall morbidity. The lack of 
effect on all episodes in spite of a 30% reduction of malaria episodes means that 
malaria episodes have been replaced by another (other) disease(s). There was 
no trend for incidence of all ARI or GI to be higher in the treatment arms. 
However, there was an indication that severe LRTI could be more frequent in 
those who received IPTi (IRR for SP-AQ3=1.38, p=0.18). Outside being due to 
chance, this observation suggests that an interaction might exist between malaria 
and respiratory infections, malaria providing some protection against some types 
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of ARI. This is rather contraintuitive, the hypothesis being more for an 
aggravation of respiratory infections in the presence of malaria parasites. In a 
recent trial on efficacy of the RTS,S/AS02D malaria vaccine, children receiving 
the vaccine had significantly less pneumonia compare to the placebo group 
(receiving hepatitis B vaccine). (Abdulla, Oberholzer et al. 2008) It was never 
clear if this was an effect due to the decrease of malaria (disease interaction) or 
a protection due to the vaccine via the adjuvant boosting a non-specific immunity. 
In the IPTi trial in PNG, the tendency for severe pneumonia to be more frequent 
in the treatment arms would be in favour of the second hypothesis as we 
observed more pneumonia in the treatment arms (where malaria incidence was 
lower).  
It is unlikely that side effects du to the study drugs could have “filled the gap”. 
Indeed, the safety profiles of the study drugs used are well known and recent 
data from Africa confirm that no more side effects are observed in children who 
received these drugs compared to other treatments of placebo. (Bojang, Akor et 
al. 2010)  
Part of the explanation could be attributed to co-infections. Indeed, in chapter 6, it 
is described that about 20% of children with a confirmed diagnosis of malaria 
(based on RDT) have overlapping signs and symptoms with LRTI or 
gastroenteritis. This would mean that by preventing malaria parasitemia with 
IPTi, we still don’t get rid of some other co-infections, which are the real causes 
of outpatient attendances. This raises the important question of defining “malaria 
disease” and its use as outcome in drug trials. 
 
If the IPTi trial in PNG did not show protection neither against overall morbidity 
nor against severe diseases (malaria-related or not), it showed a surprisingly 
protective efficacy on all-cause mortality. The effect on mortality is important and 
could justify by itself on deciding to implement this intervention in PNG. This 
finding needs however to be taken cautiously for several reasons. First, none of 
the Africans trial has shown any effect on mortality. Second the number of deaths 
is limited (9 during the intervention period, 13 over the entire study period). Third, 
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as shown in table 8.1, it is likely that most of the children died of other diagnoses 
than malaria in the placebo group; making less likely the hypothesis of a 
protection against mortality of the IPTi (no effect against other diseases has been 
shown). Fourth, if an effect attributable to the intervention is observed on 
mortality, we would expect to find at least a trend for severe illnesses to be less 
frequent in the treatment arms (a reduction of all-cause hospital admissions was 
observed in some African trial using SP alone [23% reduction], but not in other 
trials using alternative drug combinations). Finally, the study was neither 
designed nor powered to identify any effect on mortality. For all these reasons, it 
is possible that this result, even tough statistically significant, might have 
occurred by chance and should therefore not be used as argument to implement 
IPTi in PNG. 
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Table 8-1: Death review based on medical records and verbal autopsies 
Arm
number of 
days since 
previous visit
Age at 
death 
(Months)
place of 
death
malaria 
status Likely diagnosis comments
1 AQ-SP 50 22 home unknown TB with neurological involvement (paraplegic)
2 AR-SP 4 14 home Neg LRTI
3 AR-SP 304 20 Health Centre (night duty) unknown unknown 
verbal autopsy at H/C: 
severe dehydration +/- 
malaria 
4 AR-SP 61 7 home unknown possible malnutrition 
At last visit was wasted 
(at 60 percentile) with oral 
thrush. Twin
5 PLACEBO n/a 4 home unknown LRTI Based on verbal autopsy 
6 PLACEBO 7 7 hospital Neg Meningitis 
Already admitted for LRTI 
for 10 days and 
developed  meningitis 
7 PLACEBO 25 4 home unknown Severe Bronchiolitis Based on verbal autopsy 
8 PLACEBO 2 6 hospital Neg Severe respiratory infection 
9 PLACEBO 1 4 home Pv (RDT + BS pos)
Severe malaria with severe 
anemia +/- severe 
respiratory infection
Treatment with Co-artem 
started on prvious visit
10 PLACEBO 35 unknown home (outside province) unknown unknown
11 PLACEBO 15 9 home unknown Severe Dehydration
Verbal autopsy: severe 
diarrhoea, pallor and 
fever)
12 PLACEBO 1 14  Hospital Neg Severe Gastro-enteritis 
with dehydration
13 PLACEBO 1 4 Hospital Pf  (RDT pos & BS neg) LRTI (vs malaria)
 Patient was treated for 
malaria 10 days before 
(RDT=pos Pf)
 
 
Even if the reasons for an absence of benefits of IPTi on the overall morbidity are 
not totally clear, this important observation calls for some comments: 
• It is highly surprising that none of the trial’s publications and even more 
none of the reviews on IPTi, including an extensive letter report by the 
Institute of Medicine(IOM 2008), raised the problem of IPTi having no 
impact on the overall incidence of diseases during the first year of life.  
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• An intervention that has no impact on overall morbidity and severe 
illnesses is not going to provide any benefits to the health system, since 
the workload will be same or even increased because of the intervention.  
• When designing a study investigating the impact of an intervention such 
as IPTi, it is important to carefully choose the outcomes of interest, not 
only malaria-related, but also on the overall morbidity, including severe 
diseases or all-cause mortality.  
• It is questionable to consider IPTi as a control tool when no effect on 
morbidity is observed. More generally, when countries are embarking on 
malaria control programs, it is essential to measure their impact on non-
malaria related outcomes as well.   
• To confirm these findings from PNG (and the rare published information 
from African trials), it is urgent to perform again pooled analysis of all 
available data from IPTi trials and to look at the overall and non-malarial 
morbidities 
• Policy makers in PNG should consider the absence of benefits of IPTi on 
overall morbidity before to decide on a potential implementation of the 
intervention 
 
In summary, these observations raise important concerns about the real benefits 
of the IPTi intervention in PNG, especially when it should be used as a control 
tool for malaria. Indeed, which country would like to implement a malaria control 
intervention that does have no impact on the overall morbidity or on severe 
diseases? Additionally, it might be difficult to explain the “IPTi paradox” (efficacy 
against malaria, no impact on overall morbidity) to parents, see figure 8.2.  
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Figure 8-2: Translation in simple words: the IPTi paradox explained by a 
nurse to a mother visiting the EPI clinic in Madang province (PNG). 
 
 
8.4.4 The choice of the drug combination 
The drug combination including two rather one long acting drugs was the most 
effective to reduce malaria, confirming findings from Africa that it is the post-
treatment prophylactic effect that counts. However, in the case of IPTi in PNG, 
these two drugs (SP and AQ) are rather imperfect. Indeed, high levels of 
resistance against Pf are documented with AQ (high prevalence of fixation of the 
SVMNT pfcrt haplotype and pfmdr1 86Y mutation) and SP with Pv with high 
prevalence of quadruple pvdhfr mutation (see chapter 5). These data are in line 
with previous findings by Marfurt et al that high levels of resistance of Pf and Pv 
to SP-AQ3 are observed in Madang province.(Marfurt, Mueller et al. 2007; 
Marfurt, de Monbrison et al. 2008; Marfurt, Muller et al. 2008) Few trials have 
investigated other long acting drugs, alone or in combination, but the only that 
has shown encouraging results is mefloquine even if its tolerability was poor. 
(Gosling, Schellenberg et al. 2006) The main issue with SP, apart from 
resistance, is the potential of severe side effects (Steven-Johnson Syndrome). 
Therefore if one would like to pursue with IPTi and investigating alternative 
regimens, research should focus on long-acting drugs, well tolerated and with a 
favourable resistance profile. Not many drugs fulfil these criteria, but the recently 
developed combination of dihydroartemether /piperaquine (DP) might be a good 
Mama,  
IPTi marasin, em bai banisim 
pikinini long malaria. Tasol, 
pikinini bilong yu bai sik wankain 
taim long bipo… ???????* 
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candidate. Piperaquine is a bisquinoline having one of the longest half-life of all 
antimalarial and is active against Pv.(Karunajeewa, Mueller et al. 2008; Awab, 
Pukrittayakamee et al. 2010) At present, a trial is going on in Burkina Faso to 
investigate the efficacy of DP used as seasonal IPTc (ClinicalTrial.gov register 
number: NCT00941785). It is still questionable to use ACT for IPT interventions 
when these efficient treatments are also used as first line therapies in the country 
as this might contribute to speed up the level of resistance. Furthermore, it is 
probable that short acting drugs such as artemisinin derivates do not contribute 
much to the overall protective efficacy of IPTi. On the other hand, adding a highly 
efficient drug that will rapidly treat existing blood stage parasites might help to 
protect the efficacy of the associated long acting drug. This question remains 
open.  
However, if a new and more efficient drug regimen is investigated, it will be 
important to consider also the impact on the overall morbidity. In line with this, 
some research group are looking at the efficacy of broad spectrum antibiotics 
with antimalarial activities (such as azitromycine) on malaria and non-malaria 
outcomes in pregnant women. However, using antibiotics as preventive mass 
drug administration raises major issues though in terms of emergence of drug 
resistance in countries who cannot afford expensive alternatives.  
 
8.4.5 Acceptability 
One key aspect when planning to introduce a new intervention such as IPTi is its 
acceptability. Indeed, beside the efficacy itself, it is important that parents who 
are going to give the drugs to their child agree with it. This was investigated in 
Africa and acceptability was found to be very good.(Pool, Mushi et al. 2008) The 
same team investigated the acceptability of IPTi in PNG, because the social and 
health context is completely different from Africa. Similar reassuring results were 
found in PNG, where IPTi seems to be well understood and accepted by the care 
takers.  
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8.4.6 Feasibility of IPTi in PNG 
IPTi has been conceived to be easily implementable since it uses the EPI 
delivery platform. Access should not be an issue if EPI clinics are well organized. 
EPI coverage in PNG is low (about 50%), which will affect the delivery of IPTi, 
and hence its effectiveness. Appropriate training of staff is also important. But, as 
this intervention is very simple (giving a malaria treatment course to infants 
coming for immunization), a minimal training of 1-2 days is sufficient to achieve a 
good understanding of the intervention by health staff and a correct delivery of 
treatment (which was more complex than it would be in routine practice because 
of the trial constrains).  
The nature of the intervention implies that parents administer themselves the 
second and third dose of treatment (AQ). This was a concern and non-adherence 
to the 2nd and 3rd doses was feared. We established a community reporters’ 
network which was responsible to record if parents gave the drugs. According to 
their reports, it appears that adherence was good with more than 90% of 
treatment given. To better document these observations, drug levels have been 
measured in a random sample of 200 children on the day following the last IPTi 
dose given by parents. Analyses of data are still ongoing and results will be 
available in a near future. But according to preliminary results, it appears that 
drugs levels were high in all treatment groups (except placebo).  
The availability of the drugs used is also important. But this was not a problem as 
the treatments used in the PNG trial were SP, AQ or AS which were all first line 
treatments in the country at the time of the trial. The only concern might be 
related to the quality of the administration. Indeed, no infant formulation (syrup or 
granules) does exist for any of the drugs that were used, which could make their 
delivery more complex. It has been shown in a recent review that infant 
formulations of antimalarial drugs improve the uptake of the treatment. (Kurth, 
Belard et al. 2010) In the present trial, tablets were crushed, mixed with syrup 
and administered with a spoon or a syringe. This procedure was acceptable but 
could be much more satisfactory if infant formulations would exist. The NGO 
Medicines for Malaria Venture (MMV, www.mmv.org) is committed to promote 
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the development of such convenient drug formulations, which would render IPTi 
easier to implement and eventually more effective. 
In summary, IPTi in PNG seems feasible, similarly to what was shown in 
Tanzania (Armstrong Schellenberg, Shirima et al. 2010; Willey, Armstrong 
Schellenberg et al. 2011), even if the EPI coverage is certainly the strongest 
limitation. 
8.4.7 Cost-effectiveness of IPTi in PNG 
Because of the limited resources, many interventions in developing countries are 
evaluated for their usefulness as public health tool through the prism of cost-
effectiveness. IPTi makes no exception to this, and it was extensively studied in 
Africa. Two studies investigated the cost effectiveness of IPTi using SP, AQ3-
AS3 and mefloquine. The cost per malaria episode averted ranged from 1.4 to 
4.0 US$ with SP used alone. It was 4.7 US$ for AQ3-AS3. The intervention was 
considered to be highly cost-effective in most of the studies with 2.9 to 39.6 US$ 
per DALY averted. (Hutton, Schellenberg et al. 2009; Conteh, Sicuri et al. 2010) 
Another study developed a model to estimate the cost-effectiveness of IPTi with 
SP or AQ3-AS3 according to specificities of different settings and concluded that 
IPTi with these drugs is likely to be cost-effective in settings with high 
transmission intensities, good implementation and “not too high” resistance 
levels. (Ross, Maire et al. 2011) The figures for PNG are not known even if a 
study has been carried out, but results are not yet available. It is however likely 
that conclusions might be similar to what was already published.  
This approach, focused on malaria outcomes, could be however criticized. 
Indeed, all these studies are assuming that reducing the burden of malaria will 
also reduce the overall burden of diseases (DALY’s are not related to a particular 
disease). This was already highlighted by Donaldson et al in the British Medical 
Journal in 2002, where they warned against the danger of choosing the wrong 
efficiency question. (Donaldson, Currie et al. 2002)  In the case of the IPTi trial in 
PNG, no impact was detected on the overall morbidity measured as the 
incidence of outpatient attendances (this was extensively discussed above). It is 
  
171
not very clear why no effect was observed on the overall morbidity, but it seems 
however reasonable to integrate this aspect into the model assessing the cost-
effectiveness of IPTi. Thus, an intervention that has no impact on the overall 
morbidity or on severe illnesses is by definition only costly.   
 
8.4.8 Implications for policy decision  
On the long pathway towards moving health interventions from innovation, to 
validation, policy making and application, several aspects need to be considered. 
Figure 8.3 displays a general diagram of health system framework.  
 
Figure 8-3: Basic health system framework summarizing the key features of 
a health system. 
 
 
Many aspects presented in figure 8.1 are directly related to policy decision. At the 
present stage of IPTi development, the items in the red frame are especially 
interesting in regards to policy decision. 1) The efficiency of IPTi has been 
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extensively described above and concerns have been raised about the overall 
benefit on morbidity and severe illnesses, while the intervention significantly 
decreased the burden of malaria. 2) The four next items accessibility, 
affordability, availability and acceptability refer to an access model developed by 
Penchansky and Thomas in the 80’ (Penchansky and Thomas 1981) and was 
further developed by other health researchers. (Obrist, Iteba et al. 2007) In the 
present IPTi trial, acceptability was good (see chapter 7). Both affordability and 
availability are also not much of a concern, as the drug regimen proposed 
included SP and AQ, which are cheap and available in PNG even if their 
availability is strongly dependant on the EPI coverage. Accessibility is likely to be 
the most challenging, also because of the low coverage of EPI. Finally, quality 
and safety are not important barriers to IPTi implementation as it was showed in 
the trial.  
In addition to all these points, there is still a controversy on the role of IPTi in the 
panel of strategies to fight malaria. Indeed, if some experts consider IPTi as a 
useful additional control tool (in conjunction with LLINs, IRS and ACT-based 
therapies), (Aponte, Schellenberg et al. 2009), for others, it is simply a way to 
improve malaria case management by reducing the incidence of severe illnesses 
without having a significant impact on malaria transmission. (Aguas, Lourenco et 
al. 2009) All these expert opinions refer to the African situation. What should be 
considered for the PNG context? It is probably more complex as the endemicity 
is very different from Africa, being high for both Pf and Pv. As it was described all 
along this thesis, PNG is still highly endemic for malaria and no important drop 
was observed compared to what has been seen in several African countries. 
PNG is considered to be in the control phase, according to WHO definition (WHO 
2010), and rather far away from embarking on an elimination program. The main 
reason is that control strategies such as LLINs, IRS and ACT-based treatments 
have just been recently implemented and it is too early to measure any impact of 
these interventions on the burden of malaria. In such a context of rapidly evolving 
endemicity, it might be hazardous to introduce simultaneously an additional 
intervention that did not show a clear effect on overall morbidity and that is not 
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meant to have a significant effect on malaria transmission. A strong effort should 
rather be put on achieving high coverage of recently introduced interventions.  
In summary and from a public health perspective, it might be not recommended 
to introduce IPTi for the time being in PNG despite its proven efficacy against 
malaria. The main reasons are 1) no impact on the overall morbidity is expected, 
2) with the current reported EPI coverage, the effectiveness of IPTi on malaria is 
likely to be marginal, 3) in a phase of multi-strategies introduction (LLINs and 
ACT), it might be wise to achieve high coverage of existing effective interventions 
instead of adding another one that is unlikely to be cost-effective. Table 8.2 tries 
to summaries pros and cons for deciding on the establishment of an IPTi policy in 
PNG. 
Table 8-2: pros and cons for deciding on the establishment of an IPTi 
policy in PNG 
Determinants of effectiveness comments
Efficacy
overall morbidity no effect
all malaria episodes 30% reduction, mainly on Pf
anemia < 8g/dl 41% reduction in ATP analysis only
all severe diseases/admissions no effect
malaria-related severe diseases no effect
all-cause mortality Cave: sole trial with efficacy on mortality
EPI coverage max 50% expected
Choice of the drug (SP-AQ3) high resistance levels
Malaria endemicity endemicity changing rapidly (ITN, ACT)
Feasibility low because EPI coverage is low
Adherence to treatment at home tested, good in trial setting
Access
Acceptability tested, excellent in trial setting
Availability strongly related to EPI coverage
Affordability Cheap intervention
Accessibility strongly related to EPI coverage
Cost-effectiveness
all morbidity
malaria-related morbidity Highly cost-effective in African settings
Pros ….. Cons
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8.5 Clinical management of malaria and other diseases in PNG  
Chapters 4 and 6 investigated the management of childhood illnesses in 
outpatient facilities. Even if these aspects are not directly linked to the IPTi 
intervention, they cannot be ignored in the overall context of malaria intervention 
evaluation. Indeed, it is now well recognized that a combination of efficient 
strategies is required to achieve significant reduction of the malaria burden. Apart 
from preventive interventions such as LLINs and IRS, accurate diagnosis of 
malaria and efficient treatment is also mandatory. (WHO 2010) If the benefits of 
using RDT and ACT therapies are well established in Africa where Pf is the 
predominant species, it is not the case in PNG where Pv accounts for more than 
half of the burden of malaria. RDT have shown to be less sensitive on Pv than on 
Pf (WHO 2008). Similarly, in settings of well controlled clinical trials, ACT’s were 
found to be less effective on Pv than on Pf. (Karunajeewa, Mueller et al. 2008). 
These observations called for a careful assessment of medical practices in this 
context of different epidemiology and suboptimal tools. Chapter 4 & 6 investigate 
these key aspects of the management of malaria: what is happening in real-life 
outpatient clinics if infants are treated with AL based solely on the result of the 
RDT alongside the IMCI guidelines?  
 
8.5.1 Safety of RDT & utility within IMCI 
The observations made in the present project showed that, even if there are 
imperfect to detect low Pv parasitemia, malaria treatment guided by the use of 
RDT is safe in infants in PNG routine practice. Indeed, no case which might have 
gone to severe malaria or death (out of almost 4000 negative tests results) was 
missed with this procedure. The recent development of RDT more sensitive for 
Pv is an additional reassurance in this regards. (Maltha, Gillet et al. 2010; Singh, 
Shukla et al. 2010) This work is in line with findings from Africa, where the safety 
of withholding antimalarial when RDT was negative was confirmed for Pf 
infections. (d'Acremont, Malila et al. 2010 )  
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The present work allowed also investigating how the introduction of RDT could fit 
in and potentially improve the PNG treatment guidelines (IMCI). This was done in 
chapter 6 were it was shown that the use of RDT within IMCI improved the 
accuracy of malaria diagnosis by health staff with a correlation of 0.99 (kappa) 
between the diagnosis posed by the clinicians and a standardized diagnosis 
generated by computer (based on recorded signs/symptoms). On the other hand, 
the result of the test significantly changed the antibiotics prescription’s habits of 
health care workers as 56% of children received antibiotics when RDT was 
negative compare to 16% only when it was positive (excluding all other diagnosis 
requiring the prescription of antibiotics). It is not entirely clear how RDT results 
influence the prescription of antibiotics: if it decreases it when it is positive or if it 
increases it when the RDT result is negative (or both). However, it seems 
important to provide clear recommendations to health workers on the 
management of children with negative RDT. 
These data provide solid evidence that RDT’s used in the frame of IMCI are safe 
and accurate for the management of malaria in young children in PNG. 
 
8.5.2 Safety and effectiveness of artemether-lumefantrine for Pf and 
Pv  
 With the emergence of chloroquine-resistant P vivax strains and the risk of 
misdiagnosis (Pf instead of Pv or mixed infections), especially in settings such as 
PNG with high mix-endemicity for both species, having one treatment efficient on 
all species, a so-called unified treatment, would be welcome and is advocated by 
some experts. (Douglas, NM. et al. 2010) However, if one trial has investigated 
the efficacy of ACT on Pv in PNG, (Karunajeewa, Mueller et al. 2008) none have 
looked at the effectiveness of these treatments in routine practice. This is what 
was done in chapter 4, where re-attendance rates of young children with positive 
RDT result and treated with AL irrespective of the species were investigated.   
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AL appears to be a safe drug in the Melanesian population as no severe AE 
related to the drug was reported. The results on efficacy of AL on both Pf and Pv 
are very reassuring. AL showed to be equally efficacious to clear initial 
parasitemia for both Pf and Pv. Indeed, the re-attendance rates within 28 days 
for same species (uncorrected for new infections, recrudescences and relapses) 
were around 1%.  The main issue that remains is to known how to deal with late 
Pv treatment failures (9% of re-attendance by day 42 for Pv compare to 3% with 
Pf), mostly due to liver stage parasites not affected by AL. One option could be to 
add a single dose of primaquine, the only efficient drug against dormant forms of 
the parasite, as it was proposed by several experts. (Douglas, NM. et al. 2010; 
Smithuis, Kyaw et al. 2010). This raises a safety concern due to the risk of 
haemolysis in G6PD deficient patients.(Shekalaghe, ter Braak et al. 2010) 
Experts recommend systematic testing for enzyme deficiency to be performed 
prior to treatment, even if the effect of primaquine on red blood cells is dose-
dependant. (Moonen, Cohen et al. 2010) Further studies are thus needed to 
clarify both the effectiveness and the safety of this strategy in PNG. On the other 
hand, in a country highly endemic for Pv, it is questionable to know if it is 
worthwhile, at an individual level, to treat a patient for hypnozoites if the risk of 
being re-infected quickly is high. It is however clear that in terms of controlling 
parasites’ transmission countrywide, treating these liver-stage forms is essential 
(Wells, Burrows et al. 2010) 
In a context such as PNG, introducing a unified treatment of AL has some 
advantages and disadvantages. Among the main advantages, having one single 
treatment for all species clearly simplifies the task of health workers in routine 
practice. Because the resistance to chloroquine (or amodiaquine) is common in 
PNG, (Marfurt, Mueller et al. 2007) the use of AL is safer in case of missed Pf 
diagnosis or mixed infection. However, there are also some drawbacks 
compared to the use of a differential medication. Indeed AL is more expensive 
than chloroquine or amodiaquine. If AL is used to treat all malaria episodes, this 
strategy will be more costly than a dual treatment. The other main issue that 
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remains unsolved with a unified treatment is the problem of hypnozoites that are 
not cured with AL. This was discussed in the previous paragraph. 
 Therefore, from our data and in absence of a better treatment alternative, AL 
could be recommended as first line unified treatment in PNG.  
 
8.5.3 Feasibility of using RDT-based unified treatment with AL in 
PNG 
The IPTi trial in PNG was a good opportunity to evaluate the feasibility of using 
RDT and AL in routine practice, even if the trial was not designed for that. This 
evaluation was timely for PNG since health authorities were discussing on 
diagnostic and treatment policies. 
All nurses using the RDT routinely during the study were working in public health 
facilities prior to their employment for this trial and were not familiar to the 
procedure of RDT. At the time of the trial, AL was not a standard treatment in 
PNG and the nurses never used it before. The effectiveness data detailed in the 
different chapters of this thesis tend to show that RDT use and AL prescription by 
the health staff were appropriate and that the treatment was well taken by 
children.  
In terms of staff training, each nurse attended approximately 1-2 days of training 
on the use of RDT and on the prescription of AL. Additionally, regular on-site 
quality assessments were performed to ensure that the device was appropriately 
used. This corresponds more or less to the training provided by the health 
department to staff in routine clinics (outside trial setting). Informally, staff often 
reported that they found the new approach towards malaria management better 
than the previously presumptive treatment. These data confirm findings of many 
other studies performed around the world, that the implementation of RDT-based 
treatment is feasible in routine practice (Kyabayinze, Asiimwe et al. 2010; 
Masanja, McMorrow et al. 2010; D'Acremont, Kahama-Maro et al. 2011)  
See appendix 2 for detailed procedure for malaria in the IPTi trial. 
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8.5.4 Performance of IMCI on non-malaria illnesses 
IMCI supplemented with RDT was detailed above and proved to significantly 
improve the management of malaria but strongly influenced the prescription of 
antibiotics, being much higher when the RDT was negative with 56% of 
antibiotics prescription and only 16% when the test is positive (excluding all other 
reasons to prescribe antibiotics).  
On the opposite, the findings exposed in chapter 6 clearly show that the 
management of other important syndromes is unsatisfactory, especially for acute 
respiratory infections: inaccuracy of diagnosis by health workers (К =0.42 for 
URTI and 0.47 for LRTI), inappropriateness of current guidelines to identify 
patients with LRTI or gastroenteritis requiring antibiotics (re-attendance rates 
within 14 days are similar, 8% vs 9% wether children received antibiotics or not 
with a clinical diagnosis of LRTI [p=0.44]. Rates for gastroenteritis were 9% and 
8% respectively [p=0.51]) and inadequacy of antibiotics prescription (25% of 
children received treatment when they should not or did not receive when they 
should).  
This is especially important for respiratory infections as ARI represent the 
majority of the burden in Papuan infants (almost one episode of LRTI per child 
per year below 1 year). It seems therefore urgent to improve the strategy to 
manage respiratory infections in children. The purpose of the revision should aim 
at: 1) better identifying children with bacterial LRTI that require antibiotics 2) 
better identifying children with LRTI that require more intensive care support. 
These two aspects are complementary and need to be considered together as 
young children might suffer from a severe LRTI of viral aetiology that requires 
oxygen therapy and not necessarily antibiotics (ex: complications of a 
bronchiolitis due to RSV). (Dawson-Caswell and Muncie 2011) If the clinical 
differentiation between pneumonia and bronchiolitis is relatively easy for 
experienced clinicians, it is much more difficult for health workers of rural areas 
not familiar to the use of stethoscope. Following the example of the new strategy 
developed to manage malaria cases, a potential strategy could be to combine: 1) 
better clinical definition (increase threshold of respiratory rate and/or include 
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fever) 2) rapid tests for potential common aetiologies of LRTI and 3) makers of 
severity of LRTI such as pro-calcitonin, c-reactive protein or the analysis of 
exhaled gases.(Schmidt, Bhandari et al. 2010) All these measures should both 
improve the identification of potential severe cases and lead to a more rational 
use of antibiotics. It is however clear that the problem of management of acute 
respiratory infections is far more complex than with malaria and it will not be 
possible to solve the problem by just developing one single diagnosis test as it 
was done with RDT for malaria. Further research and resources are therefore 
urgently needed to explore new strategies.  
 
8.5.5 Implications for policy decision of updating IMCI with RDT-
based treatment 
All the data presented in the different chapters confirm that the use of RDT and 
AL within IMCI guidelines can be applied in the PNG setting and has the potential 
to greatly improve the management of malaria in regions highly endemic for non-
Pf malaria. It seems therefore reasonable to move WHO’s health policies forward 
by updating IMCI and incorporating RDT to guidelines in countries endemic for 
any malaria species and not only in Africa. On the opposite, it is urgent to 
improve the guidelines for the management of other diseases, especially 
respiratory infections. All these changes should be accompanied with a 
reinforcement of staff training, not only on the use of these guidelines but also on 
the understanding of their medical meanings.  
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9 Conclusions 
 
The present work demonstrates that treating young children with 
artemther/lumefantrine based on RDT results is safe and effective and greatly 
improves the management of malaria cases in PNG compare to presumptive 
treatment. This work shows also for the first time that IPTi is efficacious and 
reduces the risk of malaria by 29% when using SP associated to 3 days of AQ in 
a region of the world with a highly mix-endemicity for Pf and Pv. However the 
IPTi intervention seems not to provide any benefit on the overall burden of 
diseases or on severe illnesses. This is a concern and mitigates the interest of 
implementing this intervention in PNG. Furthermore, other factors such as a low 
EPI coverage and rapidly changing malaria endemicity due to the recent 
introduction of LLINs and ACT are likely to drastically reduce the potential 
benefits of IPTi on malaria in PNG. 
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10 Recommendations and future research areas  
 
10.1  Recommendations for health authorities and policy makers 
in PNG 
 
Burden of diseases in PNG 
• Respiratory infections are the leading cause of illnesses in young children in 
PNG and their incidence are high compared to other developing countries. 
Health authorities should consider reinforcing prevention measures that could 
decrease this important burden. In that regards, the introduction of a vaccine 
against S. pneumoniae should be considered. Programs aiming at improving 
nutrition status and better living conditions (indoor pollution) should be 
conducted. These measures should be accompanied by a better training of 
health staff on the management of ARI and LRTI.   
• Measuring the impact of malaria control interventions recently introduced in 
PNG (ITN, ACT) is essential, especially in the perspective of eventually 
implementing IPTi. The use of population Hb metrics (anemia prevalence or 
population mean Hb) to estimate the malaria endemicity is a valuable and 
easy-to-perform tool and could be added to the panel of more traditional 
metrics such as parasite rate.   
 
IPTi implementation in PNG 
• Despite its efficacy against Pf and Pv malaria, IPTi is not recommendable as 
universal policy in malaria endemic areas of PNG for the time being for the 
following reasons: 1) absence of efficacy on the overall morbidity and on 
severe illnesses. 2) Low EPI coverage in PNG. 3) Rapidly changing malaria 
endemicity that might jeopardize the benefits of IPTi as a control strategy. 4) 
Unfavourable cost-effectiveness ratio.   
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• If health authorities would still pursue to consider IPTi as a malaria control 
intervention for endemic areas of PNG, the following aspects are 
recommended: 
o Only a combination of two long acting drugs (SP-AQ3) is 
recommended for IPTi in PNG, as it is the only tested combination to 
be efficient on both Pf and Pv parasites.  
o EPI coverage is a fundamental aspect of IPTi effectiveness. Therefore, 
implementation of IPTi should be accompanied by an improvement of 
the overall EPI coverage. The recommended IPTi schedule is four 
doses at 3, 6, 9 and 12 months of age. 
o Because ITN and ACT, two efficient malaria prevention strategies, 
have just been recently introduced in PNG, it might be important to 
measure first their impact on malaria transmission prior to the 
implementation of IPTi. This should also help to map the regions where 
IPTi could be implemented as only areas with moderate to high 
transmission intensities can benefit from IPTi.  
o Levels of resistance of Pf and Pv against SP and AQ are high in PNG 
and will require to be closely monitored if IPTi would be implemented. 
As the first line treatment has recently changed, and SP and AQ are 
not any longer used as treatment, this might decrease the selection 
pressure of resistant parasites.  
o More generally, and because of the mentioned doubts on the real 
benefits of IPTi intervention in PNG, it will be essential that its 
effectiveness is closely monitored following its implementation. 
Besides malaria outcomes and overall morbidity, the impact on 
mortality should be especially considered as an important outcome 
because the trial showed a surprisingly and unexpected effect on it.  
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Use of RDT and AL for the management of malaria within the PNG national 
guidelines 
• Malaria case management in small children based only on RDT results 
and a unified treatment for Pf and Pv using artemether/lumefantrine is 
safe and effective in areas endemic for different species of Plasmodium. 
This provides a confirmation that the recent decision made by PNG health 
authorities to introduce RDT and AL is feasible, safe and effective in 
routine clinics of PNG.  
• RDT for malaria in PNG should include both Pf and non-Pf detection. 
• Knowing the high prevalence of Pv infections in PNG, the use of AL alone 
is highly effective on initial parasitemia but does not provide any benefits 
for relapsing forms of hypnozoites liver-stage parasites. Strategies that 
could also treat these dormant forms should be considered. For example a 
treatment that includes a single dose of primaquine could be investigated 
for both its efficacy and safety in PNG.     
10.2  General recommendations for IMCI guidelines 
• Updating IMCI guidelines with RDT significantly improved the accuracy of 
malaria diagnosis and its management in small children in a region of the 
world highly endemic for Pf and Pv. Therefore WHO IMCI policies could 
be updated and complemented with RDT for malaria for all endemic 
areas, independently of the local epidemiology of species.  
• The introduction of RDT into IMCI guidelines might lead to an overuse of 
antibiotics. Therefore, IMCI guidelines updated with RDT for malaria 
should also include clear recommendations when the RDT result is 
negative and appropriate training should be provided to health care 
providers. 
• Current IMCI recommendations for the management of pneumonia are 
unsatisfactory leading to high rates of inaccurate diagnosis and 
inappropriate use of antibiotics. Therefore new strategies should be 
evaluated in order to be able to better identify children that need 
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antimicrobial therapy or more intensive support. For example, a potential 
strategy could be to combine more discriminative clinical criteria (increase 
threshold of respiratory rate and/or include fever) and objective testing for 
potential common aetiologies of LRTI (rapid tests) and markers of severity 
of LRTI such as pro-calcitonin or c-reactive protein. 
• The syndromic approach of the IMCI guidelines towards diagnosis and 
diseases management leads to an important overlap of signs and 
symptoms, inaccurate diagnosis and an inappropriate use of antibiotics. It 
will be thus recommended to redefine the definitions of the main 
syndromes/diseases by introducing better clinical criteria or new 
diagnostic tools with increased specificities. 
 
10.3  General recommendations for the IPTi intervention 
• IPTi using SP-AQ3 is similarly effective in regions highly endemic for non-
Pf infections compared to Africa and reduces the risk of malaria (all 
species) by 29%. Therefore recommendations on the use of IPTi could be 
generalised to all malaria endemic areas and not only Sub-Saharan Africa.     
• WHO statement recommends to use in Africa IPTi-SP in regions with 
moderate to high malaria endemicity with “not to high” levels of resistance 
to SP because of its impact on malaria and severe illnesses. However, 
policy makers should also integrate the impact on the overall morbidity (all 
illness episodes, outpatient attendances) in order to provide a 
comprehensive picture of the overall benefits of IPTi on health.  
• Among the possible reasons to explain the apparent absence of benefits 
on overall morbidity, in spite of a 30% reduction of malaria, is the problem 
of definition of “malaria disease”, as the overlap of signs and symptoms 
with non-malaria diseases is important. Therefore, it would be 
recommended to work out a better definition of “malaria disease” in order 
to better assess the true benefits of the intervention.  
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10.4  Further research areas  
• Because the IPTi trial in PNG highlighted the absence of benefits on the 
overall morbidity and only incomplete data have been published from the 
African trials, it would be important to perform a pool analysis in order to 
investigate the impact of IPTi with SP and other drug regimens on overall 
morbidity and non-malaria illnesses.  
• To investigate other drug combinations for IPTi with long half-life, better 
resistance and safety profiles and providing possible benefits on non-
malaria illnesses. DHA-piperaquine might be a good candidate because of 
its good efficacy against Pv. Mefloquine could be also a good candidate 
for PNG, but its tolerability was poor in one IPTi study in Africa. Broad 
spectrum antibiotics with antimalarial activities such as azithromycine are 
not recommended because of the risk of promoting resistance.   
• To investigate other IPT schedules than IPTi for the delivery of malaria 
preventive interventions (seasonal, children) in the PNG population in 
order to improve the efficacy on both malaria-related and -unrelated 
morbidities 
• To identify and investigate new strategies for the diagnosis and 
management of respiratory infections in routine settings. These new 
strategies should be able to better identify 1) LRTI that need antibiotics 
and 2) LRTI that need more intense supportive care (hospitalisation, 
oxygenotherapy). 
• In order to better identify new strategies towards the management of 
respiratory tract infections in PNG and elsewhere, it is mandatory to 
investigate the epidemiology of ARI and LRTI and the spectrum of 
causative agents.  
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Appendix 2: Case report forms used in the IPTi trial to record all 
signs, symptoms, diagnoses and treatments of illness episodes 
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Appendix 3: Treatment of malaria & anemia (IPTi trial 
procedures) and extracts of the PNG treatment book (IMCI) for 
danger signs, fever, respiratory infections, gastroenteritis and 
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